



## **2025 Prior Authorization (PA) Criteria**

Certain drugs require prior authorization from EmblemHealth Medicare HMO/PPO Medicare Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and to provide information describing the use and administration of the drug, so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ACTEMRA

### Products Affected

- ACTEMRA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial - approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Orencia, Rinvoq or Xeljanz/XR (Note: if the patient does not meet this requirement, previous trial(s) with the following drugs will be counted towards meeting the try TWO requirement: Cimzia, Kevzara, infliximab, golimumab SC/IV, or a non-preferred adalimumab product will also count.). OR B) patient has heart failure or a previously treated lymphoproliferative disorder. PJIA, initial-approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, Orencia, Rinvoq, Xeljanz or a preferred adalimumab product. (Note: if the patient does not meet this requirement, a previous trial with the drug Kevzara, infliximab or a non-preferred adalimumab product will be counted towards meeting the try TWO requirement.), OR B) patient has heart failure or a previously treated lymphoproliferative disorder. Systemic-onset JIA, approve for

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	patients who have tried one other systemic agent for SJIA (eg, a corticosteroid [oral, IV], a conventional synthetic DMARD [eg, MTX, leflunomide, sulfasalazine], Kineret (anakinra), or Ilaris (canakinumab for SC injection), or a 1-month trial of a nonsteroidal anti-inflammatory drug [NSAID]). Giant cell arteritis, initial-approve if the patient has tried one systemic corticosteroid. Cont tx, RA/PJIA/SJIA/GCA - approve if the pt had a response as determined by the prescriber. Cytokine release syndrome associated with chimeric antigen receptor (CAR) T-Cell therapy-approve. Please Note: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ACTEMRA SQ

### Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS
- TYENNE AUTOINJECTOR
- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	Interstitial lung disease-18 years and older (initial and continuation)
<b>Prescriber Restrictions</b>	RA/GCA/PJIA/SJIA - Prescribed by or in consultation with a rheumatologist (initial therapy only). Lung disease-presc/consult-pulmonologist or rheum (initial and cont)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA) [A or B]: A) tried two of the following: Enbrel, preferred adalimumab product (see Example 1), Orencia, Rinvoq or Xeljanz/XR (Note: trials with the following will also count towards meeting the try two requirement: Cimzia, infliximab, Kevzara, golimumab SC/IV, non-preferred adalimumab product), or B) heart failure or a previously treated lymphoproliferative disorder. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A or B]: A) tried two of the following: Enbrel, Orencia, Rinvoq, Xeljanz, preferred adalimumab product. (Note: trials with Kevzara, infliximab or a non-preferred adalimumab product will also count towards meeting the try two requirement), or B) heart failure or a previously treated lymphoproliferative disorder. SYSTEMIC-ONSET JIA (SJIA) [one of A, B, or C]: A) tried one other systemic agent (e.g., corticosteroid [CS], conventional synthetic DMARD [e.g., MTX, leflunomide, sulfasalazine], or B) tried Kineret (anakinra) or Ilaris (canakinumab for SC injection), or C) one-month trial of an NSAID. GIANT CELL ARTERITIS: tried one

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	systemic CS. INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (A and B): A) elevated acute phase reactants and B) diagnosis confirmed by high-resolution computed tomography. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Example 1: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ACTIMMUNE

---

### Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Chronic granulomatous disease - prescribed by or in consultation with an immunologist, hematologist or infectious disease specialist. Malignant osteopetrosis- prescribed by or in consultation with an endocrinologist or hematologist.
Coverage Duration	1 year
Other Criteria	Chronic granulomatous disease - approve if diagnosis has been established by a molecular genetic test identifying a gene-related mutation linked to chronic granulomatous disease. Malignant osteopetrosis, severe - approve if pt has had radiographic (X-ray) imaging demonstrating skeletal features related to osteopetrosis or pt had a molecular genetic test identifying a gene-related mutation linked to severe, malignant osteopetrosis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ACYCLOVIR (TOPICAL)

---

### Products Affected

- *acyclovir topical ointment*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ADALIMUMAB

### Products Affected

- CYLTEZO(CF) PEN
- CYLTEZO(CF) PEN CROHN'S-UC-HS
- CYLTEZO(CF) PEN PSORIASIS-UV
- CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML
- HUMIRA (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA PEN (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML
- HUMIRA(CF) PEN (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- HUMIRA(CF) PEN CROHNS-UC-HS (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074)
- YUFLYMA(CF) AI CROHN'S-UC-HS
- YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another biologic DMARD or targeted synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Initial therapy only: Crohn's disease (CD)-6 or older, Ulcerative colitis (UC)-5 or older, PP/ Pyoderma gangrenosum/ sarcoidosis/ scleritis/ sterile corneal ulceration/ non-radiographic axial spondyloarthritis-18 years and older, Behcet's disease-2 years and older
<b>Prescriber Restrictions</b>	Initial therapy only for all dx, prescribed by or in consultation with one of the following specialists-RA/JIA/JRA/Ankylosing spondylitis/nr-axSpA, rheumatologist. PsA, rheumatologist or dermatologist. PP, dermatologist. UC/ CD, gastroenterologist. HS/pyoderma gangrenosum - dermatologist.UV/scleritis/sterile corneal ulceration-ophthalmologist.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	Behcet's- rheum, dermatol, ophthalmol, gastro, neuro. Sarcoidosis, pulm, ophthalmol, dermatol.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>INITIAL THERAPY: CROHN'S DISEASE (CD) [one of A, B, C, or D]: A) tried or currently taking corticosteroid (CS) or CS is contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX], certolizumab, infliximab, ustekinumab, vedolizumab), C) had ileocolonic resection, or D) enterocutaneous (perianal or abdominal) or rectovaginal fistulas.</p> <p>JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA (one of A, B, C, D, or E): A) tried one other systemic therapy (e.g., MTX, sulfasalazine, leflunomide, NSAID), B) tried a biologic (e.g., etanercept, abatacept, infliximab, anakinra, tocilizumab), C) will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide, D) patient has absolute contraindication to MTX, sulfasalazine, or leflunomide, or E) patient has aggressive disease.</p> <p>HIDRADENITIS SUPPURATIVA (HS): tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics, isotretinoin).</p> <p>PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of a biologic will also count) or B) contraindication to MTX.</p> <p>RHEUMATOID ARTHRITIS (RA): tried one conventional synthetic DMARD for at least 3 months (Note: a 3-month trial of a biologic will also count).</p> <p>ULCERATIVE COLITIS (A or B): A) tried a systemic therapy (e.g., 6-MP, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a CS) or B) has pouchitis and tried therapy with an antibiotic, probiotic, CS enema, or mesalamine (Rowasa) enema.</p> <p>BEHCET'S DISEASE (A or B): A) tried one conventional therapy (e.g., systemic CS, azathioprine, MTX, CSA, chlorambucil, cyclophosphamide, interferon alfa), or B) has ophthalmic manifestations.</p> <p>SARCOIDOSIS (A and B): A) tried one CS, and B) tried one immunosuppressant (e.g. MTX, mycophenolate mofetil, chlorambucil, thalidomide, infliximab, chloroquine).</p> <p>SCLERITIS/STERILE CORNEAL ULCERATION: tried one other therapy (e.g. CS, CSA).</p> <p>NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: objective signs of inflammation defined as either (A or B): A) C-reactive protein elevated beyond upper limit of normal, or B) sacroiliitis on MRI.</p> <p>CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Behcet's disease, pyoderma gangrenosum, sarcoidosis, scleritis/sterile corneal ulceration, non-radiographic axial spondyloarthritis.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ADBRY

### Products Affected

- ADBRY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy (i.e., Dupixent, Cinqair, Fasenra, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical].
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	AD-12 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	Atopic Dermatitis-prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
<b>Coverage Duration</b>	Initial-Atopic Dermatitis-4 months, Continuation-1 year
<b>Other Criteria</b>	Atopic Dermatitis, initial-patient has atopic dermatitis involvement estimated to be greater than or equal to 10 percent of the body surface area and patient meets a and b: a. Patient has tried at least one medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroid AND b. Inadequate efficacy was demonstrated with the previously tried topical corticosteroid therapy. Continuation- Approve if the patient has been receiving Adbry for at least 4 months and patient has responded to therapy. Note: A patient who has received less than 4 months of therapy or who is restarting therapy with Adbry should be considered under initial therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ADEMPAS

---

### Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Phosphodiesterase Inhibitors Used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	1 year
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ADSTILADRIN

---

### Products Affected

- ADSTILADRIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a urologist or an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Muscle Invasive Bladder Cancer, approve initial therapy if the patient meets (A and B): A) patient has high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive disease, and B) the patient has carcinoma in situ (CIS) with or without high-grade papillary Ta/T1 tumors OR the patient has high-grade papillary Ta/T1 tumors without CIS. Non-Muscle Invasive Bladder Cancer, continuation of therapy - approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AIMOVIG

---

### Products Affected

- AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with another cGRP inhibitor for migraine headache prevention
Required Medical Information	Diagnosis, number of migraine headaches per month
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) If pt is currently taking Aimovig, the pt has had significant clinical benefit from the medication.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AKEEGA

### Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer- Approve if the patient meets the following (A, B, C, and D): A)Patient has metastatic castration-resistant prostate cancer, AND B)Patient has a BReast CAncer (BRCA) mutation, AND C)The medication is used in combination with prednisone, AND D)Patient meets one of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog, Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), and Orgovyx (relugolix tablets).OR ii. Patient has had a bilateral orchiectomy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ALDURAZYME

---

### Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic alpha-L-iduronidase gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ALECENSA

### Products Affected

- ALECENSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Pediatric diffuse high grade glioma- less than or equal to 21 years old, All others- 18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Non-small cell lung cancer-approve if the patient has both (A and B): A) either (i or ii): i) medication is used as adjuvant treatment following tumor resection (note: for tumors greater than or equal to 4 cm or node positive) or ii) advanced or metastatic disease and B) anaplastic lymphoma kinase (ALK)-positive disease as detected by an approved test. Anaplastic large cell lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease and (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory Myofibroblastic Tumor- pt has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) pt has advanced, recurrent or metastatic disease, or (ii) tumor is inoperable. Large B-Cell Lymphoma- pt has ALK-positive disease AND pt has relapsed or refractory disease. Pediatric diffuse high grade glioma- approve if (A and B): A) ALK-positive disease, and B) either (i or ii): i) medication is used as adjunctive treatment AND

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	tumor is not diffuse midline glioma, H3 K27-altered or pontine location, or ii) medication is used for recurrent or progressive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anaplastic large cell lymphoma, Erdheim Chester disease, Inflammatory Myofibroblastic Tumor, Large B-Cell Lymphoma, Pediatric Diffuse High Grade Glioma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ALOSETRON

---

### Products Affected

- *alosetron*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ALPHA 1 PROTEINASE INHIBITORS

---

### Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Alpha1-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease)-approve if the patient has a baseline (pretreatment) AAT serum concentration of less than 80 mg/dL or 11 micromol/L.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ALUNBRIG

### Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	ALK status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has ALK positive disease and has advanced, recurrent or metastatic disease or the tumor is inoperable. NSCLC, must be ALK-positive, as detected by an approved test, have advanced or metastatic disease and patients new to therapy must have a trial of Alecensa or Lorbrena prior to approval of Alunbrig. Peripheral T-Cell Lymphoma- approve if patient has ALK-positive anaplastic large cell lymphoma (ALCL).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Erdheim-Chester disease, Inflammatory myofibroblastic tumor (IMT), Peripheral T-Cell Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# ANKTIVA

## Products Affected

- ANKTIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or urologist (initial/maintenance therapy)
<b>Coverage Duration</b>	Initial-6 months, Maintenance-3 months
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL-NON-MUSCLE INVASIVE BLADDER CANCER-all of (i, ii, iii): i) Patient has Bacillus Calmette-Guerin (BCG) unresponsive disease, AND ii) Patient has carcinoma in situ with or without papillary tumors, AND iii) Medication is used in combination with BCG. MAINTENANCE THERAPY-NON-MUSCLE INVASIVE BLADDER CANCER-all of (i and ii): i) Patient has an ongoing complete response defined as ONE of the following (a or b): a) Patient has negative cystoscopy and meets ONE of the following [(1) or (2)]: 1. Negative urine cytology, OR 2. Malignant urine cytology if cancer found in the upper tract or prostatic urethra and random bladder biopsies are negative, OR b) Patient has positive cystoscopy with biopsy-proven benign or low-grade Ta non-muscle invasive bladder cancer and negative urine cytology, AND ii) Medication is used in combination with BCG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ANTIBIOTICS (IV)

---

### Products Affected

- amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml
- ampicillin sodium injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg
- ampicillin sodium intravenous
- ampicillin-sulbactam
- azithromycin intravenous
- aztreonam
- BICILLIN L-A
- cefoxitin
- cefoxitin in dextrose (iso-osm)
- ceftazidime
- cefuroxime sodium injection recon soln 750 mg
- cefuroxime sodium intravenous
- ciprofloxacin in 5 % dextrose
- clindamycin in 5 % dextrose
- clindamycin phosphate injection
- colistin (colistimethate na)
- doxy-100
- doxycycline hyclate intravenous
- ertapenem
- gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml
- gentamicin injection
- gentamicin sulfate (ped) (pf)
- imipenem-cilastatin
- levofloxacin in d5w
- levofloxacin intravenous
- lincomycin
- linezolid in dextrose 5%
- linezolid-0.9% sodium chloride
- meropenem intravenous recon soln 1 gram, 500 mg
- metro i.v.
- metronidazole in nacl (iso-osm)
- moxifloxacin-sod.chloride(iso)
- nafcillin in dextrose (iso-osm) intravenous piggyback 2 gram/100 ml
- nafcillin injection
- oxacillin
- oxacillin in dextrose (iso-osm) intravenous piggyback 2 gram/50 ml
- PENICILLIN G POT IN DEXTROSE INTRAVENOUS PIGGYBACK 2 MILLION UNIT/50 ML, 3 MILLION UNIT/50 ML
- penicillin g potassium
- penicillin g sodium
- pfizerpen-g
- STREPTOMYCIN
- sulfamethoxazole-trimethoprim intravenous
- tazicef
- TEFLARO
- tigecycline
- tobramycin sulfate injection recon soln
- tobramycin sulfate injection solution
- VANCOMYCIN IN 0.9 % SODIUM CHL INTRAVENOUS PIGGYBACK 1 GRAM/200 ML, 500 MG/100 ML, 750 MG/150 ML
- vancomycin intravenous recon soln 1,000 mg, 10 gram, 5 gram, 500 mg, 750 mg
- VIBATIV INTRAVENOUS RECON SOLN 750 MG

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ANTIFUNGALS (IV)

---

### Products Affected

- *fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml*
- *voriconazole*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# ARCALYST

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent biologic therapy
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS/Pericarditis-Greater than or equal to 12 years of age.
Prescriber Restrictions	Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, allergist/immunologist, or dermatologist. DIRA initial-rheum, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders. Pericarditis-cardiologist or rheum
Coverage Duration	CAPS-3 mos initial, 1 yr cont. DIRA-6 mos initial, 1 yr cont. Pericard-3 mos initial, 1 yr cont
Other Criteria	INITIAL THERAPY: DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA) [ all of A, B, and C]: A) weighs at least 10 kg, B) genetic test confirms a mutation in the IL1RN gene, and C) had clinical benefit with anakinra subcutaneous injection. PERICARDITIS: pericarditis is recurrent. CONTINUATION THERAPY: ALL INDICATIONS: patient had a positive response to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ARIKAYCE

### Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous medication history (as described in Other Criteria field)
<b>Age Restrictions</b>	MAC-18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	MAC initial-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>INITIAL THERAPY: MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE (all of A, B, and C): A) positive sputum culture for MAC [Note: any positive sputum culture taken after completion of a background multidrug regimen (throughout, see Example 1 below) fulfills this criterion], B) MAC isolate is susceptible to amikacin, and C) Arikayce will be used in combination with a background multidrug regimen.</p> <p>CONTINUATION THERAPY: MAC LUNG DISEASE (A and B): A) Arikayce prescribed in combination with a background multidrug regimen and B) patient meets one of the following (a or b): a) patient has not achieved negative sputum cultures for MAC or b) patient has achieved negative sputum cultures for MAC for less than 12 months. Example 1: background multidrug regimen example - a macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (rifampin or rifabutin).</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ASPARLAS

---

### Products Affected

- ASPARLAS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 month to 21 years
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## AUBAGIO

---

### Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of teriflunomide with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of MS, to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AUGTYRO

### Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC - 18 years and older, Solid tumors - 12 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Non-Small Cell Lung Cancer-approve if the patient has locally advanced or metastatic disease, patient has ROS1-positive non-small cell lung cancer and the mutation was detected by an approved test. Solid tumors - approve if tumor is positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusion AND tumor is locally advanced or metastatic or surgical resection will likely result in severe morbidity AND disease has progressed following treatment or there are no satisfactory alternative therapies.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AUSTEDO

### Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Chorea-prescribed by or in consult with a neuro. TD-Prescribed by or in consultation with a neurologist or a psychiatrist
Coverage Duration	1 year
Other Criteria	Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing. Tardive dyskinesia-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AVONEX

### Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## AYVAKIT

### Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	GIST-approve if the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation or if the patient has tried two of the following: Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib) or Qinlock (ripretinib). Myeloid/Lymphoid Neoplasms with eosinophilia-approve if the tumor is positive for PDGFRA D842V mutation. Systemic mastocytosis-Approve if the patient has a platelet count greater than or equal to 50,000/mcL and patient has either indolent systemic mastocytosis or one of the following subtypes of advanced systemic mastocytosis-aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid/Lymphoid neoplasms with Eosinophilia
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BALVERSA

---

### Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies, test results
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Urothelial Carcinoma, locally advanced or metastatic-approve if the patient has susceptible fibroblast growth factor receptor 3 genetic alterations AND the patient has progressed during or following prior platinum-containing chemotherapy, other chemotherapy or checkpoint inhibitor therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BENLYSTA

### Products Affected

- BENLYSTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Biologics or Lupkynis
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Lupus Nephritis: 18 years and older (initial). SLE: 5 years and older (initial).
<b>Prescriber Restrictions</b>	SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont)
<b>Coverage Duration</b>	SLE-Initial-4 months, cont-1 year. Lupus Nephritis-6 mo initial, 1 year cont
<b>Other Criteria</b>	Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to Benlysta subcutaneous or intravenous. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA [anti-dsDNA] antibody AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	be intolerant due to a significant toxicity,. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity AND The patient has responded to Benlysta subcutaneous or intravenous.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BENLYSTA IV

### Products Affected

- BENLYSTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	5 years and older (initial).
<b>Prescriber Restrictions</b>	SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont)
<b>Coverage Duration</b>	SLE-Initial-4 months, cont-1 year, Lupus Nephritis-6 mo initial, 1 year cont
<b>Other Criteria</b>	Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to Benlysta subcutaneous or intravenous. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA [anti-dsDNA] antibody AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity. Continuation-Benlysta is being

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity AND The patient has responded to Benlysta subcutaneous or intravenous.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BESREMI

---

### Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other interferon products
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BETASERON/EXTAVIA

---

### Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agent used for multiple sclerosis
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or after consultation with a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BEXAROTENE (ORAL)

---

### Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BEXAROTENE (TOPICAL)

### Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	Adult T-Cell Leukemia/Lymphoma- approve if the patient has chronic/smoldering subtype and this medication is used as first-line therapy. Primary cutaneous B-Cell lymphoma-approve if used as skin-directed therapy for either (a or b): a) primary cutaneous marginal zone lymphoma or b) follicle center lymphoma.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adult T-Cell Leukemia/Lymphoma, Primary Cutaneous B-Cell Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BIZENGRI

### Products Affected

- BIZENGRI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	<p>NON-SMALL CELL LUNG CANCER-All of (A, B and C): A) Patient has advanced, unresectable, or metastatic disease, AND B) The disease is neuregulin 1 (NRG1) gene fusion positive, AND C) Patient has tried at least one systemic regimen. Note: Examples of a systemic regimen include one or more of the following drugs: carboplatin, cisplatin, or programmed cell death protein 1 (PD)-1 or PD-ligand 1 (PD-L1) blockers.</p> <p>PANCREATIC ADENOCARCINOMA-All of (A, B and C): A) Patient has advanced, unresectable, or metastatic disease, AND B) The disease is neuregulin 1 (NRG1) gene fusion positive, AND C) Patient has tried at least one systemic regimen. Note: Examples of systemic regimen include one or more of the following drugs: fluorouracil, leucovorin, irinotecan, oxaliplatin, gemcitabine, paclitaxel, capecitabine.</p>
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BONIVA INJECTION

### Products Affected

- *ibandronate intravenous*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other medications for Osteoporosis
<b>Required Medical Information</b>	Diagnosis, test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Treatment of postmenopausal osteoporosis, must meet ONE of the following 1. T-score (current or at any time in the past) at or below -2.5 at the lumbar spine, femoral neck, or total hip, 2. has had osteoporotic fracture or fragility fracture, 3. had a T-score (current or at any time in the past) between 1.0 and -2.5 at the lumbar spine, femoral neck, or total hip and the physician determines the patient is at high risk for fracture AND has had an inadequate response to oral bisphosphonate therapy after a trial duration of 12 months as determined by the prescribing physician (e.g., ongoing and significant loss of bone mineral density (BMD), lack of BMD increase), had an osteoporotic fracture or fragility fracture while receiving oral bisphosphonate therapy, or experienced intolerability to an oral bisphosphonate (e.g., severe GI-related adverse effects) OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	zoledronic acid) OR the patient has had an osteoporotic fracture or a fragility fracture.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BOSENTAN/AMBRISENTAN

### Products Affected

- ambrisentan*
- bosentan oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	For treatment of pulmonary arterial hypertension, ambrisentan or bosentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. CTEPH - prescribed by or in consultation with a cardiologist or pulmonologist
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	CTEPH - pt must have tried Adempas, has a contraindication to Adempas, or is currently receiving bosentan for CTEPH. Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chronic thromboembolic pulmonary hypertension (CTEPH) (bosentan)
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BOSULIF

### Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	ALL - 15 years and older. Myeloid/lymphoid neoplasms w eosinophilia- 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	CML-approve if the patient has Ph-positive or BCR::ABL1-positive CML. For Ph-positive ALL-approve. Myeloid/lymphoid neoplasms with eosinophilia - approve if tumor has an ABL1 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with Philadelphia chromosome positive Acute Lymphoblastic Leukemia, myeloid/lymphoid neoplasms with eosinophilia
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BRAFTOVI

### Products Affected

- BRAFTOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, BRAF V600 status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation. Colon or Rectal cancer- approve if the patient meets the following (A and B): A) The patient has BRAF V600E mutation-positive disease AND B) meets (i or ii): i) will be used as first-line systemic therapy for metastatic disease in combination with Erbitux (cetuximab intravenous infusion) and mFOLFOX6 (5-FU, leucovorin, and oxaliplatin) or ii) patient has previously received a chemotherapy regimen for colon or rectal cancer and this is prescribed as part of a combination regimen for colon or rectal cancer. NSCLC- approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Mektovi (binimetinib tablets). Appendiceal adenocarcinoma-approve if (A, B and C): A) BRAF V600E mutation-positive, and B) used as subsequent therapy for advanced or metastatic disease, and C) used in combination with Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	Appendiceal adenocarcinoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## BRIUMVI

---

### Products Affected

- BRIUMVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of MS, to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BRUKINSA

### Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Follicular Lymphoma - approve if pt tried at least two other systemic regimens and will use this in combination with Gazyva (obinutuzumab intravenous infusion). Mantle Cell Lymphoma/CLL/SLL - approve. Marginal zone lymphoma-approve if the patient has tried at least one systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma-approve. Hairy Cell Leukemia - approve if pt has received therapy for relapsed or refractory disease AND pt has progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Hairy Cell Leukemia
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## BYOOVIZ

---

### Products Affected

- BYOOVIZ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Retinopathy of prematurity, diabetic retinopathy, diabetic macular edema
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## C1 ESTERASE INHIBITORS

---

### Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
Coverage Duration	1 year
Other Criteria	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Cinryze for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Cinryze as prophylactic therapy compared with baseline.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CABLIVI

---

### Products Affected

- CABLIVI INJECTION KIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, concurrent medications
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	Approve for 12 months
Other Criteria	aTTP-approve if the requested medication was initiated in the inpatient setting in combination with plasma exchange therapy AND patient is currently receiving at least one immunosuppressive therapy AND if the patient has previously received Cablivi, he/she has not had more than two recurrences of aTTP while on Cablivi.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CABOMETYX

### Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, histology, RET gene rearrangement status for NSCLC
Age Restrictions	Neuroendocrine tumor/Thyroid carcinoma-12 years and older, other dx (except bone cancer)-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Renal Cell Carcinoma-Approve if the patient has relapsed or stage IV disease. Hepatocellular Carcinoma-approve if the patient has been previously treated with at least one other systemic therapy (e.g., Nexavar, Lenvima). Bone cancer-approve if the patient has Ewing sarcoma or osteosarcoma and has tried at least one previous systemic regimen. Thyroid carcinoma-approve if the patient has differentiated thyroid carcinoma, patient is refractory to radioactive iodine therapy and the patient has tried Lenvima or sorafenib. Endometrial carcinoma-approve if the patient has tried one systemic regimen. GIST-approve if the patient has tried two of the following-imatinib, Ayvakit, sunitinib, dasatinib, Stivarga or Qinlock. NSCLC-approve if the patient has RET rearrangement positive tumor. Neuroendocrine tumors- approve if (A and B): A) pt has locally advanced, unresectable, or metastatic disease, and B) meets (i or ii): i) patient has well-differentiated neuroendocrine tumors, or ii) patient has pancreatic or extra-pancreatic neuroendocrine tumors and the medication will be used as subsequent therapy. Adrenal gland tumor- approve if pt has locoregional unresectable or metastatic adrenocortical carcinoma.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



<b>PA Criteria</b>	<b>Criteria Details</b>
	Pheochromocytoma/paraganglioma- approve if pt has locally unresectable disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Non-Small Cell Lung Cancer, Gastrointestinal stromal tumors (GIST), Bone cancer, Endometrial carcinoma, Adrenal gland tumor, Pheochromocytoma/paraganglioma
<b>Part B Prerequisite</b>	No

Updated: 08/2025 Y0026\_205074\_C  
 EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.  
 EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# CALQUENCE

## Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	CLL and SLL-approve. Mantle Cell Lymphoma- approve if the patient meets (A or B): A) has tried at least one systemic regimen or is not a candidate for a systemic regimen (e.g., rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, bortezomib, or lenalidomide) or B) this medication is used in combination with rituximab. Marginal Zone Lymphoma-approve if patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide, or chlorambucil). Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen (e.g., Brukinsa [zanubrutinib capsules], Imbruvica [ibrutinib tablets and capsules], rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, fludarabine, or cladribine)
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Marginal zone lymphoma.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CAMZYOS

### Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial and continuation)
Prescriber Restrictions	Prescribed by a cardiologist (initial and continuation)
Coverage Duration	Initial-8 months, continuation- 1 year
Other Criteria	Obstructive hypertrophic cardiomyopathy, initial-Approve if the pt meets the following criteria (i, ii and iii): i.Pt meets both of the following (a and b): a)Pt has at least 1 symptom associated w/obstructive hypertrophic cardiomyopathy (Note: examples include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise), AND b)Pt has New York Heart Association Class II or III symptoms of heart failure (Note:Class II signifies mild symptoms with moderate physical activity and some exercise limitations whereas Class III denotes noticeable symptoms with minimal physical activity and patients are only comfortable at rest), AND ii.Pt has left ventricular hypertrophy and meets 1 of the following (a or b): a)Pt has maximal left ventricular wall thickness greater than or equal to 15 mm, OR b)Pt has familial hypertrophic cardiomyopathy with a maximal left ventricular wall thickness greater than or equal to 13 mm, AND iii.Pt has a peak left ventricular outflow tract gradient greater than or equal to 50 mmHg (at rest or after provocation [Valsalva maneuver or post exercise]). Cont-Approve if pt meets ALL of the following criteria (i, ii, iii and iv): i.Pt has been established on therapy for at least 8 months (Note: pt who has received less

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>than 8 months of therapy or who is restarting therapy is reviewed under initial therapy), AND ii. Pt meets both of the following (a and b):</p> <p>a) Currently or prior to starting therapy, pt has or has experienced at least 1 symptom associated with obstructive hypertrophic cardiomyopathy, AND</p> <p>b) Currently or prior to starting therapy, pt is in or was in New York Heart Association Class II or III heart failure, AND</p> <p>iii. Pt has a current left ventricular ejection fraction of greater than or equal to 50 percent, AND</p> <p>iv. Pt meets at least 1 of the following (a or b):</p> <p>a) Pt experienced a beneficial clinical response when assessed by at least 1 objective measure (Note: Examples include improved peak oxygen consumption/mixed venous oxygen tension, decreases in left ventricular outflow tract gradient, reductions in N-terminal pro-B-type natriuretic peptide levels, decreased high-sensitivity cardiac troponin I levels, reduced ventricular mass index, and/or a reduction in maximum left atrial volume index), OR</p> <p>b) Pt experienced stabilization or improvement in at least 1 symptom related to obstructive hypertrophic cardiomyopathy (Note: Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, ability to perform physical exercise, and/or favorable changes in the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) Clinical Summary Score (CSS) or Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath domain scores.)</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CAPRELSA

---

### Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	MTC - approve. DTC - approve if refractory to radioactive iodine therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CARGLUMIC ACID

### Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases
<b>Coverage Duration</b>	NAGS-Pt meets criteria no genetic test - 3mo. Pt had genetic test - 12mo, other-approve 7 days
<b>Other Criteria</b>	N-Acetylglutamate synthase deficiency with hyperammonemia-Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia or Methylmalonic Acidemia with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater than or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (generic carglumic acid)
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CAYSTON

---

### Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist, infectious diseases specialist or a physician who specializes in the treatment of cystic fibrosis.
Coverage Duration	1 year
Other Criteria	Approve if the patient has <i>Pseudomonas aeruginosa</i> in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CEPROTIN

### Products Affected

- CEPROTIN (BLUE BAR)
- CEPROTIN (GREEN BAR)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Protein C Deficiency, Severe-approve if the patient meets the following criteria A, B and C: A) The diagnosis of protein C deficiency is confirmed by at least one of the following (i, ii, or iii): i. Plasma protein C activity below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR ii. Plasma protein C antigen below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR iii. Genetic testing demonstrating biallelic mutations in the PROC gene AND B) Acquired causes of protein C deficiency have been excluded AND C) Patient has a current or prior history of symptoms associated with severe protein C deficiency (e.g., purpura fulminans, thromboembolism).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CHEMET

---

### Products Affected

- CHEMET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Blood lead level
<b>Age Restrictions</b>	Approve in patients between the age of 12 months and 18 years
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist)
<b>Coverage Duration</b>	Approve for 2 months
<b>Other Criteria</b>	Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CIBINQO

### Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD). Concurrent use with an Anti-Interleukin Monoclonal Antibody. Concurrent use with other Janus Kinase Inhibitors. Concurrent use with a biologic immunomodulator. Concurrent use with other potent immunosuppressants.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	AD-12 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	Atopic Dermatitis-prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
<b>Coverage Duration</b>	Initial-Atopic Dermatitis-3 months, Continuation-1 year
<b>Other Criteria</b>	Atopic Dermatitis, initial-approve if the patient has had a 4-month trial of at least one systemic therapy OR patient has tried at least one systemic therapy but was unable to tolerate a 4-month trial. Note: Examples of systemic therapies include Dupixent (dupilumab subcutaneous injection) or Adbry (tralokinumab-ldrm subcutaneous injection). Methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil also count towards a trial of one systemic therapy. Continuation-Approve if the patient has been receiving Cibinqo for at least 90 days AND patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Cibinqo) in at least one of the following: estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, and/or a decreased requirement for other topical or systemic therapies for atopic dermatitis AND compared with baseline (prior to receiving Cibinqo), patient experienced an improvement in at least one symptom, such as decreased itching. Note: A patient who has received less

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	than 3 months of therapy or who is restarting therapy with Cibinqo should be considered under initial therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CIMERLI

---

### Products Affected

- CIMERLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Retinopathy of prematurity
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CIMZIA

### Products Affected

- CIMZIA POWDER FOR RECONST
- CIMZIA STARTER KIT
- CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried
<b>Age Restrictions</b>	18 years and older for CD and PP (initial therapy). 2 years and older for JIA (initial therapy).
<b>Prescriber Restrictions</b>	All dx initial therapy only. RA, AS, JIA, prescribed by or in consultation with a rheumatologist. Crohn's disease, prescribed by or in consultation with a gastroenterologist. PsA prescribed by or in consultation with a rheumatologist or dermatologist. PP, prescribed by or in consultation with a dermatologist. nr-axSpA-prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	AS initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Xeljanz/XR, Cosentyx. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. PsA initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Cosentyx, Tremfya, a preferred ustekinumab product, Otezla, Orencia, Rinvoq, Skyrizi or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab/ustekinumab product will also count. RA initial tx, approve if the patient has tried two of the following drugs in the past: Enbrel, a preferred adalimumab product, Orencia, Rinvoq or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>trial of another non-preferred adalimumab product will also count. CD initial tx, approve if patient has previously tried ONE of the following drugs in the past: a preferred adalimumab product, a preferred infliximab product, a preferred ustekinumab product, Skyrizi, Rinvoq, or Tremfya. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab/infliximab/ustekinumab product will also count. Plaque Psoriasis (PP), initial tx-approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Skyrizi, a preferred ustekinumab product, Otezla, Cosentyx, Tremfya, Sotyktu. A trial of a non-preferred adalimumab/ustekinumab also counts. JIA initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, Orencia, Rinvoq/LQ, Xeljanz, a preferred adalimumab product. Note pt does not meet this requirement, a trial with a non-preferred adalimumab, Simponi Aria, tocilizumab, Kevzara, or infliximab will also count. Cont tx, AS/PsA/RA/CD/PP/JIA - approve if the pt had a response as determined by the prescriber. Non-radiographic axial spondylitis (nr-axSpA), initial tx-approve if the patient has objective signs of inflammation, defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroilitis reported on MRI. nr-axSpA continuation tx-approve if the patient has had a response as determined by the prescriber. Please Note: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma. Preferred infliximab products include Remicade, Zymfentra. Preferred ustekinumab products include Stelara, Selarsdi, Yesintek.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CINACALCET

### Products Affected

- cinacalcet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Hypercalcemia d/t parathyroid CA-prescr/consult w/onco or endo. Hypercalcemia w/primary hyperparathyroidism-prescr/consult w/nephro or endo. Hyperparathyroidism in post-renal transplant-prescr/consult w/transplant physician/nephro/endo.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Hypercalcemia due to parathyroid carcinoma-approve. Hypercalcemia in patients with primary hyperparathyroidism-approve if the patient has failed or is unable to undergo a parathyroidectomy due to a contraindication. Secondary Hyperparathyroidism in patients with chronic kidney disease on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundles payment benefit). Hyperparathyroidism in Post-Renal Transplant Patients-approve if the baseline (prior to starting cinacalcet therapy) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	hyperparathyroidism in post-renal transplant patients
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# CLOBAZAM

## Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications tried
Age Restrictions	2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Lennox-Gastaut Syndrome, initial therapy-patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex or valproic acid. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Dravet Syndrome and treatment-refractory seizures/epilepsy
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CLOMIPHENE

### Products Affected

- *clomid*
- *clomiphene citrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Use in patients for infertility
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Woman (a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Male hypogonadism
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## COLUMVI

### Products Affected

- COLUMVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	<p>Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma-approve if the patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: Examples of diffuse large B-cell lymphoma (DLBCL) include DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from indolent lymphoma. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) +/- rituximab. Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma-approve if the patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL. Note:</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Post-transplant lymphoproliferative disorders- approve if the patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzumab intravenous infusion before the first dose of Columvi. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma.Post-transplant lymphoproliferative disorders.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## COMETRIQ

### Products Affected

- COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY), 140

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	MTC - approve. Non-Small Cell Lung Cancer with RET Gene Rearrangements - approve. Differentiated (i.e., papillary, follicular, and oncocyctic) Thyroid Carcinoma-approve if the patient's carcinoma is refractory to radioactive iodine therapy and patient has tried a Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-Small Cell Lung Cancer with RET Gene Rearrangements, Differentiated (i.e., papillary, follicular, and oncocyctic) Thyroid Carcinoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## COPIKTRA

### Products Affected

- COPIKTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma - approve if the patient has tried one systemic regimen (e.g., Imbruvica (ibrutinib capsules, tablets and oral solution), Venclexta (venetoclax tablets), rituximab, Gazyva (obinutuzumab intravenous infusion), chlorambucil, fludarabine, cyclophosphamide, bendamustine, high-dose methylprednisolone, Campath (alemtuzumab intravenous infusion), Calquence (acalabrutinib capsules), Brukinsa (zanubrutinib capsules), or Arzerra (ofatumumab intravenous infusion). T-cell lymphoma- For peripheral T-cell lymphoma, approve. For breast implant-associated anaplastic large cell lymphoma, or hepatosplenic T-cell lymphoma, approve if the patient has relapsed or refractory disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	T-cell Lymphoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## COSENTYX

### Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis and previous medications use
<b>Age Restrictions</b>	PP-6 yr and older.AS/Spondy/HS initial - 18 years of age and older. PsA-2 years and older. Enthesitis-4 years and older
<b>Prescriber Restrictions</b>	PP initial-presc/consult derm. PsA initial - prescribed by or in consultation with a dermatologist or rheumatologist. AS/spondylo/enthesitis initial- by or in consultation with rheumatologist. HS initial - by or in consult w/ dermatologist
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: HIDRADENITIS SUPPURATIVA (HS): tried at least one other therapy (e.g. systemic antibiotics, isotretinoin). NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: objective signs of inflammation and meets a or b: a) C-reactive protein elevated beyond the upper limit of normal or b) sacroiliitis reported on MRI. PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of at least one biologic that is not Cosentyx or a Cosentyx biosimilar also counts) or B) contraindication to MTX. CONTINUATION THERAPY: ALL INDICATIONS: patient has experienced benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## COSENTYX IV

### Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	PsA initial - Prescribed by or in consultation with a dermatologist or rheumatologist. AS/Non-radio Axial Spondy-Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	Non-Radiographic Axial Spondyloarthritis, initial therapy- approve if pt has objective signs of inflammation defined as (a or b): a) C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or b) sacroiliitis reported on magnetic resonance imaging. For continuation of therapy for all covered indications - approve if the pt has benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## COTELLIC

### Products Affected

- COTELLIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Melanoma (unresectable, advanced or metastatic) - being prescribed in combination with Zelboraf AND patient has BRAF V600 mutation positive disease. CNS Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma/neuroglioma/glioneuronal tumor OR ii. Recurrent or progressive disease for one of the following conditions (a or b): a) glioma/circumscribed glioma OR b) Glioblastoma, OR iii. Melanoma with brain metastases AND medication will be taken in combination with Zelboraf (vemurafenib tablets). Histiocytic Neoplasm-approve if the patient meets one of the following (i, ii, or iii): i. Patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR ii. Patient has Erdheim Chester disease OR iii. Patient has Rosai-Dorfman disease.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	Central Nervous System Cancer
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CRESEMBA (ORAL)

---

### Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Candidiasis of the esophagus - HIV infection, sepsis
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CRYSVITA

### Products Affected

- CRYSVITA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Chronic Kidney Disease (CKD), Severe Renal Impairment or End Stage Renal Disease
<b>Required Medical Information</b>	Diagnosis, lab values
<b>Age Restrictions</b>	TIO-2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or nephrologist (initial therapy)
<b>Coverage Duration</b>	XLH-1 year (initial/cont), TIO-initial-6 months, cont-1 year
<b>Other Criteria</b>	<p>XLH-Initial therapy-Approve if the patient has had a baseline (prior to any XLH treatment serum phosphorus level that was below the normal range for age and patient meets ONE of the following (a or b): a) The patient has had a baseline (i.e., prior to any XLH treatment tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender OR b) The patient has had a genetic test confirming the diagnosis of X-linked hypophosphatemia via identification of a PHEX pathogenic variant AND if the patient is greater than or equal to 18 years of age, the patient is currently exhibiting one or more signs or symptoms of XLH. Continuation-approve if the patient is continuing to derive benefit as determined by the prescribing physician.</p> <p>TIO-approve if the patient has a mesenchymal tumor that cannot be curatively resected or identified/localized AND the patient is currently exhibiting one or more signs or symptoms of TIO AND patient has had a baseline (prior to any TIO treatment) serum phosphorus level that was below the normal range for age AND patient has had a baseline (prior to any TIO treatment) tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	age and gender. Cont-approve if the patient is continuing to derive benefit as determined by the prescribing physician.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## CYSTEAMINE (OPHTHALMIC)

---

### Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases
Coverage Duration	1 year
Other Criteria	Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## CYSTEAMINE (ORAL)

### Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Cystagon and Procysbi
Required Medical Information	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	1 year
Other Criteria	Cystinosis, nephropathic-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming a mutation of the CTNS gene OR white blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DALFAMPRIDINE

---

### Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older (initial and continuation therapy)
<b>Prescriber Restrictions</b>	MS. If prescribed by, or in consultation with, a neurologist or MS specialist (initial and continuation).
<b>Coverage Duration</b>	Initial-4months, Continuation-1 year
<b>Other Criteria</b>	Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DANZITEN

### Products Affected

- DANZITEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	ALL - 15 years and older, GIST/Myeloid/lymphoid neoplasms/melanoma, cutaneous-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CML- approve if BCR::ABL1-mutation positive or Philadelphia chromosome positive. ALL-Philadelphia chromosome positive. Pigmented villonodular synovitis/tenosynovial giant cell tumor-patient has tried Turalio or Romvimza or cannot take Turalio or Romvimza. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. For melanoma, cutaneous - approve if the patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Acute lymphoblastic leukemia, Pigmented villonodular synovitis/Tenosynovial giant cell tumor, GIST, cutaneous melanoma and myeloid/lymphoid neoplasms with eosinophilia

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# DATROWAY

## Products Affected

- DATROWAY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. BREAST CANCER - All of (A, B, C, D and E): A) Unresectable or metastatic disease, AND B) Hormone receptor (HR)-positive disease, AND C) Human epidermal growth factor receptor 2 (HER2)- negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH]-negative) disease, AND D) Patient has received prior endocrine-based therapy, Note: Examples of endocrine therapy are tamoxifen, anastrozole, letrozole, exemestane, AND E) Patient has received prior chemotherapy for unresectable or metastatic disease. Note: Examples are paclitaxel, doxorubicin, liposomal doxorubicin, gemcitabine, capecitabine, vinorelbine, Halaven (eribulin intravenous infusion), cyclophosphamide, docetaxel.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DAURISMO

---

### Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medications that will be used in combination, comorbidities
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML - approve if Daurismo will be used in combination with cytarabine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DEFERASIROX

### Products Affected

- *deferasirox*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Transfusion-related chronic iron overload, initial therapy - approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy - approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DEFERIPRONE

---

### Products Affected

- *deferiprone*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias Initial therapy - approve. Continuation therapy - approve is the patient is benefiting from therapy as confirmed by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DIABETIC SUPPLY - ALCOHOL PADS

---

### Products Affected

- *alcohol pads*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DIABETIC SUPPLY - GAUZE PADS

---

### Products Affected

- GAUZE PADS 2 X 2

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DIABETIC SUPPLY - NEEDLES

---

### Products Affected

- NOVO PEN NEEDLE
- EMBECTA PEN NEEDLE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DIABETIC SUPPLY - SYRINGES

---

### Products Affected

- EMBECTA INSULIN SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## DIACOMIT

---

### Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of diagnosis.
Age Restrictions	6 months and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Dravet Syndrome-Initial therapy-approve if the patient is concomitantly receiving clobazam or is unable to take clobazam due to adverse events. Dravet Syndrome-Continuation-approve if the patient is responding to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DIMETHYL FUMARATE

---

### Products Affected

- *dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DOPTelet

### Products Affected

- DOPTelet (10 TAB PACK)
- DOPTelet (15 TAB PACK)
- DOPTelet (30 TAB PACK)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (for chronic ITP-initial therapy only)
<b>Prescriber Restrictions</b>	Chronic ITP-prescribed by or after consultation with a hematologist (initial therapy)
<b>Coverage Duration</b>	Thrombo w/chronic liver disease-5 days, chronic ITP initial-3 months, cont-1 year
<b>Other Criteria</b>	THROMBOCYTOPENIA WITH CHRONIC LIVER DISEASE (A and B): A) current platelet count less than 50 x 10 <sup>9</sup> /L and B) scheduled to undergo a procedure within 10 to 13 days after starting Doptelet therapy. CHRONIC ITP, INITIAL THERAPY (A and B): A): (i or ii): i) platelet count less than 30,000 microliters or ii) platelet count less than 50,000 microliters and patient is at an increased risk of bleeding, and B) tried one other therapy (e.g., systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, eltrombopag tablets and oral suspension, romiplostim subcutaneous injection, fostamatinib tablets, rituximab) or had a splenectomy. CHRONIC ITP, CONTINUATION THERAPY: patient had beneficial clinical response and remains at risk for bleeding complications.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DROXIDOPA

### Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Medication history (as described in Other Criteria field)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a neurologist
Coverage Duration	12 months
Other Criteria	NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DUAL OREXIN RECEPTOR ANTAGONIST

---

### Products Affected

- BELSOMRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Treatment of insomnia, characterized by difficulties with sleep onset and /or sleep maintenance-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## DUPIXENT

### Products Affected

- DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML
- DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Xolair or another Anti-interleukin (IL) Monoclonal Antibody (i.e., Adbry, Cinqair, Fasenra, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical].
<b>Required Medical Information</b>	Diagnosis, prescriber specialty, other medications tried and length of trials. COPD INITIAL: meets (all of A, B, and C): A) blood eosinophil at least 300 cells per microliter within previous 6 weeks or prior to Dupixent or another monoclonal antibody, and B) received at least 3 months of combination therapy with at least two of LAMA, LABA or ICS, and C) meets (i or ii): i) two or more COPD exacerbations in previous 12 months requiring systemic CS or antibiotics or ii) COPD exacerbation requiring hospitalization in previous 12 months. COPD CONTINUATION (all of A, B and C): A) received Dupixent for at least 6 months and B) continues LABA and LAMA, and C) beneficial response (e.g. reduced symptoms, exacerbations, hospitalizations, ED/urgent care visits, improved lung function). CSU INITIAL: urticaria for greater than 6 weeks (prior to Dupixent), with symptoms at least 3 days/week despite daily non-sedating H1 antihistamine tx. CSU CONTINUATION (A and B): A) received at least 6 months of Dupixent and B) experienced a beneficial clinical response, defined by decreased itch severity, decreased number of hives or decreased size of hives.
<b>Age Restrictions</b>	Initial therapy only: AD-6 months and older, asthma-6 years of age and older, Esophagitis-1 yr and older, Chronic Rhinosinusitis/CSU- 12 and older, Prurigo nodularis/COPD-18 and older
<b>Prescriber Restrictions</b>	Initial therapy only: Atopic Dermatitis/prurigo nodularis/CSU-Prescribed by or in consultation with an allergist, immunologist or dermatologist, asthma-prescribed by or in consultation with an allergist, immunologist or pulmonologist. Rhinosinusitis-prescribed by or in consultation with an allergist, immunologist or otolaryngologist. Esophagitis-presc/consult-

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	allergist or gastro. COPD-prescribed by or in consultation with an allergist, immunologist, or pulmonologist
<b>Coverage Duration</b>	Pending CMS Review
<b>Other Criteria</b>	<p>INITIAL CRITERIA: AD: tried at least 1 medium to super-high-potency topical corticosteroid (CS), unless topical CS therapy not advisable or pt is less than 2 years old. ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks or within 6 weeks prior to Dupixent or another monoclonal antibody or has oral CS-dependent asthma, B) used an ICS in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (one of a, b, c, d, or e): a) two or more asthma exacerbations requiring oral CS in the past year, b) one or more asthma exacerbations requiring hospital/urgent care/ED visit in the past year, c) FEV1 less than 80 percent predicted (adults only), d) FEV1/FVC less than 0.8, or e) worsened asthma with oral CS taper. CRSwNP (all of A, B, C and D): A) concurrent use with nasal CS, B) presence of at least two of the following symptoms for 6 months: nasal congestion, nasal obstruction, nasal discharge, reduction/loss of smell, C) received oral CS at least 5 days in last 2 years (unless contraindicated) or patient had prior surgery for nasal polyps, and D) diagnosis confirmed by direct exam, endoscopy, or sinus CT. EoE (all of A, B, C, and D): A) weighs 15 kg or more, B) endoscopic biopsy demonstrating greater than or equal to 15 intraepithelial eosinophils per high-power field, C) does not have a secondary cause of EoE, and D) received an Rx-strength PPI for at least 8 weeks. PRURIGO NODULARIS: approve if pt has pruritus lasting at least 6 weeks.</p> <p>CONTINUATION CRITERIA: AD: responding positively to therapy. ASTHMA: responding positively to therapy and concurrent use with ICS. CRSwNP (all of A, B, and C): A) received Dupixent for at least 6 months, B) responding positively to therapy, and C) concurrent use with intranasal CS. EoE (A and B): A) received Dupixent for at least 6 months and B) reduction in intraepithelial eosinophil count, decreased dysphagia/pain upon swallowing, or reduced frequency/severity of food impaction. PRURIGO NODULARIS (A and B): A) received Dupixent for at least 6 months and B) reduction in nodular lesion count, pruritis, or nodular lesion size.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ELAHERE

---

### Products Affected

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-approve if the patient meets (A and B): A) Patient has folate receptor alpha positive disease and either (1 or 2): 1) greater than or equal to 75% folate receptor alpha positive tumor cells or 2) patient is using this medication in combination with bevacizumab, AND B) Patient has platinum-resistant disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ELAPRASE

---

### Products Affected

- ELAPRASE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum or plasma OR a molecular genetic test demonstrating iduronate-2-sulfatase gene variant.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ELREXFIO

---

### Products Affected

- ELREXFIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EMGALITY

---

### Products Affected

- EMGALITY PEN
- EMGALITY SUBCUTANEOUS SYRINGE 120 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination therapy with another cGRP inhibitor for migraine headache prevention
<b>Required Medical Information</b>	Diagnosis, number of migraine or cluster headaches per month
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Pending CMS Review
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ENBREL

### Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with biologic therapy or targeted synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried.
<b>Age Restrictions</b>	PP-4 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Initial only-RA/AS/JIA/JRA,prescribed by or in consult w/ rheumatologist. Psoriatic arthritis, prescribed by or in consultation w/ rheumatologist or dermatologist.Plaque psoriasis (PP), prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center.Behcet's disease,prescribed by or in consult w/ rheumatologist,dermatologist,ophthalmologist,gastroenterologist,or neurologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA): tried one conventional synthetic DMARD for at least 3 months (see Note 1). JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA (one of A, B, C, or D): A) patient has aggressive disease, B) tried one other systemic therapy (e.g., methotrexate [MTX], sulfasalazine, leflunomide, NSAID, or a biologic that is not a biosimilar of the requested product), C) patient will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide, or D) patient has an absolute contraindication to MTX, sulfasalazine, or leflunomide. PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent for at least 3 months, unless intolerant (e.g., MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA) [see Note 1] or B)

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	patient has a contraindication to one oral agent for psoriasis such as MTX. GRAFT VERSUS HOST DISEASE (GVHD): approve. BEHCET'S: tried at least one conventional therapy (e.g., systemic corticosteroid, immunosuppressant, interferon alfa, mycophenolate), adalimumab, or infliximab. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Note 1: a biologic that is not a biosimilar of the requested product will also count.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Graft versus host disease (GVHD), Behcet's disease
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ENDARI

---

### Products Affected

- *glutamine (sickle cell)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prescriber specialty
<b>Age Restrictions</b>	Greater than or equal to 5 years of age
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a physician who specializes in sickle cell disease (e.g., a hematologist)
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ENTYVIO

### Products Affected

- ENTYVIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Biologics or with Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) used for an Inflammatory Condition
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	CD/UC - adults (initial therapy)
<b>Prescriber Restrictions</b>	CD/UC initial - Prescribed by or in consultation with a gastroenterologist. (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	CD Initial - the patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient OR the patient has tried one conventional systemic therapy for Crohn's disease (e.g., azathioprine, 6-mercaptopurine, or methotrexate) OR the patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas OR patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Note: an exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried a biologic. Cont tx - had a response to Entyvio, as determined by the prescribing physician. UC initial-the patient has had a trial of one systemic agent (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone). NOTE: A trial of a biologic (e.g., an adalimumab product [e.g., Humira], an infliximab product [e.g., Remicade, Inflectra, or Renflexis], or Simponi [golimumab for SC injection]) also counts as a trial of one systemic agent for UC. Cont tx - had a response to Entyvio (for

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	example, decreased stool frequency or rectal bleeding), as determined by the prescribing physician.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EPIDIOLEX

### Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies
<b>Age Restrictions</b>	Patients 1 year and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Dravet Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Tuberous Sclerosis Complex-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Continuation of therapy-approve if the patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EPKINLY

### Products Affected

- EPKINLY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma - approve if the patient has received one or more lines of systemic therapy. Classic follicular lymphoma - approve if pt has received two or more lines of systemic therapy and medication will be given as a single agent. Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma - approve if the patient has received one or more lines of systemic therapy. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL. Post-transplant lymphoproliferative disorders - approve if the patient has received one or more lines of systemic therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma. Post-transplant lymphoproliferative disorders.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EPOETIN ALFA

### Products Affected

- PROCRIT
- RETACRIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	MDS anemia = 18 years of age and older
<b>Prescriber Restrictions</b>	MDS anemia, myelofibrosis- prescribed by or in consultation with, a hematologist or oncologist.
<b>Coverage Duration</b>	Chemo-6m, Transfus-1m, CKD-1yr, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr
<b>Other Criteria</b>	Anemia in a pt with Chronic Kidney Disease (CKD) not on dialysis- for initial therapy, approve if hemoglobin (Hb) is less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children, or for continuation of therapy in a pt currently on an erythropoiesis-stimulating agent (ESA) approve if Hb is less than or equal to 12 g/dL. Anemia in a pt with cancer due to chemotherapy- approve if pt is currently receiving myelosuppressive chemo as a non-curative treatment and (for initial therapy) Hb is less than 10.0 g/dL or (if currently on ESA) Hb is less than or equal to 12.0 g/dL. Anemia in HIV with zidovudine- for initial therapy, approve if Hb is less than 10.0 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA, approve if Hb is 12.0 g/dL or less. Surgical pts to reduce RBC transfusions - Approve if Hb is less than or equal to 13, AND surgery is elective, nonvascular and non-cardiac AND pt is unwilling or unable to donate autologous blood prior to surgery. MDS- for initial therapy, approve if Hb is less than 10 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA approve if Hb is 12.0 g/dL or less. Myelofibrosis- for Initial therapy approve if patient has a Hb less than 10

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	or serum erythropoietin less than or equal to 500 mU/mL, or for continuation of therapy in pt currently on ESA hemoglobin is less than or equal to 12g/dL. Anemia in patients with chronic renal failure on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anemia due to myelodysplastic syndrome (MDS), Myelofibrosis
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ERIVEDGE

### Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	BCC (La or Met) - must not have had disease progression while on Odomzo.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Basal cell carcinoma, locally advanced-approve. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has medulloblastoma, the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway. Basal cell carcinoma, metastatic (this includes primary or recurrent nodal metastases and distant metastases)-approve. Diffuse Basal Cell Carcinoma Formation, including basal cell nevus syndrome (Gorlin syndrome) or other genetic forms of multiple basal cell carcinoma - approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Central nervous System Cancer, diffuse basal cell carcinoma formation
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ERLEADA

### Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) analog [for example: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets)] or if the patient has had a bilateral orchiectomy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ERLOTINIB

### Products Affected

- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Advanced or Metastatic NSCLC, approve if the patient has EGFR mutation positive non-small cell lung cancer as detected by an approved test. Note-Examples of EGFR mutation-positive non-small cell lung cancer include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. RCC, approve if the patient has recurrent or advanced non-clear cell histology RCC or if the patient had hereditary leiomyomatosis and renal cell carcinoma and erlotinib will be used in combination with bevacizumab. Bone cancer-approve if the patient has chordoma and has tried at least one previous therapy. Pancreatic cancer-approve if the medication is used in combination with gemcitabine and if the patient has locally advanced, metastatic or recurrent disease. Vulvar cancer-approve if the patient has advanced, recurrent or metastatic disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Renal Cell Carcinoma, vulvar cancer and Bone Cancer-Chordoma.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EVEROLIMUS

### Products Affected

- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- *torpenz*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Breast Cancer-HER2 status, hormone receptor (HR) status.
<b>Age Restrictions</b>	All dx except TSC associated SEGA, renal angiomyolipoma or partial onset seizures-18 years and older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Breast Cancer-approve if pt meets ALL the following (A, B, C, D, E, and F):A)pt has recurrent or metastatic,HR+ disease AND B)pt has HER2-negative breast cancer AND C)pt has tried at least 1 prior endocrine therapy AND D)pt meets 1 of the following conditions (i or ii):i.pt is a postmenopausal woman or man OR ii.pt is pre/perimenopausal woman AND is receiving ovarian suppression/ablation with a GnRH agonist, or has had surgical bilateral oophorectomy or ovarian irradiation AND E)pt meets 1 of the following conditions (i or ii): i.Everolimus will be used in combo with exemestane and pt meets 1 of the following:pt is male and is receiving a GnRH analog or pt is a woman or ii. Everolimus will be used in combo with fulvestrant or tamoxifen AND F)pt has not had disease progression while on Everolimus. RCC, relapsed or Stage IV disease-approve if using for non-clear cell disease or if using for clear cell disease, pt has tried 1 prior systemic therapy (e.g., Inlyta, Votrient, Sutent, Cabometyx, Nexavar).TSC Associated SEGA-approve if pt requires therapeutic intervention but cannot be curatively resected. Thymomas and

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>Thymic Carcinomas-approve if pt has tried chemotherapy or cannot tolerate chemotherapy. TSC associated renal angiomyolipoma -approve. WM/LPL - approve if pt has progressive or relapsed disease or if pt has not responded to primary therapy. Thyroid Carcinoma, differentiated-approve if pt is refractory to radioactive iodine therapy. Endometrial Carcinoma-approve if everolimus will be used in combo with letrozole. GIST-approve if pt has tried 2 of the following drugs: Sutent, Sprycel, Stivarga, Ayvakit, Qinlock or imatinib AND there is confirmation that everolimus will be used in combo with 1 of these drugs (Sutent, Stivarga, or imatinib) in the treatment of GIST. TSC-associated partial-onset seizures-approve. NET tumors of the pancreas, GI Tract, Lung and Thymus (carcinoid tumors)-approve. Soft tissue sarcoma-approve if pt has perivascular epitheloid cell tumors (PE Coma) or recurrent angiomyolipoma/lymphangiomyomatosis. Classic hodgkin lymphoma-approve if pt has relapsed or refractory disease AND has tried at least three prior lines of chemotherapy. Histiocytic neoplasm-approve if pt has Erdheim-Chester disease or, Rosai-Dorfman disease or Langerhans cell histiocytosis. Patient must also have PIK3CA mutation. Meningioma-approve if pt has recurrent or progressive disease AND pt has surgically inaccessible disease and radiation therapy is not possible AND medication will be used in combination with a somatostatin analogue. Uterine Sarcoma-approve if the patient has advanced, recurrent, metastatic, or inoperable disease, AND has a perivascular epithelioid cell tumor (PEComa), AND has tried at least one systemic regimen. Note: Examples of systemic regimen include doxorubicin, docetaxel, gemcitabine, ifosfamide, dacarbazine.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	<p>neuroendocrine tumors of the thymus (Carcinoid tumors). Soft tissue sarcoma, classical Hodgkin lymphoma, Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Thymomas and Thymic carcinomas, Differentiated Thyroid Carcinoma, Endometrial Carcinoma, Gastrointestinal Stromal Tumors (GIST), men with breast cancer, Pre-peri-menopausal women with breast cancer, Histiocytic Neoplasm, uterine sarcoma, meningioma</p>
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## EYLEA

---

### Products Affected

- EYLEA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FABRAZYME

---

### Products Affected

- FABRAZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Galafold (migalastat oral capsules) or Elfabrio (pegunigalsidase alfa intravenous infusion).
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient alpha-galactosidase A activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating a pathogenic variant in the galactosidase alpha (GLA) gene.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FASENRA

### Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Asthma: 6 years of age and older, EGPA: 18 years and older
<b>Prescriber Restrictions</b>	Asthma: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA: Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist
<b>Coverage Duration</b>	Asthma: 6 months initial, 12 months continuation. EGPA: 8 months initial, 12 months continuation.
<b>Other Criteria</b>	INITIAL THERAPY: ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks or within 6 weeks prior to Fasenra or another monoclonal antibody, B) used an inhaled corticosteroid (ICS) in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (a, b, c, d, or e): a) one or more exacerbations requiring a systemic CS in the past year, b) one or more exacerbations requiring hospital/urgent care/emergency department visit in the past year, c) FEV1 less than 80 percent predicted or less than 90 percent predicted for patients less than 18, d) FEV1/FVC less than 0.80, or e) worsened asthma with systemic CS taper. EGPA: (all of A, B, and C): A) active disease, and B) currently on systemic CS for at least 4 weeks, and C) blood eosinophil greater than or equal to 150 cells per microliter within previous 4 weeks or prior to treatment with any monoclonal antibody that may alter eosinophil levels. CONTINUATION THERAPY: ASTHMA (A and B): A) patient

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	has responded to therapy (e.g., decrease in any of the following: asthma exacerbations, asthma symptoms, hospitalizations, emergency department/urgent care visits, physician visits, requirement for oral corticosteroid therapy) and B) continues to receive therapy with an ICS. EGPA: patient has responded to therapy (e.g. reduced rate of relapse, CS dose reduction, reduced eosinophil levels).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FINGOLIMOD

---

### Products Affected

- *fingolimod*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of fingolimod with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	10 years and older
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FINTEPLA

---

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Dravet Syndrome-Initial therapy-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or patient has tried or is concomitantly receiving Epidiolex, Clobazam or Diacomit. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. Lennox-Gastaut Syndrome, initial-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Lennox-Gastaut Syndrome, continuation-approve if the patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FIRMAGON

---

### Products Affected

- FIRMAGON KIT W DILUENT  
SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Patients new to therapy, are required to try Eligard or Orgovyx prior to approval of Firmagon.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## FOTIVDA

### Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Renal Cell Carcinoma (RCC)-approve if the patient has relapsed or Stage IV disease and has tried at least two other systemic regimens. Note: Examples of systemic regimens for renal cell carcinoma include axitinib tablets, axitinib + pembrolizumab injection, cabozantinib tablets, cabozantinib + nivolumab injection, sunitinib malate capsules, pazopanib tablets, sorafenib tablets, and lenvatinib capsules + everolimus.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FRUZAQLA

### Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Colon cancer, rectal cancer, or appendiceal cancer-Approve if the patient meets the following (A and B): A.Patient has advanced or metastatic disease, AND B.Patient has previously been treated with the following (i, ii, and iii): i.Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, Note: Examples of fluoropyrimidine agents include 5-fluorouracil (5-FU) and capecitabine. AND ii.An anti-vascular endothelial growth factor (VEGF) agent, Note: Examples of anti-VEGF agents include bevacizumab. AND iii. If the tumor is RAS wild-type (KRAS wild-type and NRAS wild-type) [that is, the tumor or metastases are KRAS and NRAS mutation negative], the patient meets ONE of the following (a or b): a.According to the prescriber, anti-epidermal growth factor receptor (EGFR) therapy is NOT medically appropriate, OR b. The patient has received an anti-EGFR therapy. Note: Examples of anti-EGFR therapy includes Erbitux (cetuximab intravenous infusion) and Vectibix (panitumumab intravenous infusion).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Appendiceal cancer
<b>Part B Prerequisite</b>	No

## FULPHILA

### Products Affected

- FULPHILA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC - prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
<b>Coverage Duration</b>	Cancer pts receiving chemo-6 mo. PBPC-30 days.
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, or 3) patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Patients undergoing PBPC collection and therapy
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## FYARRO

---

### Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Perivascular Epithelioid Cell Tumor (PEComa), Malignant-approve if the patient has locally advanced unresectable disease or metastatic disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## GATTEX

### Products Affected

- GATTEX 30-VIAL
- GATTEX ONE-VIAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 year and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced improvement.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## GAVRETO

### Products Affected

- GAVRETO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	NSCLC-18 years and older, thyroid cancer-12 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	NSCLC-approve if the patient has advanced, recurrent, or metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an Food and Drug Administration (FDA) approved test.Differentiated Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has RET fusion-positive or RET-mutation-positive disease AND disease requires treatment with systemic therapy AND the disease is radioactive iodine-refractory. Anaplastic thyroid cancer or Medullary Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has RET fusion-positive or RET-mutation-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Medullary Thyroid Cancer, Anaplastic Thyroid Cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## GEFITINIB

### Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced or metastatic disease and the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	NSCLC with EGFR L861Q, G719X, or S768I mutations.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# GILOTRIF

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For NSCLC - EGFR exon deletions or mutations, or if NSCLC is squamous cell type
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	NSCLC EGFR pos - For the treatment of advanced or metastatic non small cell lung cancer (NSCLC)-approve if the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: examples of sensitizing EGFR mutation-positive NSCLC include the following mutations : exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. NSCLC metastatic squamous cell must have disease progression after treatment with platinum based chemotherapy. Head and neck cancer-approve if the patient has non-nasopharyngeal head and neck cancer and the patient has disease progression on or after platinum based chemotherapy. (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan)
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Head and neck cancer
<b>Part B Prerequisite</b>	Yes

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## GLATIRAMER

### Products Affected

- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agent used for multiple sclerosis
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or after consultation with a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## GLUCAGON-LIKE PEPTIDE-1 AGONISTS

---

### Products Affected

- BYDUREON BCISE
- *exenatide subcutaneous pen injector 10 mcg/dose(250 mcg/ml) 2.4 ml, 5 mcg/dose (250 mcg/ml) 1.2 ml*
- MOUNJARO
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## GNRH AGONIST IMPLANTS

### Products Affected

- ZOLADEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Endometriosis-18 years and older
<b>Prescriber Restrictions</b>	Prostate cancer/Breast cancer/Head and Neck/Ovarian/Uterine-prescribed by or in consultation with an oncologist. Endometriosis/abnormal uterine bleeding-prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health.
<b>Coverage Duration</b>	Abnormal uterine bleeding-2 months, Endometriosis-6 months, all other dx-1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Abnormal uterine bleeding-Zoladex 3.6mg is used as an endometrial-thinning agent prior to endometrial ablation.Endometriosis-approve Zoladex 3.6 mg. Prostate cancer-approve Zoladex 3.6 mg and/or 10.8 mg. Head and Neck Cancer - Salivary Gland Tumors: approve if patient has recurrent, unresectable, or metastatic disease AND has androgen receptor-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Zoladex 3.6mg only: head and neck cancer - salivary gland tumors, Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, and Uterine Cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## GOMEKLI

### Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NEUROFIBROMATOSIS TYPE 1- patient has or had symptomatic plexiform neurofibromas prior to starting Gomekli and the tumor is not amenable to complete resection.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## GONADOTROPIN-RELEASING HORMONE AGONISTS - ONCOLOGY

### Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- *leuprolide subcutaneous kit*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prostate cancer- prescribed by or in consultation with an oncologist or urologist. Head and neck-salivary gland tumors- prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer- salivary gland tumors (Eligard only)
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## GRALISE/HORIZANT/LYRICA CR

---

### Products Affected

- *gabapentin oral tablet extended release 24 hr 300 mg, 600 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

**Products Affected**

- OMNITROPE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are less than 10ng/mL OR had at least 1 GH test and results are less than 10ng/mL and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test less than 10ng/mL or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test less than 10ng/mL OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has multiple pituitary deficiencies and pt has 3 or more pituitary hormone deficiencies or pt has had one GH test less than 10ng/mL 5.pt had a hypophysectomy. Cont-pt responding to therapy
<b>Age Restrictions</b>	ISS 5 y/o or older, SGA 2 y/o or older, SBS 18 y/o or older
<b>Prescriber Restrictions</b>	GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Noonan (initial), Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist.
<b>Coverage Duration</b>	ISS - 6 mos initial, 12 months cont tx, SBS 1 month, others 12 mos

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known perinatal insults, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, age and gender adjusted IGF1 below the lower limits of the normal reference range AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. Cont tx - prescriber confirms response to therapy. CKD initial - CKD defined by abnormal CrCl. Noonan initial - baseline height less than 5th percentile. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile for age/gender. SGA initial -baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational age/gender and didn't have sufficient catch up growth by 2-4 y/o). Cont tx - prescriber confirms response to therapy. Cont Tx for CKD, Noonan, PW in child/adoles, SHOX, and TS - prescriber confirms response to therapy. SBS initial pt receiving specialized nutritional</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	support. Cont tx - 2nd course if pt responded to tx with a decrease in the requirement for specialized nutritional support.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Short bowel syndrome
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## HIGH RISK MEDICATIONS - BENZODIAZEPINES

### Products Affected

- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*
- *diazepam injection*
- *diazepam intensol*
- *diazepam oral concentrate*
- *diazepam oral solution*
- *diazepam oral tablet*
- *lorazepam injection*
- *lorazepam intensol*
- *lorazepam oral concentrate*
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Procedure-related sedation = 1mo. All other conditions = 12 months.
<b>Other Criteria</b>	All medically accepted indications other than insomnia, approve if the physician has assessed risk versus benefit in using the High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. Insomnia, may approve lorazepam if the patient has had a trial with two of the following: ramelteon, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon and the physician has assessed risk versus benefit in using the HRM in this patient and has confirmed that he/she would still like initiate/continue therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

## HIGH RISK MEDICATIONS - BENZTROPINE

---

### Products Affected

- *benztropine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For all medically-accepted indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing benztropine for the patient and he/she would still like to initiate/continue therapy
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## HIGH RISK MEDICATIONS - CYCLOBENZAPRINE

---

### Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

### Products Affected

- *hydroxyzine hcl oral tablet*
- *promethazine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For hydroxyzine hydrochloride, authorize use without a previous drug trial for all FDA-approved indications other than anxiety. Approve hydroxyzine hydrochloride if the patient has tried at least two other FDA-approved products for the management of anxiety. Prior to approval of promethazine and hydroxyzine, approve if the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## HIGH RISK MEDICATIONS - PHENOBARBITAL

---

### Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for use in sedation/insomnia.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the treatment of seizures, approve only if the patient is currently taking phenobarbital.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## HIGH RISK MEDICATIONS- ESTROGENS

### Products Affected

- *dotti*
- *estradiol oral*
- *estradiol transdermal patch semiweekly*
- *estradiol transdermal patch weekly*
- *estradiol-norethindrone acet*
- *fyavolv*
- *jinteli*
- *lyllana*
- *mimvey*
- *norethindrone ac-eth estradiol oral tablet*  
0.5-2.5 mg-mcg, 1-5 mg-mcg

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Previous medication use
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months
<b>Other Criteria</b>	For the treatment of Vulvar Vaginal Atrophy, approve if the patient has had a trial of one of the following for vulvar vaginal atrophy (brand or generic): Estradiol Vaginal Cream, Imvexxy, Premarin Vaginal Cream or estradiol valerate injection. For prophylaxis of Postmenopausal Osteoporosis, approve if the patient has had a trial of one of the following (brand or generic): alendronate, ibandronate, risedronate or Raloxifene. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IBRANCE

### Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast cancer - approve recurrent or metastatic, hormone receptor positive (HR+) [i.e., estrogen receptor positive- (ER+) and/or progesterone receptor positive (PR+)] disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and Ibrance will be used in combination with anastrozole, exemestane, or letrozole 2, pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonists, or has had surgical bilateral oophorectomy, or ovarian irradiation AND meets one of the following conditions: Ibrance will be used in combination with anastrozole, exemestane, or letrozole or Ibrance will be used in combination with fulvestrant 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Ibrance with be used in combination with anastrozole, exemestane or letrozole or Ibrance will be used in combination with fulvestrant 4. Pt is postmenopausal and Ibrance will be used in combination with fulvestrant. Liposarcoma-approve if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS).

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Liposarcoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# ICATIBANT

## Products Affected

- *icatibant*
- *sajazir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] - Treatment of Acute Attacks, Initial Therapy-the patient has HAE type I or type II as confirmed by the following diagnostic criteria (i and ii): i. the patient has low levels of functional C1-INH protein (less than 50 percent of normal) at baseline, as defined by the laboratory reference values AND ii. the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values. Patients who have treated previous acute HAE attacks with icatibant - the patient has treated previous acute HAE type I or type II attacks with icatibant AND according to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ICLUSIG

### Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status
Age Restrictions	All indications except ALL - 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Acute lymphoblastic leukemia, Philadelphia chromosome positive or ABL-class translocation-approve. Chronic myeloid leukemia-approve. GIST - approve if the patient tried all of the following therapies first to align with NCCN recommendations which include: Imatinib or Ayvakit (avapritinib tablets), AND Sunitinib or Sprycel (dasatinib tablets), AND Stivarga (regorafenib tablets), AND Qinlock (ripretinib tablets). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has ABL1 rearrangement or FGFR1 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Gastrointestinal Stromal Tumor, Myeloid/Lymphoid Neoplasms with Eosinophilia
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IDHIFA

---

### Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	IDH2-mutation status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	AML - approve if the patient is IDH2-mutation status positive as detected by an approved test
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ILARIS

### Products Affected

- ILARIS (PF)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	When used in combination with concurrent biologic therapy (e.g.TNF antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or rilonacept.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	CAPS-4 years of age and older (initial). SJIA/HIDS/MKD/FMF/TRAPS-2 years of age and older (initial). Still's disease-18 years and older (initial) Note-patients less than 18 should be referred to criteria for systemic juvenile idiopathic arthritis. Acute gout flare-18 years of age and older
<b>Prescriber Restrictions</b>	CAPS initial- Prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist. SJIA/Still's disease (initial), Acute gout flare (initial/cont)- prescribed by or in consultation with a rheumatologist. FMF initial - rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, hematologist. HIDS/MKD/TRAPS initial - rheumatologist, nephrologist, geneticist, oncologist, hematologist.
<b>Coverage Duration</b>	Acute gout flare-6 mos, all other diagnoses-6 months initial, 1 year cont.
<b>Other Criteria</b>	For renewal of CAPS/SJIA/FMF/HIDS/MKD/TRAPS/Still's - After pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician. SJIA, initial therapy - approve if the pt has tried at least one other biologic for SJIA or started on Ilaris while in the hospital. Adult Onset Still's Disease-Initial-approve if the patient has tried at least one other biologic or started on Ilaris while in the hospital. Acute gout flare- approve if (i and ii): (i) pt has intolerance, contraindication, or lack of response to NSAIDs and colchicine for the treatment of acute gout flares OR pt is unable to be retreated with a repeat

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>course of corticosteroids (oral or injectable) for acute gout flare, and (ii) patient is receiving or will be taking concomitant urate lowering medication for prevention of gout unless contraindicated (ex: allopurinol, febuxostat, probenecid). FMF, initial-approve if pt has tried colchicine, unless contraindicated and will be taking Ilaris in combination with colchicine, unless colchicine is contraindicated or not tolerated, AND prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) pt has a history of at least one flare per month despite use of colchicine, OR was hospitalized for a severe flare. HIDS/MKD, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least three febrile acute flares within the previous 6-month period OR was hospitalized for a severe flare. TRAPS, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least six flares per year OR was hospitalized for a severe flare.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IMATINIB

### Products Affected

- *imatinib oral tablet 100 mg, 400 mg*
- IMKELDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported.
<b>Age Restrictions</b>	ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms/Kaposi Sarcoma/Cutaneous Melanoma-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For ALL-approve for Ph-positive or ABL-class translocation ALL. CML-approve for Ph-positive or BCR::ABL1-mutation positive CML. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or Romvimza or according to the prescriber, the patient cannot take Turalio or Romvimza. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Cutaneous melanoma-approve if the patient has an activating KIT mutation, metastatic or unresectable melanoma, and has tried at least one systemic regimen. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFR A or PDGFRB rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Chordoma, desmoid tumors (aggressive fibromatosis), cKit positive metastatic or unresectable cutaneous melanoma, Kaposi's Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia, GVHD, chronic.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IMBRUVICA

### Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- IMBRUVICA ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	GVHD-1 year and older, other-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CLL- Approve. GVHD-Approve if the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi [ruxolitinib tablets]). B-cell lymphoma-approve if the patient has tried at least one systemic regimen (e.g., cisplatin, cytarabine, rituximab, oxaliplatin, gemcitabine, ifosfamide, carboplatin, etoposide, or rituximab). Central nervous system Lymphoma (primary)- approve if the patient is not a candidate for or is intolerant to high-dose methotrexate OR has tried at least one therapy (e.g., methotrexate, rituximab, vincristine, procarbazine, cytarabine, thiotepea, carmustine, intrathecal methotrexate, cytarabine, or rituximab). Hairy Cell Leukemia - approve if the patient has tried at least two systemic regimens (cladribine, Nipent [pentostatin injection], rituximab, or Pegasys [peginterferon alfa-2a subcutaneous injection]).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	Central Nervous System Lymphoma (Primary), Hairy Cell Leukemia, B-Cell Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## IMDELLTRA

---

### Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. SMALL CELL LUNG CANCER-patient has relapsed or refractory extensive stage disease and has previously received platinum-based chemotherapy. Note: Examples of platinum medications include cisplatin and carboplatin.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IMJUDO

### Products Affected

- IMJUDO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	HCC, Esophageal/Esophagogastric Junction Ca, Gastric Ca-30 days, NSCLC-6 months
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. HCC-approve if the patient has unresectable or metastatic disease or the patient is not a surgical candidate, Imjudo will be used as first-line systemic therapy in combination with Imfinzi. Non-Small Cell Lung Cancer-Approve if the patient meets ALL of the following criteria (A, B, and C ): A) Patient has recurrent, advanced, or metastatic disease, AND B) Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion), AND C) Patient meets ONE of the following (i, ii, iii, or iv): i. Patient meets BOTH of the following (a and b): a) The tumor is negative for actionable molecular markers-Note: Examples of actionable molecular markers include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) genomic tumor aberrations, KRAS, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2), AND b) Imjudo is used as first-line therapy, OR ii. Patient meets both of the following (a and b): a) The tumor is positive for ONE of the following [(1), (2), or (3)]: (1) Epidermal growth factor receptor (EGFR) exon 20 mutation positive, OR (2) KRAS G12C mutation positive, OR (3) ERBB2 (HER2) mutation positive, AND b) Imjudo is used as first-line therapy, OR

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>iii. Patient meets BOTH of the following (a and b): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) BRAF V600E mutation positive, OR (2) NTRK1/2/3 gene fusion positive, OR (3) MET exon 14 skipping mutation positive, OR (4) RET rearrangement positive, AND b) Imjudo is used as first-line or subsequent therapy, OR iv. Patient meets ALL of the following (a, b, and c): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) EGFR exon 19 deletion or exon 21 L858R mutation positive, OR (2) EGFR S768I, L861Q, and/or G719X mutation positive, OR (3) ALK rearrangement positive, OR (4) ROS1 rearrangement, AND b) The patient has received targeted drug therapy for the specific mutation-Note: Examples of targeted drug therapy include Gilotrif (afatinib tablets), Tagrisso (osimertinib tablets), erlotinib, Iressa (gefitinib tablets), Xalkori (crizotinib capsules), Zykadia (ceritinib capsules), Alecensa (alectinib capsules), Alunbrig (brigatinib tablets), Lorbrena (lorlatinib tablets), Rozlytrek (entrectinib capsules), or Vizimpro (dacomitinib tablets), AND c) Imjudo is used as subsequent therapy. Esophageal and Esophagogastric Junction Cancers, Gastric Cancer-approve if pt has locoregional disease AND has microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease AND Imjudo is used as neoadjuvant therapy AND Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion) AND patient is medically fit for surgery.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Esophageal and Esophagogastric Junction Cancers, Gastric Cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## INBRIJA

---

### Products Affected

- INBRIJA INHALATION CAPSULE,  
W/INHALATION DEVICE

PA Criteria	Criteria Details
Exclusion Criteria	Asthma, COPD, other chronic underlying lung disease
Required Medical Information	Diagnosis, medications that will be used in combination
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Approve if the patient is currently taking carbidopa-levodopa and is experiencing off episodes.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## INGREZZA

### Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)
- INGREZZA SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	TD - Prescribed by or in consultation with a neurologist or psychiatrist. Chorea HD - prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Chorea associated with Huntington's Disease- approve if diagnosis is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## INJECTABLE TESTOSTERONE PRODUCTS

### Products Affected

- *testosterone cypionate*
- *testosterone enanthate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, lab results
<b>Age Restrictions</b>	Delayed puberty or induction of puberty in males-14 years and older, 12 years and older (testosterone cypionate)
<b>Prescriber Restrictions</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients.
<b>Coverage Duration</b>	Delayed puberty or induction of puberty in males-6 months, all others-12 months
<b>Other Criteria</b>	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. Delayed puberty or induction of puberty in males - Approve testosterone enanthate or testosterone cypionate. Breast cancer in females-approve testosterone enanthate. Male is defined as an individual with the biological traits of a

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	man, regardless of the individual's gender identity or gender expression. Female is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression. Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-approve. Note: For a patient who has undergone gender reassignment, use this FTM criterion for hypogonadism indication.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization).
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## INLYTA

### Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Advanced Renal cell carcinoma-approve. Differentiated thyroid cancer, approve if patient is refractory to radioactive iodine therapy. Soft tissue sarcoma-approve if the patient has alveolar soft part sarcoma and the medication will be used in combination with Keytruda (pembrolizumab).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma, Soft tissue sarcoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## INPEFA

---

### Products Affected

- INPEFA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Heart Failure, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve. Type 2 Diabetes, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve if the patient has chronic kidney disease AND has one or more cardiovascular risk factor(s).Note: Patients with heart failure should be reviewed under criteria for Heart Failure.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# INQOVI

---

## Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Neoplasms
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## INREBIC

### Products Affected

- INREBIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has intermediate-2 or high-risk disease. Myeloid/Lymphoid Neoplasms with Eosinophilia-approve if the tumor has a JAK2 rearrangement. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease-related symptom (examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid/Lymphoid Neoplasms with Eosinophilia, accelerated or blast phase myeloproliferative neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ITOVEBI

### Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>BREAST CANCER (all of A, B, C, D, E and F): A. Patient meets ONE of the following (i or ii): i. Patient is a postmenopausal female, OR ii. Patient meets BOTH of the following (a and b): a. Patient is a pre/perimenopausal female or a male, AND b. Patient is receiving a gonadotropin-releasing hormone (GnRH) agonist OR had surgical bilateral oophorectomy or ovarian irradiation (female) or orchiectomy (male), Note: Examples of a GnRH agonist include leuprolide acetate, leuprolide acetate intramuscular injection, triptorelin pamoate intramuscular injection, goserelin acetate subcutaneous injection. AND B. Patient has locally advanced or metastatic hormone receptor (HR)-positive disease, AND C. Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D. Patient has PIK3CA-mutated breast cancer as detected by an approved test, AND E. Patient meets (i or ii): i) has disease progression while on adjuvant endocrine therapy or ii) had disease recurrence within 12 months after completing adjuvant endocrine therapy, Note: Examples of endocrine therapy include tamoxifen, anastrozole, letrozole, exemestane, toremifene. AND F. The medication will be used in combination with palbociclib capsules/tablets and fulvestrant injection.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IVERMECTIN (ORAL)

### Products Affected

- *ivermectin oral tablet 3 mg, 6 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	Pediculosis-approve if the patient has infection caused by pediculus humanus capitis (head lice), pediculus humanus corporis (body lice), or has pediculosis pubis caused by phthirus pubis (pubic lice). Scabies-approve if the patient has classic scabies, treatment resistant scabies, is unable to tolerate topical treatment, has crusted scabies or is using ivermectin tablets for prevention and/or control of scabies.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Ascariasis, Enterobiasis (pinworm infection), Hookworm-related cutaneous larva migrans, Mansonella ozzardi infection, Mansonella streptocerca infection, Pediculosis, Scabies. Trichuriasis, Wucheria bancrofti infection
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## IVIG

### Products Affected

- PRIVIGEN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pt's home.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## IWILFIN

---

### Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Neuroblastoma-Approve if the patient meets the following (A, B and C): A) Patient has high-risk disease, AND B) The medication is being used to reduce the risk of relapse, AND C) Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Note: Examples of anti-GD2 immunotherapy includes Unituxin (dinutuximab intravenous infusion).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## JAKAFI

### Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	ALL-1 to 21 years of age, GVHD-12 and older, MF/PV/accelerated or blast phase MPN/CMML-2/essential thrombo/myeloid/lymphoid neoplasm/T-cell Lymphoma-18 and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	For polycythemia vera patients must have tried hydroxyurea or peginterferon alfa-2a or Besremi (ropeginterferon alfa-2b-njft subcutaneous injection). ALL-approve if the mutation/pathway is Janus associated kinase (JAK)-related. GVHD, chronic-approve if the patient has tried one conventional systemic treatment for graft versus host disease (for example: prednisone, ibrutinib capsules/tablets). GVHD, acute-approve if the patient has tried one systemic corticosteroid. Atypical chronic myeloid leukemia-approve if the patient has a CSF3R mutation or a janus associated kinase 2 (JAK2) mutation. Chronic monomyelocytic leukemia-2 (CMML-2)-approve if the patient is also receiving a hypomethylating agent. Essential thrombocythemia-approve if the patient has tried hydroxyurea, peginterferon alfa-2a or anagrelide. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the tumor has a janus associated kinase 2 (JAK2) rearrangement. T-Cell Lymphoma - approve if pt has (A or B): A) peripheral T-cell lymphoma or B) meets (i and ii): i) pt has T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia,

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	hepatosplenic T-cell lymphoma, or breast implant-associated anaplastic large cell lymphoma and ii) pt has tried at least one systemic regimen. Accelerated or blast phase myeloproliferative neoplasm-approve if pt has at least one disease-related symptom (examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Acute lymphoblastic leukemia, atypical chronic myeloid leukemia, chronic monomyelocytic leukemia-2 (CMML-2), essential thrombocythemia, myeloid/lymphoid neoplasms, T-Cell lymphoma, accelerated or blast phase myeloproliferative neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## JAYPIRCA

### Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>Mantle cell lymphoma-approve if the patient has tried at least one systemic regimen or patient is not a candidate for a systemic regimen (i.e., an elderly patient who is frail), AND the patient has tried one Bruton tyrosine kinase inhibitor (BTK) for mantle cell lymphoma. Note: Examples of a systemic regimen contain one or more of the following products: rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, Velcade (bortezomib intravenous or subcutaneous injection), lenalidomide, gemcitabine, and Venclexta (venetoclax tablets). Note: Examples of BTK inhibitors indicated for mantle cell lymphoma include Brukinsa (zanubrutinib capsules), Calquence (acalabrutinib capsules), and Imbruvica (ibrutinib capsules, tablets, and oral suspension). CLL/SLL-patient meets (A or B): A) patient has resistance or intolerance to Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules) or B) patient has relapsed or refractory disease and has tried a Bruton tyrosine kinase (BTK) inhibitor and Venclexta (venetoclax tablet)-based regimen.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	Examples of BTK inhibitor include: Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules). Richter's Transformation to DLBCL- pt has tried at least one chemotherapy regimen or is not a candidate for a chemotherapy regimen. Marginal Zone Lymphoma - approve if pt has tried at least one Bruton tyrosine kinase inhibitor.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Richter's Transformation to Diffuse Large B-Cell Lymphoma, Marginal Zone Lymphoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## JEMPERLI

### Products Affected

- JEMPERLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Endometrial cancer-approve if the patient has recurrent, advanced or metastatic disease. Mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) Solid tumors-approve if the patient has progressed on or after prior treatment and according to the prescriber, the patient does not have any satisfactory alternative treatment options. Small Bowel Adenocarcinoma-approve if the patient has dMMR or MSI-H disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation and has advanced or metastatic disease and Jemperli will be used as initial therapy when the patient has received adjuvant oxaliplatin or has a contraindication to oxaliplatin OR Jemperli is used as subsequent therapy and the patient has NOT received oxaliplatin in the adjuvant setting and the patient does NOT have a contraindication to oxaliplatin. Colon, Rectal, or Appendiceal Cancer- approve if patient has mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation AND has advanced or metastatic disease AND is being used for neoadjuvant therapy or primary or subsequent therapy.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Small Bowel Adenocarcinoma, Colon, Rectal or Appendiceal Cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## JYNARQUE

---

### Products Affected

- *tolvaptan (polycystic kidney dis) oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patient is currently receiving Samsca (tolvaptan tablets) . Patients with Stage 5 CKD
<b>Required Medical Information</b>	Diagnosis, renal function
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	1 year (initial and continuation)
<b>Other Criteria</b>	Approve if the patient has rapidly-progressing autosomal dominant polycystic kidney disease (ADPKD) (e.g., reduced or declining renal function, high or increasing total kidney volume [height adjusted]), according to the prescriber.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KADCYLA

### Products Affected

- KADCYLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	Breast Cancer-Recurrent/metastatic-1 yr, Breast Cancer-Adjuvant tx-approve 1 yr total, other-1yr
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has human epidermal growth factor receptor 2 (HER2)-positive disease and the patient is using for recurrent or metastatic breast cancer OR if using for adjuvant therapy. NSCLC-approve if the disease has activating human epidermal growth factor receptor 2 (HER2) mutations and the patient has metastatic disease. Salivary gland tumor-approve if the patient has recurrent, unresectable, or metastatic disease and the patient has human epidermal growth factor receptor 2 (HER2)-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-small cell lung cancer (NSCLC), salivary gland tumor
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KALYDECO

### Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with Orkambi, Trikafta or Symdeko
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	1 month of age and older
<b>Prescriber Restrictions</b>	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - must meet A, B, and C: A) pt must have one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KANUMA

### Products Affected

- KANUMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient lysosomal acid lipase activity in leukocytes, fibroblasts, or liver tissue OR a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic lysosomal acid lipase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KERENDIA

### Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with spironolactone or eplerenone
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial and continuation therapy)
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Diabetic kidney disease-initial-approve if the patient meets the following criteria (i, ii and iii)i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy AND iii. At baseline (prior to the initiation of Kerendia), patient meets all of the following (a, b, and c): a) Estimated glomerular filtration rate greater than or equal to 25 mL/min/1.73 m<sup>2</sup> AND b) Urine albumin-to-creatinine ratio greater than or equal to 30 mg/g AND c) Serum potassium level less than or equal to 5.0 mEq/L. Diabetic kidney disease-continuation-approve if the patient meets the following criteria (i and ii): i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## KESIMPTA

---

### Products Affected

- KESIMPTA PEN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KEYTRUDA

### Products Affected

- KEYTRUDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Melanoma - 12 and older, Glioma - less than 18 years, all others- 18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	adrenal gland tumor, anal carcinoma, extranodal NK/T-Cell Lymphoma, nasal type, Gestational trophoblastic neoplasia, mycosis fungoides/Sezary syndrome, primary cutaneous anaplastic large cell lymphoma, small cell lung cancer, soft tissue sarcoma, squamous cell skin cancer, thymic carcinoma, vulvar cancer, glioma, Kaposi sarcoma, ovarian/fallopian tube/peritoneal cancer, small bowel adenocarcinoma, thyroid carcinoma, vaginal cancer, chronic lymphocytic leukemia/small lymphocytic leukemia, penile cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# KISQALI

## Products Affected

- KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast cancer - approve for hormone receptor positive (HR+) [i.e., estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)]disease, and HER2-negative early (stage II or III), recurrent, or metastatic breast cancer [for early breast cancer must be adjuvant treatment and high risk of recurrence] when the pt meets ONE of the following 1. Pt is postmenopausal and Kisqali will be used in combination with anastrozole, exemestane, or letrozole 2. pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonist, or has had surgical bilateral oophorectomy, or ovarian irradiation AND Kisqali will be used in combination with anastrozole, exemestane, or letrozole 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Kisqali with be used in combination with anastrozole, exemestane or letrozole. 4. Patient is postmenopausal, pre/perimenopausal (patient receiving ovarian suppression/ablation with a GnRH agonist or has had surgical bilateral

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	oophorectomy or ovarian irradiation) or a man, and Kisqali (not Co-Pack) will be used in combination with fulvestrant. If the request is for Kisqali Femara, patients do not need to use in combination with anastrozole, exemestane or letrozole. Endometrial cancer - approve if pt meets all of (A, B and C): A) pt has recurrent or metastatic disease, and B) has estrogen receptor (ER)-positive tumors, and C) if request is for Kisqali (not Co-Pack), Kisqali will be used in combination with letrozole.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Endometrial cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KORLYM

### Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior surgeries
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Endogenous Cushing's Syndrome-Approve if mifepristone is being used to control hyperglycemia secondary to hypercortisolism in patients who have type 2 diabetes mellitus or glucose intolerance AND pt meets (i, ii or iii): i) patient is not a candidate for surgery or surgery has not been curative, or (ii) patient is awaiting surgery for endogenous Cushing's Syndrome or (iii) patient is awaiting therapeutic response after radiotherapy for endogenous Cushing's Syndrome.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KOSELUGO

### Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>Neurofibromatosis Type 1-approve if prior to starting Koselugo, the patient has symptomatic, inoperable plexiform neurofibromas and if the patient is 2 to 18 years old OR if the patient is 19 years or older if the patient started on therapy with Koselugo prior to becoming 19. Circumscribed Glioma-approve if the patient has recurrent, refractory or progressive disease AND the tumor is BRAF fusion positive OR BRAF V600E activating mutation positive OR patient has neurofibromatosis type 1 mutated glioma AND this medication will be used as a single agent AND the patient is 3-21 years of age OR is greater 21 and has been previously started on therapy with Koselugo prior to becoming 21 years of age. Langerhans Cell Histiocytosis- approve if the patient meets the following criteria (A and B): A) Patient meets one of the following (i, ii, iii, or iv): i. Patient meets both of the following (a and b): a) Patient has multisystem Langerhans cell histiocytosis, AND b) Patient has symptomatic disease or impending organ dysfunction, OR ii. Patient has single system lung Langerhans cell histiocytosis, OR iii. Patient meets all of the following (a, b, and c): a) Patient has single system bone disease, AND b) Patient has not responded to treatment with a bisphosphonate, AND c) Patient has more than 2 bone</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	lesions, OR iv. Patient has central nervous system disease, AND B) The medication is used as a single agent.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Circumscribed Glioma, Langerhans Cell Histiocytosis
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## KRAZATI

### Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>Non-Small Cell Lung Cancer (NSCLC)-approve if (A and B): A) the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test AND B) patient meets either (i or ii): i) has been previously treated with at least one systemic regimen [Examples of systemic regimens include those containing one or more of the following products: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Alimta (pemetrexed intravenous infusion), Yervoy (ipilimumab intravenous infusion), Abraxane (albumin-bound paclitaxel intravenous infusion), bevacizumab, cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine.] or ii) patient has brain metastases. Colon or Rectal Cancer- approve if pt has unresectable, advanced, or metastatic disease AND pt has KRAS G12C mutation-positive disease AND medication is prescribed as part of a combination regimen or the patient is unable to tolerate combination therapy AND pt has has previously received a chemotherapy regimen for colon or rectal cancer. Ampullary adenocarcinoma-approve if (A, B and C): A) metastatic disease, B) KRAS G12C mutation-positive disease, and C) will be used as subsequent</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	therapy. Biliary tract cancer- approve if (A, B and C): A) unresectable or metastatic disease, B) KRAS G12C mutation-positive disease, and C) previously treated with at least one systemic regimen. Pancreatic adenocarcinoma- approve if (A and B): A) KRAS G12C mutation-positive disease, and B) either (i or ii): (i) locally advanced or metastatic disease and previously treated with at least one systemic regimen, or (ii) recurrent disease after resection. Small bowel adenocarcinoma- approve if (A, B and C): A) advanced or metastatic disease, B) KRAS G12C mutation-positive disease, and C) will be used as subsequent therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Ampullary adenocarcinoma, biliary tract cancer, pancreatic adenocarcinoma, small bowel adenocarcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## LANREOTIDE

### Products Affected

- lanreotide subcutaneous syringe 120 mg/0.5 ml
- SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML, 90 MG/0.3 ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescribed by or in consultation with an endocrinologist. Carcinoid syndrome-prescribed by or in consultation with an oncologist, endocrinologist or gastroenterologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro.
Coverage Duration	1 year
Other Criteria	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)-approve. Carcinoid Syndrome-approve.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pheochromocytoma/paraganglioma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LAPATINIB

### Products Affected

- *lapatinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which lapatinib is being used. Metastatic breast cancer, HER2 status or hormone receptor (HR) status.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	HER2-positive recurrent or metastatic breast cancer, approve if lapatinib will be used in combination with capecitabine OR trastuzumab and the patient has tried at least two prior anti-HER2 based regimens OR the medication will be used in combination with an aromatase inhibitor and and the patient has HR+ disease and the patient is a postmenopausal woman or the patient is premenopausal or perimenopausal woman and is receiving ovarian suppression/ablation with a GnRH agonist, surgical bilateral oophorectomy or ovarian irradiation OR the patient is a man and is receiving a GnRH analog. Colon or rectal cancer-approve if the patient has unresectable advanced or metastatic disease that is human epidermal receptor 2 (HER2) amplified and with wild-type RAS and BRAF disease and the patient has tried at least one chemotherapy regimen or is not a candidate for intensive therapy and the medication is used in combination with trastuzumab (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) and the patient has not been previously treated with a HER2-inhibitor. Bone Cancer-approve if the patient has recurrent chordoma and if the patient has epidermal growth-factor receptor (EGFR)-positive disease.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Bone cancer-chordoma, colon or rectal cancer, breast cancer in pre/peri-menopausal women and men
<b>Part B Prerequisite</b>	Yes

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## LAZCLUZE

---

### Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER-ALL of the following (A, B, C, and D): A. Locally advanced or metastatic disease, AND B. Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test, AND C. Used in combination with Rybrevant, AND D. Used as first-line treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LEDIPASVIR/SOFOSBUVIR

---

### Products Affected

- LEDIPASVIR-SOFOSBUVIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with other direct acting antivirals, excluding ribavirin
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	3 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LENALIDOMIDE

### Products Affected

- *lenalidomide*
- REVLIMID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and previous therapies or drug regimens tried.
<b>Age Restrictions</b>	18 years and older (except Kaposi's Sarcoma, Castleman's Disease, CNS Lymphoma)
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Follicular lymphoma-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one prior therapy. MCL-approve -if the patient is using lenalidomide in combination with rituximab or has tried at least two other therapies or therapeutic regimens. MZL-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one other therapy or therapeutic regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). B-cell-lymphoma (other)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve. CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-approve if the patient has tried at least three other regimens. Castleman's disease-approve if the patient has

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	relapsed/refractory or progressive disease. Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide is used in combination with dexamethasone. Histiocytic neoplasms-approve if the patient has Langerhans cell histiocytosis with single-system multifocal skin disease or Rosai-Dorfman disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma (Non-Hodgkin's Lymphoma), Myelofibrosis. Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system Lymphoma, Kaposi's sarcoma, histiocytic neoplasms.
<b>Part B Prerequisite</b>	No

## LENVIMA

### Products Affected

- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY (10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY (10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>DTC - must be refractory to radioactive iodine treatment for approval. RCC - approve if the pt meets ALL of the following criteria: 1) pt has advanced disease AND if the patient meets i or ii-i. Lenvima is being used in combination with Keytruda OR ii. Lenvima is used in combination with Afinitor/Afinitor Disperz and the patient meets a or b-a. Patient has clear cell histology and patient has tried one antiangiogenic therapy or b. patient has non-clear cell histology. MTC-approve if the patient has tried at least one systemic therapy. Endometrial Carcinoma-Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) AND B) The medication is used in combination with Keytruda (pembrolizumab for intravenous injection) AND C) the disease has progressed on at least one prior systemic therapy AND D) The patient is not a candidate for curative surgery or radiation. HCC-approve if the patient has unresectable or metastatic disease. Thymic carcinoma-approve</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	if the patient has tried at least one chemotherapy regimen. Melanoma - approve if the patient has unresectable or metastatic melanoma AND the medication will be used in combination with Keytruda (pembrolizumab intravenous injection) AND the patient has disease progression on anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy. Anaplastic thyroid carcinoma-approve if the medication is used in combination with Keytruda (pembrolizumab intravenous infusion).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Medullary Thyroid Carcinoma (MTC), thymic carcinoma, Melanoma, Anaplastic thyroid carcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LIBTAYO

### Products Affected

- LIBTAYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous surgeries or radiation
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. CSCC-approve if the patient meets one of the following (i or ii): (i): pt has has locally advanced, recurrent, or metastatic disease and is not a candidate for curative surgery or curative radiation or (ii): pt has very-high risk, locally advanced, unresectable, or regional disease and this medication will be used as neoadjuvant therapy. Basal Cell Carcinoma-approve if the patient has locally advanced, nodal or metastatic disease. NSCLC-approve if the patient has recurrent, advanced, or metastatic disease and meets one of the following (i, ii, iii, or iv): (i): medication is used for first-line or continuation maintenance therapy AND tumor is negative for actionable mutations (however, may be KRAS G12C mutation positive), or (ii): medication will be used first line AND the tumor is positive for one of EGFR exon 20 mutation or ERBB2 (HER2) mutation, or (iii): medication will be used as first-line or subsequent therapy AND the tumor is positive for one of BRAF V600E mutation or NTRK1/2/3 gene fusion or MET exon 14 skipping mutation or RET rearrangement, or (iv): medication will be used as subsequent therapy AND the tumor is positive for one of EGFR

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	S768I, L861Q, and/or G719X mutation or EGFR exon 19 deletion or exon 21 L858R or ALK rearrangement or ROS1 rearrangement AND pt has received targeted drug therapy for the specific mutation. Cervical cancer- approve if pt has local or regional recurrence or distant metastatic disease AND this medication is used as subsequent therapy. Vulvar cancer- approve if pt has advanced, recurrent, or metastatic disease AND this medication is used as subsequent therapy. Vaginal cancer- approve if pt meets (A and B): A) meets (i or ii): i) local or regional recurrence, or ii) distant metastatic disease, and B) used as subsequent therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Cervical cancer, vulvar cancer, vaginal cancer
<b>Part B Prerequisite</b>	No

## LIDOCAINE PATCH

---

### Products Affected

- *dermacinrx lidocan*
- *lidocaine topical adhesive patch, medicated 5 %*
- *lidocan iii*
- *lidocan iv*
- *lidocan v*
- *tridacaine ii*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Diabetic neuropathic pain, chronic back pain
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# LIVTENCITY

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with ganciclovir or valganciclovir
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	12 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist, infectious diseases specialist, oncologist, or a physician affiliated with a transplant center.
<b>Coverage Duration</b>	2 months
<b>Other Criteria</b>	Cytomegalovirus Infection, Treatment-approve if the patient meets the following criteria (A, B, and C): A) Patient weighs greater than or equal to 35 kg, AND B) Patient is post-transplant, AND Note: This includes patients who are post hematopoietic stem cell transplant or solid organ transplant. C) Patient has cytomegalovirus infection/disease that is refractory to treatment with at least one of the following: cidofovir, foscarnet, ganciclovir, or valganciclovir or patient has a significant intolerance to ganciclovir or valganciclovir.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LONG ACTING OPIOIDS

### Products Affected

- BELBUCA
- *buprenorphine*
- *hydromorphone oral tablet extended release 24 hr*
- *methadone intensol*
- *methadone oral concentrate*
- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*
- *methadose oral concentrate*
- *morphine oral tablet extended release*
- OXYCONTIN ORAL TABLET, ORAL ONLY, EXT. REL. 12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute (ie, non-chronic) pain
<b>Required Medical Information</b>	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## LONSURF

### Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Gastric or Gastroesophageal Junction Adenocarcinoma, approve if the patient has been previously treated with at least two chemotherapy regimens for gastric or gastroesophageal junction adenocarcinoma. Colon and rectal cancer-approve per labeling if the patient has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type) they must also try Erbitux or Vectibix.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# LOQTORZI

## Products Affected

- LOQTORZI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	<p>Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Nasopharyngeal carcinoma- approve if the patient has recurrent, unresectable, oligometastatic, or metastatic disease AND the patient meets ONE of the following (i or ii): i. Patient meets BOTH of the following (a and b): a) Loqtorzi is used for first-line treatment AND b) Loqtorzi is used in combination with cisplatin and gemcitabine, OR ii. Patient meets both of the following (a and b): a) Loqtorzi is used for subsequent treatment AND b) Loqtorzi is used as a single agent or in combination with cisplatin and gemcitabine. Anal carcinoma- approve if patient meets (A and B): A) meets (i or ii): i) locally recurrent, progressive disease and medication is administered before proceeding to abdominoperineal resection, or ii) metastatic disease, medication is used as subsequent therapy and patient has not received prior immunotherapy [ex: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Libtayo (cemiplimab intravenous infusion), and Jemperli (dostarlimab intravenous infusion)], and B) medication is used as a single agent. Small bowel adenocarcinoma- approve if patient meets (A, B, C and D): A) locally unresectable or</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	medically inoperable disease, B) ultra-hypermuted phenotype (defined as tumor mutation burden greater than 50 mutations/megabase), C) patient has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease or polymerase epsilon/delta (POLE/POLD1) mutation positive disease, and D) medication is used as a single agent.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anal carcinoma, small bowel adenocarcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# LORBRENA

## Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, ALK status, ROS1 status, previous therapies
<b>Age Restrictions</b>	Pediatric Diffuse High-Grade Glioma- less than 18 years old, All others- 18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Erdheim Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has IMT with ALK translocation. NSCLC - Approve if the patient has ALK-positive advanced or metastatic NSCLC, as detected by an approved test. NSCLC-ROS1 Rearrangement-Positive, advanced or metastatic NSCLC-approve if the patient has tried at least one of crizotinib, entrectinib or ceritinib. Large B-Cell Lymphoma- approve if ALK-positive disease and disease is relapsed or refractory. Pediatric Diffuse High-Grade Glioma- approve if ALK-positive disease and (i or ii): i) used as adjuvant therapy, or ii) used for recurrent or progressive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Non-small cell lung cancer (NSCLC)-ROS1 Rearrangement-Positive, Erdheim Chester Disease, Inflammatory Myofibroblastic Tumor (IMT), Large B-Cell Lymphoma, Pediatric Diffuse High-Grade Glioma
<b>Part B Prerequisite</b>	No

## LUMAKRAS

### Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. Ampullary adenocarcinoma - approve if pt has KRAS G12C-mutated disease as determined by an approved test AND this is used as subsequent therapy. Colon or rectal cancer - approve if pt meets all (A, B, C and D): A) unresectable, advanced, or metastatic disease, and B) KRAS G12C mutation-positive disease, and C) medication is prescribed as part of a combination regimen for colon or rectal cancer [Ex: Lumakras plus cetuximab or panitumumab] or patient is unable to tolerate combination therapy, and D) previously received a chemotherapy regimen for colon or rectal cancer. Pancreatic Adenocarcinoma- approve if patient has KRAS G12C-mutated disease, as determined by an approved test AND either (i or ii): (i) patient has locally advanced or metastatic disease and has been previously treated with at least one systemic regimen OR (ii) patient has recurrent disease after resection.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pancreatic Adenocarcinoma, Ampullary Adenocarcinoma
<b>Part B Prerequisite</b>	No

## LUMIZYME

### Products Affected

- LUMIZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue OR patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic acid alpha-glucosidase (GAA) gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LUNSUMIO

### Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Follicular Lymphoma-approve if the patient has received at least two lines of systemic therapy. Note: Examples of systemic therapy for follicular lymphoma include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab or Gazyva (obinutuzumab intravenous infusion) and CVP (cyclophosphamide, vincristine, prednisone) plus rituximab or Gazyva. B-Cell Lymphoma (examples: diffuse large B-cell lymphoma, high-grade B-cell lymphoma, HIV-related B-cell lymphomas, post-transplant lymphoproliferative disorders)- approve if patient has received at least one line of systemic therapy and will be used in combination with Polivy. Note: Examples of systemic therapy for B-Cell lymphoma include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and Pola-R-CHP (Polivy [polatuzumab vedotin-piiq intravenous infusion], rituximab, cyclophosphamide, doxorubicin, prednisone).</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	B-Cell Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## LUPRON DEPOT

### Products Affected

- LUPRON DEPOT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Premenstrual disorders - 18 years and older
<b>Prescriber Restrictions</b>	Prostate cancer-prescribed by/consultation with oncologist or urologist. Other cancer diagnosis- prescribed by/consultation with an oncologist. Gender dysphoria/reassignment- prescribed by/consultation with endocrinologist or physician who specializes in treatment of transgender patients
<b>Coverage Duration</b>	uterine leiomyomata - 3 months, abnormal uterine bleeding - 6 months, all others - 12 months
<b>Other Criteria</b>	Endometriosis-approve if the pt has tried one of the following, unless contraindicated: a contraceptive, an oral progesterone or depo-medroxyprogesterone injection. An exception can be made if the pt has previously tried a gonadotropin-releasing hormone [GnRH] agonist (e.g. Lupron Depot) or antagonist (e.g. Orilissa). Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease. Premenstrual disorders including PMS and PMDD- approve if pt has severe refractory premenstrual symptoms AND pt has tried an SSRI or combined oral contraceptive. Prostate cancer - for patients new to therapy requesting Lupron Depot 7.5mg, patients are required to try Orgovyx or Eligard prior to approval.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	abnormal uterine bleeding, breast cancer, gender dysphoria/gender reassignment, head and neck cancer-salivary gland tumors, ovarian cancer including fallopian tube and primary peritoneal cancers, premenstrual disorders including premenstrual syndrome and premenstrual dysphoric disorder, prophylaxis or treatment of uterine bleeding or menstrual suppression in pts with hematologic malignancy or undergoing cancer treatment or prior to bone marrow or stem cell transplant, uterine cancer
<b>Part B Prerequisite</b>	No

## LYNPARZA

### Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Maintenance monotherapy-Approve if the patient has a germline or somatic BRCA mutation-positive disease as confirmed by an approved test AND The patient is in complete or partial response to at least one platinum-based chemotherapy regimen (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine). Ovarian, fallopian tube, or primary peritoneal cancer-maintenance, combination therapy-approve if the medication is used in combination with bevacizumab, the patient has homologous recombination deficiency (HRD)-positive disease, as confirmed by an approved test and the patient is in complete or partial response to first-line platinum-based chemotherapy regimen. Breast cancer, adjuvant-approve if the patient has germline BRCA mutation-positive, HER2-negative breast cancer and the patient has tried neoadjuvant or adjuvant therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has recurrent or metastatic disease and has (i or ii): i) germline BRCA mutation-positive breast cancer or ii) germline PALB2 mutation-positive breast cancer. Pancreatic Cancer-maintenance therapy-approve if the patient has a germline BRCA mutation-positive metastatic disease and

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	the disease has not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen. Prostate cancer-castration resistant-approve if the patient has metastatic disease, the medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog or the pateint has had a bilateral orchiectomy, and the patient meets either (i or ii): i) the patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test and the patient has been previously treated with at least one androgen receptor directed therapy or ii) the patient has a BRCA mutation and the medication is used in combination with abiraterone plus one of prednisone or prednisolone. Uterine Leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Uterine Leiomyosarcoma
<b>Part B Prerequisite</b>	No

## LYTGOBI

---

### Products Affected

- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease, tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an approved test and if the patient has been previously treated with at least one systemic regimen. Note: Examples of systemic regimens include gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin, capecitabine + cisplatin or oxaliplatin, gemcitabine + Abraxane (albumin-bound paclitaxel) or capecitabine or oxaliplatin, and gemcitabine + cisplatin + Abraxane.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MAVYRET

---

### Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	3 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MEGESTROL

### Products Affected

- *megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for weight gain for cosmetic reasons.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MEKINIST

### Products Affected

- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Mekinist is being used. For melanoma, thyroid cancer and NSCLC must have documentation of BRAF V600 mutations
<b>Age Restrictions</b>	1 year and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Melanoma must be used in patients with BRAF V600 mutation, and patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC requires BRAF V600E Mutation and use in combination with Tafenlar. Thyroid cancer, anaplastic-patient has locally advanced or metastatic anaplastic disease AND Mekinist will be taken in combination with Tafenlar, unless intolerant AND the patient has BRAF V600-positive disease. Ovarian/fallopian tube/primary peritoneal cancer-approve if the patient has recurrent disease and the medication is used for low-grade serous carcinoma or the patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma or d) Oligodendroglioma OR iii. Melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Tafenlar (dabrafenib). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease or Rosai-Dorfman disease. Metastatic or Solid Tumors-Approve if the patient meets the following (A, B, and C): A) Patient has BRAF V600 mutation-positive disease, AND B) The medication will be taken in combination with Tafenlar (dabrafenib capsules), AND C) Patient has no satisfactory alternative treatment options. Hairy Cell Leukemia, approve if pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Tafenlar. Small bowel adenocarcinoma, approve if pt has BRAF V600E mutation-positive advanced or metastatic disease and this will be used with Tafenlar AND (i or ii): i) this will be used as initial therapy and pt has received previous FOLFOX/CAPEOX therapy in the adjuvant setting within the past 12 months or has a contraindication, or (ii) this will be used as second-line and subsequent therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Histiocytic Neoplasm, Hairy Cell Leukemia
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## MEKTOVI

### Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, BRAF V600 status, concomitant medications
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation AND Mektovi will be used in combination with Braftovi. Histiocytic neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. multisystem disease OR, ii. pulmonary disease or, iii. central nervous system lesions. NSCLC-approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Braftovi (encorafenib capsules).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic Neoplasms
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MEMANTINE

---

### Products Affected

- *memantine oral capsule, sprinkle, er 24hr*
- *memantine oral solution*
- *memantine oral tablet*
- *memantine-donepezil*
- NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Indication for which memantine is being prescribed.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with mild to moderate vascular dementia.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MEPSEVII

---

### Products Affected

- MEPSEVII

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient beta-glucuronidase activity in leukocytes, fibroblasts, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic glucuronidase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# METHYLERGONOVINE

---

## Products Affected

- *methylergonovine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MODAFINIL/ARMODAFINIL

### Products Affected

- armodafinil*
- modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Excessive daytime sleepiness (EDS) associated with myotonic dystrophy (modafinil only). Adjunctive/augmentation for treatment of depression in adults (modafinil only).
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## MONJUVI

### Products Affected

- MONJUVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-Cell Lymphoma - Approve if the patient meets the following criteria: Patient has been treated with at least one prior chemotherapy regimen AND the patient is not eligible for autologous stem cell transplant AND Monjuvi will be used in combination with Revlimid (lenalidomide) OR Patient has already received 12 cycles of Monjuvi. B-cell lymphoma-Approve if the patient meets the following criteria: Patient has been treated with at least one prior chemotherapy regimen AND the patient is not eligible for autologous stem cell transplant AND Monjuvi will be used in combination with Revlimid (lenalidomide) OR Patient has already received 12 cycles of Monjuvi.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	B-Cell Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## MYFEMBREE

### Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, test results
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Fibroids-Prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health
<b>Coverage Duration</b>	24 months of total therapy between Myfembree or Oriahnn
<b>Other Criteria</b>	Uterine Fibroids (Leiomyomas)-approve if the patient is premenopausal (before menopause) and is experiencing heavy menstrual bleeding associated with the uterine fibroids, the uterine fibroids have been confirmed by a pelvic ultrasound, including transvaginal ultrasonography or sonohysterography, hysteroscopy, or magnetic resonance imaging. Endometriosis-approve if the patient is premenopausal and patient has previously tried one of the following (i or ii): i. A contraceptive (e.g., combination oral contraceptives, levonorgestrel-releasing intrauterine systems, a depo-medroxyprogesterone injection), unless contraindicated OR ii. An oral progesterone (e.g., norethindrone tablets), unless contraindicated. Note: An exception to this requirement can be made if the patient has previously used a gonadotropin-releasing hormone agonist (e.g., Lupron Depot [leuprolide depot suspension]) or Orilissa (elagolix tablets).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NAGLAZYME

---

### Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic arylsulfatase B gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NAYZILAM

---

### Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## NERLYNX

### Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Stage of cancer, HER2 status, previous or current medications tried
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Adjuvant tx-Approve for 1 year (total), advanced or metastatic disease-1 year
Other Criteria	Breast cancer, adjuvant therapy - approve if the patient meets all of the following criteria: patient will not be using this medication in combination with HER2 antagonists, patient has HER2-positive breast cancer AND Patient has completed one year of adjuvant therapy with trastuzumab OR could not tolerate one year of therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has HER-2 positive breast cancer, Nerlynx will be used in combination with capecitabine and the patient has tried at least two prior anti-HER2 based regimens.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NEXLETOL

### Products Affected

- NEXLETOL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and ezetimibe and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and ezetimibe and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NEXLIZET

### Products Affected

- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below).</p> <p>ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## NILUTAMIDE

---

### Products Affected

- *nilutamide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer-approve if nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NINLARO

### Products Affected

- NINLARO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	MM - be used in combination with dexamethasone and lenalidomide or cyclophosphamide OR pt had received at least ONE previous therapy for multiple myeloma OR the agent will be used following autologous stem cell transplantation (ASCT). Systemic light chain amyloidosis-approve if the patient has tried at least one other regimen for this condition. Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma-approve if used in combination with a rituximab product and dexamethasone (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with systemic light chain amyloidosis, Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma, Multiple myeloma after previous treatment (either monotherapy or in combination other than lenalidomide/dexamethasone) or stem cell transplant
<b>Part B Prerequisite</b>	Yes

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# NITISINONE

## Products Affected

- *nitisinone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant therapy with nitisinone products
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hereditary Tyrosinemia, Type 1-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming biallelic pathogenic/likely pathogenic variants in the FAH gene OR elevated levels of succinylacetone in the serum or urine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NIVESTYM

### Products Affected

- NIVESTYM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS.
<b>Coverage Duration</b>	chemo/SCN/AML-6 mo.HIV/AIDS-4 mo.MDS-3 mo.PBPC,Drug induce A/N,ALL,BMT, Radiation-1 mo
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: 1)patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2)patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status, or HIV infection), 3)patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor (eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	frequency of chemotherapy may compromise treatment, or 4)patient has received chemotherapy has febrile neutropenia and has at least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute neutrophil count less than 100 cells/mm <sup>3</sup> ], neutropenia expected to be greater than 10 days in duration, invasive fungal infection).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Neutropenia associated with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). Treatment of myelodysplastic syndromes (MDS). Drug induced agranulocytosis or neutropenia. Acute lymphocytic leukemia (ALL), Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome)
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NON-INJECTABLE TESTOSTERONE PRODUCTS

### Products Affected

- *testosterone transdermal gel* 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)
- *testosterone transdermal gel in metered-dose pump* 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)
- *testosterone transdermal solution in metered pump w/app*
- *testosterone transdermal gel in packet* 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram),

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients.
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.] Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-approve.Note: For a patient who has undergone gender reassignment, use this FTM criterion for hypogonadism indication.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)
<b>Part B Prerequisite</b>	No

## NUBEQA

### Products Affected

- NUBEQA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (See Note 1) or if the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration sensitive-approve if the medication will be used in combination with a GnRH analog (See Note 1) or if the patient had a bilateral orchiectomy. Note 1: examples of GnRH analogs are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NUCALA

### Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy.
<b>Required Medical Information</b>	COPD initial - Approve if pt meets all (A, B AND C): A) pt has a blood eosinophil level at least 300 cells per microliter within the previous 6 weeks or prior to treatment with Nucala or another monoclonal antibody therapy that may alter blood eosinophil levels AND B) received at least 3 months of combination therapy with at least two of LAMA, LABA or ICS, AND C) pt meets (i or ii): i) experienced two or more COPD exacerbations requiring treatment with a systemic corticosteroid with or without an antibiotic in the previous 12 months OR ii) experienced one or more COPD exacerbations requiring a hospitalization in the previous 12 months. Cont - Approve if pt meets all (A, B and C): A) has already received at least 6 months of therapy with Nucala AND B) continues to receive combination therapy with an inhaled LABA and LAMA AND C) patient has experienced a beneficial clinical response, defined by one of the following: reduced symptoms, exacerbations, hospitalizations, ED/urgent care visits, improved lung function).
<b>Age Restrictions</b>	(Initial therapy only): Asthma-6 years of age and older. EGPA/Polyps/COPD-18 years of age and older. HES-12 years and older.
<b>Prescriber Restrictions</b>	(Initial therapy only): Asthma/COPD-Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA-prescribed by or in consultation with an allergist, immunologist, pulmonologist or rheumatologist. HES-prescribed by or in consultation with an allergist, immunologist, hematologist, pulmonologist or rheumatologist. Polyps-prescribed by or in consult with allergist, immunologist or Otolaryngologist
<b>Coverage Duration</b>	Initial-Asthma/polyps/COPD-6 months, EGPA/HES-8 months. 12 months continuation.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Asthma initial - must have blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks (or prior to tx with Nucala or another monoclonal antibody therapy that may lower blood eosinophil levels) AND has received combo tx w/inhaled corticosteroid AND at least 1 additional asthma controller/maintenance med (Examples: LAMA, LABA, leukotriene receptor antagonist, monoclonal antibody) AND pt's asthma cont to be uncontrolled, or was uncontrolled prior to starting Nucala or another monoclonal antibody therapy for asthma as defined by 1 of following-pt experi 2 or more asthma exacer req tx w/systemic corticosteroids in prev yr, pt experienced 1 or more asthma exacer requiring hospitalization, urgent care visit or ED visit in the prev yr, pt has a FEV1 less than 80 percent predicted, Pt has FEV1/FVC less than 0.80, or Pt's asthma worsens upon taper of oral (systemic) corticosteroid therapy. Cont-pt responded to Nucala tx as determined by the prescribing physician AND Pt cont to receive tx with an inhaled corticosteroid. EGPA initial-approve if pt has active, non-severe disease, has/had a blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks or prior to any monoclonal antibody that may lower blood eosinophil levels. Cont-pt responded to Nucala tx as determined by the prescribing physician. HES initial-pt has had hypereosinophilic synd for greater than or equal to 6 months AND has FIP1L1-PDGFRalpha-negative dis AND pt does NOT have identifiable non-hematologic secondary cause of hypereosinophilic synd AND prior to initiating tx with monoclonal antibody that may lower blood eosinophil levels, pt has/had a blood eosinophil level of greater than or equal to 1,000 cells per microliter. Cont-approve if the patient has responded to Nucala tx. Nasal polyps, initial-approve if pt meets ALL of the following criteria(A, B, C and D):A) pt has chronic rhinosinusitis w/nasal polyposis as evidenced by direct examination, endoscopy, or sinus CT scan AND B)pt experienced 2 or more of the following sympt for at least 6 months: nasal congest/obstruct/discharge, and/or reduction/loss of smell AND C)pt meets BOTH of the following (a and b): a)Pt has received tx with intranasal corticosteroid AND b)Pt will continue to receive tx with intranasal corticosteroid concomitantly with Nucala AND D)pt meets 1 of the following (a, b or c): a)Pt has received at least 1 course of tx with a systemic corticosteroid for 5 days or more within the previous 2 years, OR b)Pt has a contraindication to systemic corticosteroid tx, OR c)Pt had prior surgery for nasal polyps. Cont-approve if the pt has received at least 6</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	months of therapy, continues to receive tx with an intranasal corticosteroid and has responded to tx.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## NUEDEXTA

---

### Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## NUPLAZID

---

### Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## NURTEC

### Products Affected

- NURTEC ODT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention if Nurtec ODT is being taking for the preventive treatment of episodic migraine.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Migraine, Acute treatment (initial and continuation)-approve. Preventive treatment of episodic migraine (initial)-approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication). Preventive treatment of episodic migraine (continuation) - approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication) and the patient has had a significant clinical benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## NYVEPRIA

### Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
<b>Coverage Duration</b>	Cancer pts receiving chemo-6 mo. PBPC-1 mo
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, or 3) patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Patients undergoing PBPC collection and therapy
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OICALIVA

### Products Affected

- OICALIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Prescriber specialty, lab values, prior medications used for diagnosis and length of trials
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial)
<b>Coverage Duration</b>	6 months initial, 1 year cont.
<b>Other Criteria</b>	Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies, including sp100 or gp210, if AMA is negative c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)). Patients new to therapy and continuing therapy must not have cirrhosis or must have compensated cirrhosis without evidence of portal hypertension.
<b>Indications</b>	All FDA-approved Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OCTREOTIDE INJECTABLE

### Products Affected

- *octreotide acetate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-prescr/consult with oncologist. Diarrhea assoc w chemo-prescr/consult with oncologist/gastro.
<b>Coverage Duration</b>	Enterocutaneous fistula/diarrhea assoc w chemo - 3 months, all others - 1 year
<b>Other Criteria</b>	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender. DIARRHEA ASSOC W CHEMO (A and B): A) grade 3 or 4 diarrhea and B) patient has tried at least one antimotility medication.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma, enterocutaneous fistulas, diarrhea associated with chemotherapy

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ODOMZO

### Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	BCC - Must not have had disease progression while on Erivedge (vismodegib).
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve, if the disease is limited to nodal metastases. (Note-This includes primary or recurrent nodal metastases. A patient with distant metastasis does not meet this requirement.) Diffuse Basal Cell Carcinoma Formation, including basal cell nevus syndrome (Gorlin syndrome) or other genetic forms of multiple basal cell carcinoma - approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Metastatic BCC, diffuse basal cell carcinoma formation
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OFEV

### Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF), INITIAL [A and B]: A) diagnosis confirmed by presence of usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) or surgical lung biopsy and B) forced vital capacity (FVC) greater than or equal to 40 percent of the predicted value. INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS, INITIAL (A and B): A) diagnosis confirmed by HRCT and B) FVC greater than or equal to 40 percent of the predicted value. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE, INITIAL (all of A, B and C): A) FVC greater than or equal to 45 percent of the predicted value, B) fibrosing lung disease impacting more than 10 percent of lung volume on HRCT, and C) clinical signs of progression. ALL INDICATIONS, CONTINUATION: approve.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OGSIVEO

---

### Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Desmoid tumors (aggressive fibromatosis)-approve if the patient has progressing desmoid tumors, the desmoid tumors are not amenable to surgery or radiotherapy and if the patient requires systemic treatment. Note: Progressing desmoid tumors are defined as greater than or equal to 20 percent progression within 12 months
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OJEMDA

### Products Affected

- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)
- OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	6 months of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	PEDIATRIC LOW GRADE GLIOMA-patient has relapsed or refractory disease and the tumor is positive for one of the following: BRAF fusion, BRAF rearrangement or BRAF V600 mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## OJJAARA

### Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Myelofibrosis-approve if the patient has (A, B or C): A) intermediate-risk or high-risk disease, or B) lower-risk disease and has one disease-related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis), or C) myelofibrosis-associated anemia. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease- related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Accelerated or blast phase myeloproliferative neoplasm
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ONUREG

### Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML - Approve if the medication is used for post-remission maintenance therapy AND allogeneic hematopoietic stem cell transplant is not planned. Peripheral T-cell lymphoma - all of (A, B, and C): A) relapsed or refractory disease, and B) pt has one of the following (i, ii or iii): i) angioimmunoblastic T-cell lymphoma, or ii) nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, or iii) follicular T-cell lymphoma, and C) medication is used as a single agent.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Peripheral T-cell lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OPDIVO

### Products Affected

- OPDIVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	colon/rectal/melanoma-12 years and older, pediatric hodgkin lymphoma-less than 18 years old, All other (except gestational trophoblastic and Kaposi sarcoma)-18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	Adjuvant treatment of melanoma-approve up to 1 year total, all other dx-1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	anal carcinoma, cervical carcinoma, endometrial carcinoma, extranodal NK/T-Cell Lymphoma, gestational trophoblastic neoplasia, merkel cell carcinoma, neuroendocrine tumors, pediatric hodgkin lymphoma, small bowel adenocarcinoma, small cell lung cancer, vulvar cancer, ampullary adenocarcinoma, bone cancer, diffuse high-grade gliomas, Kaposi sarcoma, primary mediastinal large B-cell lymphoma, biliary tract cancers, soft tissue sarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, pancreatic cancer, squamous cell skin carcinoma, thyroid carcinoma, vaginal cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## OPDIVO QVANTIG

### Products Affected

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (all diagnoses except gestational trophoblastic neoplasia, Kaposi sarcoma)
Prescriber Restrictions	Prescribed by or on consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	appendiceal cancer, ampullary adenocarcinoma, anal carcinoma, biliary tract cancers, cervical cancer, endometrial carcinoma, gestational trophoblastic neoplasia, Kaposi sarcoma, merkel cell carcinoma, mesothelioma, neuroendocrine tumors, small bowel adenocarcinoma, small cell lung cancer, squamous cell skin carcinoma, thyroid carcinoma, vaginal cancer
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## OPDUALAG

---

### Products Affected

- OPDUALAG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Melanoma-approve if the patient is greater than or equal to 40 kg and either (i or ii): (i) the patient has unresectable or metastatic disease or (ii) medication is used as neoadjuvant therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OPSUMIT

---

### Products Affected

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	PAH WHO group, right heart catheterization results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1 patients are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OPSYNVI

---

### Products Affected

- OPSYNVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with guanylate cyclase stimulators
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1-approve if patient has had a right-heart catheterization to confirm the diagnosis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ORENCIA

### Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). PsA-approve. Juvenile idiopathic arthritis (JIA) [or Juvenile Rheumatoid Arthritis (JRA)]-approve if the patient has tried one other agent for this condition or the patient will be starting on Orencia concurrently with methotrexate, sulfasalazine or leflunomide or the patient has an absolute contraindication to methotrexate, sulfasalazine or leflunomide or the patient has aggressive disease. Cont tx - responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ORENCIA IV

### Products Affected

- ORENCIA (WITH MALTOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	GVHD-2 years and other
<b>Prescriber Restrictions</b>	Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist. GVHD-prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). PsA-approve. Juvenile idiopathic arthritis (JIA) [or Juvenile Rheumatoid Arthritis (JRA)]-approve if the patient has tried one other agent for this condition or the patient will be starting on Orencia concurrently with methotrexate, sulfasalazine or leflunomide or the patient has an absolute contraindication to methotrexate, sulfasalazine or leflunomide or the patient has aggressive disease. Cont tx - responded to therapy. GVHD-approve if Orencia is being used for prevention of acute graft-versus host disease, patient will also receive a calcineurin inhibitor for prevention of acute graft-versus-host disease, patient will also receive methotrexate for prevention of acute graft-versus-host disease, patient will undergo hematopoietic stem cell transplantation from one of the following donors: matched unrelated donor OR 1-allele-mismatched unrelated donor.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ORGOVYX

---

### Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate Cancer-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ORKAMBI

### Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with Kalydeco, Trikafta or Symdeko.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	1 year of age and older
<b>Prescriber Restrictions</b>	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt meets A, B and C: A) pt has two copies of the F508del mutation in the CFTR gene, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ORSERDU

### Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast cancer in postmenopausal women or Men-approve if the patient meets the following criteria (A, B, C, D, and E): A) Patient has recurrent or metastatic disease, AND B) Patient has estrogen receptor positive (ER+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has estrogen receptor 1 gene (ESR1)-mutated disease, AND E) Patient has tried at least one endocrine therapy. Note: Examples of endocrine therapy include fulvestrant, anastrozole, exemestane, letrozole, and tamoxifen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## OTEZLA

### Products Affected

- OTEZLA MG (51), 10 MG (4)-20 MG (4)-30 MG
- OTEZLA STARTER ORAL (47)
- TABLETS,DOSE PACK 10 MG (4)- 20

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARD).
<b>Required Medical Information</b>	Diagnosis, previous drugs tried
<b>Age Restrictions</b>	PP- 6 years and older (initial), All other dx - 18 years and older (initial)
<b>Prescriber Restrictions</b>	All dx-initial only-PsA - Prescribed by or in consultation with a dermatologist or rheumatologist. PP - prescribed by or in consultation with a dermatologist. Behcet's-prescribed by or in consultation with a dermatologist or rheumatologist
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A, B or C]: A) tried at least one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial with a biologic also counts) or B) contraindication to MTX or C) patient has mild to moderate disease and the patient requires systemic therapy. PSORIATIC ARTHRITIS (PsA): approve. BEHCET'S-oral ulcers or other mucocutaneous involvement. CONTINUATION THERAPY (PP/PsA/Behcet's): received 4 months of therapy and had a response.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## OXERVATE

---

### Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 16 weeks per affected eye(s)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by an ophthalmologist or an optometrist.
Coverage Duration	Initial-8 weeks, continuation-approve for an additional 8 weeks
Other Criteria	Patients who have already received Oxervate-approve if the patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PADCEV

### Products Affected

- PADCEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Urothelial carcinoma-approve if the patient has locally advanced or metastatic disease and meets either (i or ii): (i): Padcev is used as first-line therapy and will be used in combination with Keytruda (pembrolizumab intravenous infusion), or (ii): Padcev is used as subsequent therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PANRETIN

---

### Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist, oncologist, or infectious disease specialist
Coverage Duration	1 year
Other Criteria	Kaposi Sarcoma-approve if the patient is not receiving systemic therapy for Kaposi Sarcoma.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## PAVBLU

---

### Products Affected

- PAVBLU

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## PEMAZYRE

---

### Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test AND the patient has been previously treated with at least one systemic therapy regimen. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement, as detected by an approved test and the cancer is in chronic phase or blast phase.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PENICILLAMINE

### Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Wilson's Disease-Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cystinuria-approve. Wilson's disease-approve if diagnosis is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, d): a) Presence of Kayser-Fleischer rings, b) Serum ceruloplasmin level less than 20 mg/dL, c) Liver biopsy findings consistent with Wilson's disease, d) 24-hour urinary copper greater than 40 mcg/24 hours.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PHENYLBUTYRATE

### Products Affected

- sodium phenylbutyrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant therapy with more than one phenylbutyrate product
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
<b>Coverage Duration</b>	Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval
<b>Other Criteria</b>	Urea cycle disorders-approve if genetic or enzymatic testing confirmed a urea cycle disorder or if the patient has hyperammonemia diagnosed with an ammonia level above the upper limit of the normal reference range for the reporting laboratory.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# PHEOCHROMOCYTOMA

## Products Affected

- *metyrosine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior medication trials
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial and continuation therapy for metyrosine)
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	If the requested drug is metyrosine for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). If the requested drug is metyrosine for continuation therapy, approve if the patient is currently receiving metyrosine or has received metyrosine in the past.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PHOSPHATE BINDERS AND SIMILAR AGENTS

### Products Affected

- *calcium acetate(phosphat bind)*
- *sevelamer carbonate oral tablet*
- VELPHORO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients on dialysis [non-D use]. For Auryxia when used for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis [non-D use]
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

### Products Affected

- *alyq*
- *sildenafil (pulmonary arterial hypertension) oral tablet 20 mg*
- *tadalafil (pulm. hypertension)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use With Guanylate Cyclase Stimulators.
<b>Required Medical Information</b>	Diagnosis, right heart cath results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PIQRAY

### Products Affected

- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X 1), 300 MG/DAY (150 MG X 2)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast Cancer. Approve if the patient meets the following criteria (A, B, C, D, E and F): A) The patient is a postmenopausal female, male or pre/perimenopausal and is receiving ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist or has had surgical bilateral oophorectomy or ovarian irradiation AND B) The patient has advanced or metastatic hormone receptor (HR)-positive disease AND C) The patient has human epidermal growth factor receptor 2 (HER2)-negative disease AND D) The patient has PIK3CA-mutated breast cancer as detected by an approved test AND E) The patient has progressed on or after at least one prior endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, tamoxifen, toremifene or fulvestrant) AND F) Piqray will be used in combination with fulvestrant injection.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PIRFENIDONE

### Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	IPF (initial therapy)- must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. IPF (continuation of therapy)-approve.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PLEGRIDY

### Products Affected

- PLEGRIDY INTRAMUSCULAR
- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## POLIVY

### Products Affected

- POLIVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma/High-Grade B-Cell Lymphoma-Approve if the patient has International Prognostic Index score of greater than or equal to 2 and will use Polivy as first line therapy OR the patient has been treated with at least one prior chemotherapy regimen. Note: Diffuse large B-cell lymphoma includes histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma. B-Cell Lymphoma (Examples include HIV-related B-cell lymphoma and post-transplant lymphoproliferative disorders) - approve if the patient has been treated with at least one prior chemotherapy regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	B-Cell Lymphoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## POMALYST

### Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Kaposi Sarcoma/MM-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	CNS Lymphoma-approve if the patient has relapsed or refractory disease. Kaposi Sarcoma-Approve if the patient meets one of the following (i or ii): i. patient is Human Immunodeficiency Virus (HIV)-negative OR ii. patient meets both of the following (a and b): a) The patient is Human Immunodeficiency Virus (HIV)-positive AND b) The patient continues to receive highly active antiretroviral therapy (HAART). MM-approve if the patient has received at least one other Revlimid (lenalidomide tablets)-containing regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Systemic Light Chain Amyloidosis, Central Nervous System (CNS) Lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## POSACONAZOLE (ORAL)

---

### Products Affected

- *posaconazole oral tablet, delayed release (dr/ec)*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Aspergillus/Candida prophylaxis, mucormycosis-6 mo, all others-3 months
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	mucomycosis - maintenance, fusariosis, invasive - treatment fungal infections (systemic) in patients with human immunodeficiency virus (HIV) infections (e.g., histoplasmosis, coccidioidomycosis) - treatment.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## POTELIGEO

---

### Products Affected

- POTELIGEO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Mycosis fungoides/Sezary-prescribed by, or in consultation with an oncologist or dermatologist. ATLL-prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Mycosis Fungoides/Sezary Syndrome-Approve. ATLL-patient has relapsed or refractory disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adults with T-cell leukemia/lymphoma (ATLL)
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## PREVYMIS

---

### Products Affected

- PREVYMIS INTRAVENOUS
- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PROLIA

### Products Affected

- PROLIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with other medications for osteoporosis
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Treatment of postmenopausal osteoporosis/Treatment of osteoporosis in men (to increase bone mass) [a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression], approve if the patient meets one of the following: 1. has had inadequate response after 12 months of therapy with an oral bisphosphonate, had osteoporotic fracture or fragility fracture while receiving an oral bisphosphonate, or intolerability to an oral bisphosphonate, OR 2. the patient cannot take an oral bisphosphonate because they cannot swallow or have difficulty swallowing, they cannot remain in an upright position, or they have a pre-existing GI medical condition, OR 3. pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR 4. the patient has severe renal impairment (eg, creatinine clearance less than 35 mL/min) or chronic kidney disease, or if the patient has an osteoporotic fracture or fragility fracture . Treatment of bone loss in patient at high risk for fracture receiving ADT for nonmetastatic prostate cancer, approve if the patient has prostate cancer that is not metastatic to the bone and the patient is receiving ADT (eg, leuprolide, triptorelin, goserelin) or the patient has undergone a bilateral

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>orchiectomy. Treatment of bone loss (to increase bone mass) in patients at high risk for fracture receiving adjuvant AI therapy for breast cancer, approve if the patient has breast cancer that is not metastatic to the bone and is receiving concurrent AI therapy (eg, anastrozole, letrozole, exemestane). Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PROMACTA

### Products Affected

- eltrombopag olamine*
- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts. Severe aplastic anemia, platelet counts and prior therapy. MDS-platelet counts.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Immune Thrombocytopenia or Aplastic Anemia, prescribed by, or after consultation with, a hematologist (initial therapy). Hep C, prescribed by, or after consultation with, a gastroenterologist, hematologist, hepatologist, or a physician who specializes in infectious disease (initial therapy). MDS-presc or after consult with heme/onc (initial therapy). Post-transplant, prescribed by or in consult with a hematologist, oncologist or stem cell transplant specialist physician (initial)
<b>Coverage Duration</b>	ImmuneThrombo/MDS init3mo,cont1yr,AAinit4mo,cont1yr,Thrombo/HepC1yr,Transplant-init3mo,cont6mo
<b>Other Criteria</b>	Thrombocytopenia in patients with immune thrombocytopenia, initial-approve if the patient has a platelet count less than 30,000 microliters or less than 50,000 microliters and the patient is at an increased risk for bleeding AND the patient has tried ONE other therapy (e.g., systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Nplate, Tavalisse, Doptelet, rituximab) or has undergone a splenectomy. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Treatment of thrombocytopenia in patients with Chronic Hepatitis C initial - approve if the patient will be receiving interferon-based therapy for chronic hepatitis C AND if the patient has low platelet counts at baseline (eg, less than 75,000 microliters). Aplastic anemia initial - approve if the patient has low platelet counts at

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>baseline/pretreatment (e.g., less than 30,000 microliter) AND tried one immunosuppressant therapy (e.g., cyclosporine) OR patient will be using Promacta in combination with standard immunosuppressive therapy. Cont-approve if the patient demonstrates a beneficial clinical response. MDS initial-approve if patient has low- to intermediate-risk MDS AND the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and is at an increased risk for bleeding. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Thrombocytopenia post-allogeneic transplantation, initial - approve if, according to the prescriber, the patient has poor graft function AND has a platelet count less than 50,000/mcL. Cont- patient demonstrated a beneficial clinical response.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Thrombocytopenia in Myelodysplastic Syndrome (MDS), Thrombocytopenia in a patient post-allogeneic transplantation
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PYRIMETHAMINE

### Products Affected

- pyrimethamine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient's immune status (Toxoplasma gondii Encephalitis, chronic maintenance and prophylaxis, primary)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## QINLOCK

### Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Gastrointestinal stromal tumor (GIST)-approve if the patient has tried imatinib or avapritinib tablets, AND the patient meets one of the following criteria (i, ii, or iii): i. Patient has tried sunitinib and regorafenib tablets, OR ii. Patient has tried dasatinib tablets, OR iii. Patient is intolerant of sunitinib. Melanoma, cutaneous-approve if the patient has metastatic or unresectable disease, AND the patient has an activating KIT mutation, AND the patient has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Melanoma, cutaneous
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# QULIPTA

---

## Products Affected

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Migraine headache prevention-approve if the patient meets (A and B): A) has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication, and B) if the pt is currently taking Qulipta, the pt has had significant clinical benefit.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## RADICAVA ORS

### Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT SUSP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	ALSFRS-R score
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS (initial and continuation).
Coverage Duration	Initial, 6 months. Continuation, 6 months
Other Criteria	ALS, initial therapy - approve if the patient meets ALL of the following criteria: 1. According to the prescribing physician, the patient has a definite or probable diagnosis of ALS, based on the application of the El Escorial or the revised Airlie house diagnostic criteria AND 2. Patient has a score of two points or more on each item of the ALS Functional Rating Scale - Revised (ALSFRS-R) [ie, has retained most or all activities of daily living], AND 3. Patient has adequate respiratory function according to the prescriber, AND 4. Patient has received or is currently receiving riluzole tablets. Note-a trial of Tiglutik or Exservan would also count. ALS, continuation therapy - approve if, according to the prescribing physician, the patient continues to benefit from therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RECLAST

### Products Affected

- *zoledronic acid-mannitol-water*  
*intravenous piggyback 5 mg/100 ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Medications for Osteoporosis (e.g., other bisphosphonates, Evenity, Prolia, Forteo/Bonsity, Tymlos, calcitonin nasal spray)
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Paget's 1 month. Others 12 months.
<b>Other Criteria</b>	Tx of osteo in post menopausal pt or osteo in men (a man defined as an individual with biological traits of man, regardless of the individual's gender identity/gender expression), must meet ONE of the following: pt had inadequate response after 12 mo (eg, ongoing and sign loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or pt experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot swallow or has difficulty swallowing or pt cannot remain in upright position post oral bisphos admin or pt has pre-existing GI condition (eg, pt with esophageal lesions/ulcers, or abnormal of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt had an osteo fracture or a fragility fracture OR pt has tried IV Reclast (zoledronic acid). Tx of PMO may have also tried IV Boniva (ibandronate) for approval. Prevent or tx of GIO, approve if: pt is initiating or cont therapy with systemic glucocorticoids, AND had an inadequate response after 12 months (eg, ongoing and

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>significant loss of BMD, lack of BMD increase) or pt had an osteo fracture or fragility fracture while on therapy or pt experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot swallow or has difficulty swallowing or pt cannot remain in an upright position post oral bisphos administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), or has tried Reclast OR patient had an osteo fracture or a fragility fracture. Tx of Paget's disease, approve if pt has elevations in serum alkaline phos of two times higher than the upper limit of the age-specific normal reference range, OR pt is symptomatic (eg, bone pain, hearing loss, osteoarthritis), OR pt is at risk for complications from their disease (eg, immobilization, bone deformity, fractures, nerve compression syndrome). Prevent of PMO - meets 1 of the following had inadequate response after trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or patient experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphos admin or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions/ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried Reclast or the patient has had an osteo fracture or fragility fracture.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RELEUKO

### Products Affected

- RELEUKO SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS. Radiation syndrome-prescribed by or in consultation with expert in acute radiation.
<b>Coverage Duration</b>	chemo/SCN/AML-6 mo.HIV/AIDS-4 mo.MDS-3 mo.PBPC,Drug induce A/N, ALL,BMT,Radi-1 mo
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: 1)patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), 2)patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, priorchemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status, or HIV infection), 3)patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor (eg, Leukine,

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	filgramstim products, pegfilgrastim products and a reduced dose or frequency of chemotherapy may compromise treatment, or 4)patient has received chemotherapy, has febrile neutropenia and has at least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute neutrophil count less than 100 cells/mm <sup>3</sup> ], neutropenia expected to be greater than 10 days in duration, invasive fungal infection)
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Neutropenia associated with HIV or AIDS, Treatment of myelodysplastic syndromes (MDS), Drug induced agranulocytosis or neutropenia, Acute lymphocytic leukemia (ALL), Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome), peripheral blood progenitor cell transplantation in patients with cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REMICADE

### Products Affected

- REMICADE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medication, previous medications tried
<b>Age Restrictions</b>	CD and UC, Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	All dx-initial therapy only-Prescribed by or in consult w/RA/AS/Still's/JIA/JRA-rheumatol.Plaque Psor/Pyoderma gangrenosum/HS-dermatol.Psoriatic Arthritis-rheumatol or dermatol.CD/UC-gastroenterol.Uveitis-ophthalmol.GVHD-transplant center, oncol, or hematol.Behcet's- rheumatol, dermatol,ophthalmol, gastroenterol, or neurol.Sarcoidosis-pulmonol, ophthalmol, or dermatol, cardio/neuro.
<b>Coverage Duration</b>	FDAind ini-3 mo,cont1yr,GVHD ini-1 mo,cont-3 mo,Pyo Gang-ini4 mo,cont1 yr,others-ini 3mo,cont-12 mo
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS: tried one conventional synthetic DMARD for at least 3 months (e.g., MTX, leflunomide, hydroxychloroquine, sulfasalazine. 3-month trial of a biologic also counts). CROHN'S DISEASE [one of A, B, C, or D]: A) tried or currently taking corticosteroid (CS) or CS is contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine [AZA], 6-mercaptopurine [6-MP], MTX. Trial of a biologic also counts.), C) had ileocolonic resection, or D) enterocutaneous (perianal or abdominal) or rectovaginal fistulas. ULCERATIVE COLITIS (A or B): A) tried or intolerant to a systemic therapy (e.g., 6-MP, AZA, cyclosporine [CSA], tacrolimus, or a CS. A biologic also counts.) or B) has pouchitis and tried therapy with an antibiotic, probiotic, CS enema, or mesalamine (Rowasa)

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>enema. BEHCET'S (A or B): A) tried one conventional therapy (e.g., systemic CS, immunosuppressants such as AZA, MTX, mycophenolate, CSA, tacrolimus, chlorambucil, cyclophosphamide, interferon alfa. TNF inhibitor also counts.) or B) ophthalmic manifestations. STILL'S DISEASE (A and B): A) tried one CS and B) tried one DMARD for at least 2 months or intolerant (e.g., MTX. Trial of a biologic also counts.) UVEITIS: tried periocular, intraocular or systemic CS or immunosuppressive (e.g., MTX, mycophenolate, CSA. Trial of a biologic also counts.) SARCOIDOSIS (A and B): A) tried one CS and B) tried one immunosuppressant (e.g., MTX, AZA, leflunomide, mycophenolate, hydroxychloroquine, chloroquine.) PYODERMA GANGRENOSUM (A or B): A) tried one systemic CS or B) tried one immunosuppressant for at least 2 months or intolerant (e.g., mycophenolate, CSA). HIDRADENITIS SUPPURATIVA: Tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics, isotretinoin). GRAFT VS HOST DISEASE: Tried one conventional systemic treatment (e.g., CS, antithymocyte globulin, CSA, tacrolimus, mycophenolate.) JUVENILE IDIOPATHIC ARTHRITIS: (A or B): A) tried one systemic medication (e.g., MTX, sulfasalazine, leflunomide, NSAID. Trial of a biologic also counts.) or B) has aggressive disease. PLAQUE PSORIASIS (A or B): A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Trial of a biologic will also count) or B) contraindication to MTX. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Behcet's disease (BD). Still's disease (SD). Uveitis (UV). Pyoderma gangrenosum (PG). Hidradenitis suppurativa (HS). Graft-versus-host disease (GVHD). Juvenile Idiopathic Arthritis (JIA). Sarcoidosis
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REMODULIN

### Products Affected

- treprostinil sodium*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Oral or Inhaled Prostacyclin Agents Used for Pulmonary Hypertension.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH WHO Group 1, prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation).
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Pulmonary Arterial Hypertension (PAH) [World Health Organization (WHO) Group 1], Initial Therapy- Approve if the patient meets all of the following criteria (i, ii, iii, and iv): i. Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND ii. Patient meets the following criteria (a and b): a) Patient has had a right heart catheterization, AND b) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH, AND iii. Patient meets ONE of the following criteria (a or b): a) Patient is in Functional Class III or IV, OR b) Patient is in Functional Class II and meets ONE of the following criteria [(1) or (2)]: (1) Patient has tried or is currently receiving one oral agent for PAH, OR (2) Patient has tried one inhaled or parenteral prostacyclin product for PAH, AND iv. Patient with idiopathic PAH must meet ONE of the following criteria (a, b, c, d, or e): a) Patient meets both of the following criteria [(1) and (2)]: (1) the patient has had an acute response to vasodilator testing that occurred during the right heart catheterization, AND (2) Patient has tried one calcium channel blocker (CCB) therapy, OR b) According to the

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	prescriber, the patient did not have an acute response to vasodilator testing, OR c) According to the prescriber, the patient cannot undergo a vasodilator test, OR d) Patient cannot take CCB therapy, OR e) Patient has tried one CCB. Continuation-Approve if the patient meets ALL of the following conditions (a and b): a) Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND b) Patient meets the following criteria [(1) and (2)]: (1) Patient has had a right heart catheterization, AND (2) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## REPATHA

### Products Affected

- REPATHA
- REPATHA SURECLICK
- REPATHA PUSHTRONEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of Leqvio or Praluent.
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
<b>Age Restrictions</b>	ASCVD/Primary Hyperlipidemia - 18 yo and older, HoFH/HeFH - 10 yo and older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Approve for 1 year
<b>Other Criteria</b>	<p>HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL (or 155 mg/dL if less than 16 years old), b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD, HeFH, or HoFH) [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. HYPERLIPIDEMIA WITH HoFH (both A and B): A) meets (a or b): a) phenotypic confirmation of HoFH, or b) meets (i and ii): i) untreated LDL-C greater</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>than 400 mg/dL or treated LDL-C greater than or equal to 300 mg/dL, and ii) clinical manifestations of HoFH before 10 years of age or at least one parent with untreated LDL-C or total cholesterol consistent with FH, AND B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 70 mg/dL or higher or b) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RETEVMO

### Products Affected

- RETEVMO ORAL CAPSULE 40 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Medullary Thyroid Cancer/Thyroid Cancer/Solid tumors-2 years and older, all others 18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Pending CMS Review
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anaplastic thyroid carcinoma, histiocytic neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REVUFORJ

---

### Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 year and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	ACUTE LEUKEMIA-patient has relapsed or refractory disease and the disease is positive for a lysine methyltransferase 2A (KMT2A) gene translocation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REZDIFFRA

### Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist (initial/continuation)
Coverage Duration	1 year
Other Criteria	<p>INITIAL THERAPY: METABOLIC-DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)/NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE-ADVANCED LIVER FIBROSIS: All of (i, ii and iii): i) Diagnosed by (a or b): a) Liver biopsy performed within 3 years preceding treatment with Rezdiffra showing non-alcoholic fatty liver disease activity score of greater than or equal to 4 with a score of greater than or equal to 1 in ALL of the following: steatosis, ballooning and lobular inflammation, or b) One of the following within 6 months preceding treatment with Rezdiffra (1, 2 or 3): 1) Elastography (e.g. vibration-controlled transient elastography (e.g., FibroScan), transient elastography, magnetic resonance elastography, acoustic radiation force impulse imaging, shear wave elastography) or 2) Computed tomography or 3) Magnetic resonance imaging, and ii) stage F2 or F3 fibrosis prior to Rezdiffra and iii) This will be used in combination with appropriate diet and exercise therapy (prescriber attestation the patient has received counseling on diet and exercise). CONTINUATION THERAPY (on therapy less than 1 year or restarting, review as initial therapy): MASH/NASH: All of (i, ii and iii): i) completed greater than or equal to 1</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	year of therapy and has not had worsening of fibrosis or MASH/NASH, and ii) has not progressed to stage F4 (cirrhosis) and iii) This will be used in combination with appropriate diet and exercise therapy (prescriber attestation the patient has received counseling on diet and exercise).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REZLIDHIA

---

### Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Acute myeloid leukemia-approve if the patient has relapsed or refractory disease and the patient has isocitrate dehydrogenase-1 (IDH1) mutation positive disease as detected by an approved test.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## REZUROCK

---

### Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Graft-versus-host disease-approve if the patient has chronic graft-versus-host disease and has tried at least two conventional systemic treatments (e.g., ibrutinib, cyclosporine) for chronic graft-versus-host disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RILUZOLE

---

### Products Affected

- *riluzole*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS.
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RINVOQ

### Products Affected

- RINVOQ ORAL TABLET EXTENDED  
RELEASE 24 HR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic DMARD, Concurrent use with other potent immunosuppressants, Concurrent use with an anti-interleukin monoclonal antibody, Concurrent use with other janus kinase inhibitors, or concurrent use with a biologic immunomodulator.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	PsA/JIA - 2 years and older (initial therapy), RA/UC/AS/CD/nr-axSpA/GCA-18 years and older (initial therapy), AD-12 years and older (initial therapy)
<b>Prescriber Restrictions</b>	RA/AS/Non-Radiographic Spondy/JIA/GCA, prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. AD-prescr/consult with allergist, immunologist or dermatologist. UC/CD-prescribed by or in consultation with a gastroenterologist. (all apply to initial therapy only)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA)/PSORIATIC ARTHRITIS (PsA)/ULCERATIVE COLITIS (UC)/ANKYLOSING SPONDYLITIS (AS)/CROHN'S DISEASE (CD)/ JUVENILE IDIOPATHIC ARTHRITIS (JIA): 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial. ATOPIC DERMATITIS (AD): 4-month trial of at least one systemic therapy (e.g., Dupixent [dupilumab subcutaneous injection] and Adbry [tralokinumab-ldrm subcutaneous injection]. Azathioprine, cyclosporine, or mycophenolate mofetil also count.) or unable to tolerate a 4-month trial.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (A and B): A) objective signs of inflammation defined as having at least one of the following (a or b): a) C-reactive protein elevated beyond the upper limit of normal or b) sacroiliitis reported on MRI and B) 3-month trial of at least one TNFi or was unable to tolerate a 3-month trial. GIANT CELL ARTERITIS: tried one systemic corticosteroid. CONTINUATION THERAPY: ALL INDICATIONS: patient responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RINVOQ LQ

### Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic DMARD, other potent immunosuppressants, other janus kinase inhibitors, or a biologic immunomodulator.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	PsA-2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	JIA-prescribed by or in consultation with a rheumatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or a dermatologist (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: JUVENILE IDIOPATHIC ARTHRITIS (JIA)/ PSORIATIC ARTHRITIS (PsA) - 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial. CONTINUATION THERAPY: ALL INDICATIONS - patient responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ROFLUMILAST (ORAL)

---

### Products Affected

- *roflumilast*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Chronic Obstructive Pulmonary Disease (COPD), medications tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ROMVIMZA

---

### Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	TENOSYNOVIAL GIANT CELL TUMOR (PIGMENTED VILLONODULAR SYNOVITIS)-tumor is not amenable to improvement with surgery.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ROZLYTREK

### Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC-18 years and older, Solid Tumors-1 month and older, Pediatric Diffuse High-Grade Glioma-less than 18 years old
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Solid Tumors-Approve if the patient's tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease and the mutation was detected by an approved test. Pediatric Diffuse High-Grade Glioma- approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the medication is used either as adjuvant therapy or for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pediatric Diffuse High-Grade Glioma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RUBRACA

### Products Affected

- RUBRACA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Rubraca is being used. BRCA-mutation (germline or somatic) status. Other medications tried for the diagnosis provided
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Maintenance Therapy of Ovarian, Fallopian tube or Primary peritoneal cancer-Approve if the patient is in complete or partial response after a platinum-based chemotherapy regimen and the patient is in complete or partial response to first-line primary treatment or if the patient has recurrent disease and has a BRCA mutation. Castration-Resistant Prostate Cancer - Approve if the patient meets the following criteria (A, B and C): A) The patient has metastatic disease that is BRCA-mutation positive (germline and/or somatic) AND B) The patient meets one of the following criteria (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy AND C) The patient has been previously treated with at least one androgen receptor-directed therapy. Pancreatic adenocarcinoma-approve if pt has a BRCA mutation or PALB2 mutation AND pt has tried platinum-based chemotherapy AND has not had disease progression following the most recent platinum-based chemotherapy. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	Uterine Leiomyosarcoma, Pancreatic Adenocarcinoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RUFINAMIDE

---

### Products Affected

- *rufinamide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Patients 1 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Initial therapy-approve if rufinamide is being used for adjunctive treatment. Continuation-approve if the patient is responding to therapy
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Treatment-Refractory Seizures/Epilepsy
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## RUXIENCE

---

### Products Affected

- RUXIENCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## RYBREVANT

---

### Products Affected

- RYBREVANT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Small Cell Lung Cancer (NSCLC) - approve if pt has locally advanced or metastatic disease AND either (A or B): (A) the pt has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, EGFR exon 19 deletion, or EGFR exon 21 L858R mutation, as detected by an approved test OR pt meets both of the following (a and b): a) medication is used as subsequent therapy AND b) pt has EGFR S768I, L861Q, and/or G719X mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RYDAPT

---

### Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For AML, FLT3 status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML -approve if the patient is FLT3-mutation positive as detected by an approved test. Myeloid or lymphoid Neoplasms with eosinophilia-approve if the patient has an FGFR1 rearrangement or has an FLT3 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid or lymphoid Neoplasms with eosinophilia
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## RYTELO

### Products Affected

- RYTELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist or oncologist (initial)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL THERAPY: MYELOYDYSPLASTIC SYNDROME-All of (i, ii, iii, iv, and v): i.Low- to intermediate-1 risk myelodysplastic syndrome (MDS), Note: MDS risk category is determined using the International Prognostic Scoring System (IPSS). AND, ii.Transfusion-dependent anemia, defined as requiring transfusion of greater than or equal to 4 red blood cell units over an 8-week period, AND iii. Has not responded, lost response to, or is ineligible for erythropoiesis-stimulating agents, Note: Examples of erythropoiesis-stimulating agents (ESA): epoetin alfa product (e.g., Epogen, Procrit, or Retacrit), a darbepoetin alfa product (e.g., Aranesp), or a methoxy polyethylene glycol-epoetin beta product (e.g., Mircera). AND, iv. Does NOT have deletion 5q [del(5q)] cytogenic abnormalities, AND v.Rytelo will NOT be used in combination with an ESA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SANDOSTATIN LAR

### Products Affected

- *octreotide, microspheres*
- SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE RECON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Acromegaly-prescr/consult w/endocrinologist. All neuroendocrine tumors-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro. Meningioma-prescr/consult w/oncologist, radiologist or neurosurgeon. Merkel cell/Thymoma/Thymic carcinoma-prescr/consult w/oncologist. Diarrhea assoc w chemo-presc/consult oncologist/gastro.
<b>Coverage Duration</b>	Enterocutaneous fistula/diarrhea assoc w chemo - 3 months, all others - 1 year
<b>Other Criteria</b>	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Diarrhea assoc w chemo (A and B): A) grade 3 or 4 diarrhea and B) patient has tried at least one antimotility medication. Merkel cell carcinoma (A and B): A) patient has regional or distant metastatic disease and B) has contraindications to or has progressed on checkpoint immunotherapy. Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	(including glucagonomas, gastrinomas, vasoactive intestinal peptides-secreting tumors [VIPomas], insulinomas)-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pheochromocytoma/paraganglioma, Meningioma, Thymoma and thymic carcinoma, enterocutaneous fistulas, diarrhea associated with chemotherapy, Merkel cell carcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# SAPROPTERIN

## Products Affected

- *sapropterin*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Palynziq
<b>Required Medical Information</b>	Diagnosis, Phe concentration
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases (initial therapy)
<b>Coverage Duration</b>	Initial-12 weeks, Continuation-1 year
<b>Other Criteria</b>	Initial - approve. Continuation (Note-if the patient has received less than 12 weeks of therapy or is restarting therapy with sapropterin should be reviewed under initial therapy) - approve if the patient has had a response to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SARCLISA

### Products Affected

- SARCLISA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if pt meets (A, B, or C): A) the requested medication will be used as primary therapy in combination with (i or ii): i) bortezomib, lenalidomide, and dexamethasone, or ii) Kyprolis (carfilzomib intravenous infusion), lenalidomide, and dexamethasone, or B) the requested medication will be used in combination with Pomalyst and dexamethasone and the patient has tried at least TWO prior regimens for multiple myeloma and a proteasome inhibitor was a component of at least one previous regimen and Revlimid was a component of at least one previous regimen, or C) medication will be used in combination with Kyprolis and dexamethasone and pt has tried at least one prior regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SCSEMBLIX

### Products Affected

- SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Chronic Myeloid Leukemia (CML)-approve if the patient meets the following (A and B): A) Patient has Philadelphia chromosome-positive or BCR::ABL1-positive chronic myeloid leukemia, AND B) Patient meets one of the following (i, ii or iii): i. Patient has newly diagnosed disease, OR ii. The chronic myeloid leukemia is T315I-positive, OR iii. Patient has tried at least one other tyrosine kinase inhibitor. Note: Examples of tyrosine kinase inhibitors include imatinib, Bosulif (bosutinib tablets), Iclusig (ponatinib tablets), dasatinib, and nilotinib capsules. Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has an ABL1 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid/Lymphoid Neoplasms with Eosinophilia
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SIGNIFOR

---

### Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy)
<b>Coverage Duration</b>	Cushing's disease/syndrome-Initial therapy - 4 months, Continuation therapy - 1 year.
<b>Other Criteria</b>	Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SIRTURO

---

### Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients weighing less than 15 kg
<b>Required Medical Information</b>	Diagnosis, concomitant therapy
<b>Age Restrictions</b>	Patients 5 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with an infectious diseases specialist
<b>Coverage Duration</b>	9 months
<b>Other Criteria</b>	Tuberculosis (Pulmonary) -Approve if the patient has multidrug-resistant tuberculosis or Mycobacterium tuberculosis resistant to at least rifampin and isoniazid, and the requested medication is prescribed as part of a combination regimen with other anti-tuberculosis agents
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SKYRIZI

### Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis, Previous medication use
<b>Age Restrictions</b>	PP/UC-18 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	PP-Prescribed by or in consultation with a dermatologist (initial therapy), PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy), CD/UC-presc/consult-gastro (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or PUVA) for at least 3 months, unless intolerant. (Note: a 3-month trial or previous intolerance to at least one biologic also counts) or B) contraindication to MTX. PSORIATIC ARTHRITIS (PsA): approve. CROHN'S DISEASE (CD) [one of A, B, C, or D]: A) tried or is currently taking corticosteroids, unless contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine, MTX) [Notes: a trial of a biologic that is not a biosimilar of Skyrizi also counts. A trial of mesalamine does not count as a systemic agent], C) patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or D) patient had ileocolonic resection to reduce the chance of CD recurrence. UICERATIVE COLITIS (UC)-meets ONE of the

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>following (a or b): a)Patient has had a trial of one systemic agent for ulcerative colitis, Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone, methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A trial of one biologic other than the requested drug also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count. OR b)Patient meets BOTH of the following [(1) and (2)]: (1)Patient has pouchitis, AND (2)Patient has tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema. Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema. CD/UC: Patient must be receiving induction dosing with Skyrizi IV within 3 months of initiating therapy with Skyrizi subcutaneous. CONTINUATION THERAPY: ALL INDICATIONS: patient has responded to therapy.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SKYRIZI IV

### Products Affected

- SKYRIZI INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis, Previous medication use
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Approve for 3 doses
<b>Other Criteria</b>	<p>Crohn's Disease- approve if this medication will be used as induction therapy AND the pt meets one of the following (i, ii, iii, or iv): (i) pt has tried or is currently taking a systemic corticosteroid, or a systemic corticosteroid is contraindicated in this patient, or (ii) pt has tried one other conventional systemic therapy for Crohn's disease (ex: azathioprine, 6-mercaptopurine, or methotrexate. Mesalamine does not count. An exception can be made if pt tried at least one biologic OTHER than the requested medication/biosimilar of the requested medication.) or (iii) pt has enterocutaneous (perianal or abdominal) or rectovaginal fistulas or (iv) pt had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Ulcerative colitis- approve if this medication will be used as induction therapy AND pt meets one of the following (i or ii): i) pt tried one systemic therapy (ex: 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A trial of one biologic other than the requested medication also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count.) or ii) pt has</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	pouchitis and has tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema. (Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema.)
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SOFOSBUVIR/VELPATASVIR

---

### Products Affected

- SOFOSBUVIR-VELPATASVIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with other direct acting antivirals, excluding ribavirin.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	3 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied according to AASLD guidelines.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## SOLARAZE

---

### Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 6 months.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## SOMAVERT

---

### Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapy, concomitant therapy
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	1 year
Other Criteria	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SORAFENIB

### Products Affected

- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	<p>Bone cancer, approve if the patient has recurrent chordoma or has osteosarcoma and has tried one standard chemotherapy regimen. GIST, approve if the patient has tried TWO of the following: imatinib mesylate, avapritinib, sunitinib, dasatinib, ripretinib or regorafenib. Differentiated (ie, papillary, follicular, oncocytic) thyroid carcinoma (DTC), approve if the patient is refractory to radioactive iodine treatment. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. AML - Approve if disease is FLT3-ITD mutation positive as detected by an approved test and the medication is used in combination with azacitidine or decitabine or patient has had an allogeneic stem cell transplant and is in remission. Renal cell carcinoma (RCC)-approve if the patient has relapsed or advanced clear cell histology and the patient has tried at least one systemic therapy (e.g., Inlyta, Votrient, Sutent Cabometyx). Ovarian, fallopian tube, primary peritoneal cancer-approve if the patient has platinum resistant disease and sorafenib is used in combination with topotecan. HCC-approve if the patient has unresectable or metastatic disease. Soft tissue sarcoma-approve if the patient has angiosarcoma or desmoid tumors (aggressive fibromatosis) or solitary fibrous</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	tumor/hemangiopericytoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement. Please note for all diagnoses: Part B before Part D Step Therapy applies only to beneficiaries enrolled in an MA-PD plan
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Bone cancer, Soft tissue sarcoma, gastrointestinal stromal tumors (GIST), medullary thyroid carcinoma, Acute Myeloid Leukemia, ovarian, fallopian tube, primary peritoneal cancer, myeloid/lymphoid neoplasms with eosinophilia
<b>Part B Prerequisite</b>	Yes

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SOTYKTU

### Products Affected

- SOTYKTU

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other biologics or with targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Concurrent use with other potent immunosuppressants, including methotrexate.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a dermatologist (initial)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of a biologic will also count) or B) contraindication to MTX. CONTINUATION THERAPY: patient had a response to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## SPRAVATO

---

### Products Affected

- SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by a psychiatrist
Coverage Duration	MDD w/Acute Suicidal Ideation or Behavior - 2 months, Treatment-Resistant Depression - 6 months
Other Criteria	Major Depressive Disorder with Acute Suicidal Ideation or Behavior: approve if the patient has major depressive disorder that is considered to be severe, AND if the patient is concomitantly receiving at least one oral antidepressant, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks. Treatment-Resistant Depression: approve if the patient has demonstrated nonresponse (less than or equal to 25 percent improvement in depression symptoms or scores) to at least two different antidepressants, each from a different pharmacologic class and each antidepressant was used at therapeutic dosages for at least 6 weeks in the current episode of depression, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks, AND patient's history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP).

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SPRYCEL

### Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which dasatinib is being used. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For melanoma, cutaneous- KIT mutation and previous therapies.
<b>Age Restrictions</b>	GIST/bone cancer/ melanoma, cutaneous-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	For CML, patient must have Ph-positive or BCR::ABL1-positive CML. For ALL, patient must have Ph-positive ALL or ABL-class translocation. For Bone Cancer-approve if patient has chondrosarcoma or chordoma. GIST - approve if the patient has tried imatinib or avapritinib. For melanoma, cutaneous - approve if patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	GIST, bone cancer, melanoma cutaneous
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# STELARA

## Products Affected

- SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- STELARA SUBCUTANEOUS SOLUTION
- STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- YESINTEK SUBCUTANEOUS SOLUTION
- YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	PP-6 years and older (initial therapy).
<b>Prescriber Restrictions</b>	Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY for USTEKINUMAB SC: PLAQUE PSORIASIS (PP) [A or B]: A) tried one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, psoralen plus PUVA) for at least 3 months, unless intolerant or B) contraindication to MTX. (Note: a 3-month trial or intolerance of at least one biologic that is not Stelara or a Stelara biosimilar also counts.) CROHN'S DISEASE (CD) [A and B]: A) receiving/received single IV loading dose within 2 months of initiating therapy with ustekinumab SC, and B) (a, b, c or d): a) tried or is currently taking corticosteroids (CS), or CS are contraindicated, b) tried one conventional systemic therapy, c) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or d) had ileocolonic resection to reduce the chance of CD recurrence. ULCERATIVE COLITIS (UC) [A and B]: A)

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	receiving/received single IV loading dose within 2 months of initiating therapy with ustekinumab SC and B) meets one of the following (a or b): a) tried one systemic agent or b) has pouchitis and tried an antibiotic, probiotic, CS enema or mesalamine enema. CONTINUATION THERAPY: PP/PsA/CD/UC: patient has responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## STELARA IV

### Products Affected

- SELARSDI INTRAVENOUS
- YESINTEK INTRAVENOUS
- STELARA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Approve a single dose
<b>Other Criteria</b>	INDUCTION THERAPY for USTEKINUMAB IV: UC [A or B]: A) tried one systemic agent or B) has pouchitis and has tried an antibiotic, probiotic, CS enema or mesalamine enema. Crohn's Disease [A, B, C, or D]: A) tried or is currently taking CS, or CS are contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-MP, MTX, certolizumab, vedolizumab, adalimumab, infliximab), C) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or D) had ileocolonic resection to reduce the chance of Crohn's disease recurrence.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## STIVARGA

### Products Affected

- STIVARGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Stivarga is being used. Prior therapies tried. For metastatic CRC, KRAS/NRAS mutation status.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For GIST, (A or B): A) patient has previously been treated with (i and ii): i) imatinib or Ayvakit and ii) sunitinib or Sprycel, or B) medication is used as first-line therapy for succinate dehydrogenase (SDH)-deficient disease. For HCC, patient must have previously been treated with at least one systemic regimen. Soft tissue sarcoma, advanced or metastatic disease-approve if the patient has non-adipocytic sarcoma, angiosarcoma, or pleomorphic rhabdomyosarcoma. Bone Cancer-approve if the patient has relapsed/refractory or metastatic disease AND the patient has tried one systemic chemotherapy regimen AND pt has Ewing sarcoma or osteosarcoma. Colon and Rectal cancer/Appendiceal cancer-approve if the patient has advanced or metastatic disease, has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient meets one of the following (i or ii): i. patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type), the patient has tried Erbitux or Vectibix or the patient's tumor did not originate on the left side of the colon (from the splenic fixture to rectum) or ii. the patient's tumor or metastases has a RAS mutation (either KRAS mutation or NRAS mutation). CNS tumors (Glioblastoma or H3-mutated high-grade glioma)-approve if the

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	patient has recurrent or progressive disease. Uterine sarcoma- (A and B): A) pt has recurrent, advanced, inoperable, or metastatic disease, and B) tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Soft tissue Sarcoma, Bone Cancer, CNS tumors (Glioblastoma/H3-mutated high-grade glioma), Appendiceal cancer, Uterine sarcoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## STRENSIQ

### Products Affected

- STRENSIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	Disease onset-less than or equal to 18
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of hypophosphatasia or related disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hypophosphatasia - Perinatal/Infantile- and Juvenile-Onset-Patient must meet both A and B for approval. A) Diagnosis is supported by one of the following (i, ii, or iii): i. Molecular genetic testing documenting tissue non-specific alkaline phosphatase (ALPL) gene variants OR ii. Low baseline serum alkaline phosphatase activity OR iii. An elevated level of a tissue non-specific alkaline phosphatase substrate (i.e., serum pyridoxal 5'-phosphate, serum or urinary inorganic pyrophosphate, urinary phosphoethanolamine) AND B) Patient meets one of the following (i or ii): i. Patient currently has, or has a history of clinical manifestations consistent with hypophosphatasia (e.g., skeletal abnormalities, premature tooth loss, muscle weakness, poor feeding, failure to thrive, respiratory problems, Vitamin B6-dependent seizures) OR ii. Patient has a family history (parent or sibling) of hypophosphatasia without current clinical manifestations of hypophosphatasia
<b>Indications</b>	All FDA-approved Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SUCRAID

### Products Affected

- SUCRAID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient meets the following criteria (A and B): A) The diagnosis is established by one of the following (i or ii): i. Patient has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by ALL of the following (a, b, c, and d): a) Decreased (usually absent) sucrase (normal reference: greater than 25 U/g protein), b) Decreased or normal isomaltase (palatinase) [normal reference: greater than 5 U/g protein], c) Decreased maltase (normal reference: greater than 100 U/g protein), d) Decreased or normal lactase (normal reference: greater than 15 U/g protein) OR ii. Patient has a molecular genetic test demonstrating homozygous or compound heterozygous pathogenic or likely pathogenic sucrase-isomaltase gene variant AND B) Patient has symptomatic congenital sucrose-isomaltase deficiency (e.g., diarrhea, bloating, abdominal cramping).
<b>Indications</b>	All FDA-approved Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## SUNITINIB

### Products Affected

- sunitinib malate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Gastrointestinal stromal tumors (GIST), approve if the patient has tried imatinib or Ayvakit or if the patient has succinate dehydrogenase (SDH)-deficient GIST. Chordoma, approve if the patient has recurrent disease. Differentiated thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. Meningioma, approve if the patient has recurrent or progressive disease. Thymic carcinoma - has tried at least one systemic chemotherapy. Renal Cell Carcinoma (RCC) - approve if the patient has relapsed or advanced disease. Neuroendocrine tumors of the pancreas-approve for advanced or metastatic disease. Pheochromocytoma/paraganglioma-approve if the patient has unresectable or metastatic disease. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chordoma, angiosarcoma, solitary fibrous tumor/hemangiopericytoma, alveolar soft part sarcoma (ASPS), differentiated (ie, papillary, follicular,

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	and oncocytic carcinoma) thyroid carcinoma, medullary thyroid carcinoma, meningioma, thymic carcinoma, pheochromocytoma/paraganglioma, myeloid/lymphoid neoplasms with eosinophilia, GIST-unresectable succinate dehydrogenase (SDH)-deficient GIST, or use after avapritinib.
<b>Part B Prerequisite</b>	No

## SYMDEKO

### Products Affected

- SYMDEKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients with unknown CFTR gene mutations, Combination therapy with Orkambi, Kalydeco or Trikafta
<b>Required Medical Information</b>	Diagnosis, specific CFTR gene mutations
<b>Age Restrictions</b>	Six years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt meets A, B and C: A) pt has at least one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic or patient has TWO copies of the F508 del mutation, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## SYMLIN

---

### Products Affected

- SYMLINPEN 120
- SYMLINPEN 60

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TABRECTA

## Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has advanced or metastatic disease AND the tumor is positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping or high-level MET amplification, as detected by an approved test.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer with high-level MET amplification.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TADALAFIL

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Indication for which tadalafil is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 mos.
Other Criteria	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed as once daily dosing, to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TAFAMIDIS

### Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with Onpattro or Tegsedi or Wainua. Concurrent use of Vyndaqel and Vyndamax.
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cardiomyopathy of Wild-Type or Hereditary Transthyretin Amyloidosis- approve if the diagnosis was confirmed by one of the following (i, ii or iii): i. A technetium pyrophosphate scan (i.e., nuclear scintigraphy), ii. Amyloid deposits are identified on cardiac biopsy OR iii. patient had genetic testing which, according to the prescriber, identified a TTR mutation AND Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TAFINLAR

## Products Affected

- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Tafinlar is being used. BRAF V600 mutations
<b>Age Restrictions</b>	1 year and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Melanoma with BRAF V600 mutation AND patient has unresectable, advanced (including Stage III or Stage IV disease) or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC, must have BRAF V600E mutation. Thyroid Cancer, anaplastic-must have BRAF V600-positive disease AND Tafinlar will be taken in combination with Mekinist, unless intolerant AND the patient has locally advanced or metastatic anaplastic disease. Thyroid Cancer, differentiated (i.e., papillary, follicular, or Hurthle cell) AND the patient has disease that is refractory to radioactive iodine therapy AND the patient has BRAF-positive disease. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Mekinist. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>progressive disease for one of the following conditions (a, b, c, or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma OR d) Oligodendroglioma OR iii. Melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease AND patient has BRAF V600-mutation positive disease. Metastatic or solid tumors-approve if BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets) AND patient has no satisfactory alternative treatment options. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-approve if the patient meets the following (A, B, and C): A) Patient has recurrent disease, AND B) Patient has BRAF V600 mutation-positive disease, AND C) The medication will be taken in combination with Mekinist (trametinib tablets). Hairy Cell Leukemia, approve if pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Mekinist. Small bowel adenocarcinoma, approve if pt has BRAF V600E mutation-positive advanced or metastatic disease and this will be used with Mekinist AND (i or ii): i) this will be used as initial therapy and pt has received previous FOLFOX/CAPEOX therapy in the adjuvant setting within the past 12 months or has a contraindication, or (ii) this will be used as second-line and subsequent therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Differentiated Thyroid Cancer, Biliary tract cancer, central nervous system cancer, histiocytic neoplasm, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, hairy cell leukemia, small bowel adenocarcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TAGRISSO

## Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>NSCLC-EGFR Mutation Positive (other than EGFR T790M-Positive Mutation)- approve if the patient has advanced or metastatic disease, has EGFR mutation-positive NSCLC as detected by an approved test. Note-examples of EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. NSCLC-EGFR T790M mutation positive-approve if the patient has advanced or metastatic EGFR T790M mutation-positive NSCLC as detected by an approved test and has progressed on treatment with at least one of the EGFR tyrosine kinase inhibitors. NSCLC-Post resection-approve if the patient has completely resected disease and has received previous adjuvant chemotherapy or if the patient is ineligible to receive platinum based chemotherapy and the patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test. NSCLC- Unresectable Stage III - approve if the patient has locally advanced, unresectable (stage III) disease AND EGFR exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an approved test AND not had disease progression during or following</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	platinum-based chemoradiation therapy. (Note: Patients could have received concurrent or sequential chemoradiation therapy.)
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TALVEY

## Products Affected

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TALZENNA

### Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Recurrent or metastatic breast cancer-approve if the patient has germline BRCA mutation-positive disease. Prostate cancer - approve if the patient has metastatic castration resistant prostate cancer, AND is using this medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy AND the patient has homologous recombination repair (HRR) gene-mutated disease [Note: HRR gene mutations include ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C] AND the medication is used in combination with Xtandi (enzalutamide capsules and tablets).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TASIGNA

### Products Affected

- *nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*
- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Tasigna is being used. For indication of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For indication of gastrointestinal stromal tumor (GIST) and melanoma, cutaneous, prior therapies tried. For melanoma, cutaneous, KIT mutation status.
<b>Age Restrictions</b>	GIST/Myeloid/lymphoid neoplasms/melanoma, cutaneous-18 years and older, ALL - 15 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Acute lymphoblastic leukemia, philadelphia chromosome positive-approve. CML, philadelphia chromosome positive or BCR::ABL1-mutation positive chronic myeloid leukemia- approve. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. Pigmented villonodular synovitis/tenosynovial giant cell tumor-approve if the patient has tried Turalio or Romvimza or cannot take Turalio or Romvimza, according to the prescriber. For melanoma, cutaneous - approve if the patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Philadelphia positive Acute Lymphoblastic Leukemia (ALL) and Gastrointestinal Stromal Tumor (GIST), Pigmented villonodular synovitis/tenosynovial giant cell tumor, Myeloid/Lymphoid neoplasms with Eosinophilia, melanoma cutaneous.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# TAZAROTENE

---

## Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic uses
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TAZVERIK

---

### Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Epithelioid Sarcoma-16 years and older, Follicular Lymphoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Epithelioid Sarcoma-approve if the patient has metastatic or locally advanced disease and the patient is not eligible for complete resection. Follicular Lymphoma-approve if the patient has relapsed or refractory disease and there are no appropriate alternative therapies or the patient has tried at least two prior systemic therapies.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TECVAYLI

---

### Products Affected

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Multiple Myeloma-approve if the patient has tried at least four systemic regimens which must include at least one drug from each of the following classes: proteasome inhibitor, immunomodulatory drug and Anti-CD38 monoclonal antibody
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TEPMETKO

---

### Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced or metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations or patient has high-level MET amplification, as detected by an approved test.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer with high-level MET amplification.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TERIPARATIDE

### Products Affected

- BONSITY
- TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with other medications for osteoporosis
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime.
<b>Other Criteria</b>	<p>INITIAL THERAPY: Postmenopausal Osteoporosis (PMO) Treatment, Increase Bone Mass in Men (see Note 1 below) with Primary or Hypogonadal Osteoporosis, and Treatment of Glucocorticosteroid-Induced Osteoporosis (GIO): (one of A, B, C, D or E): A) tried one oral bisphosphonate or cannot take due to swallowing difficulties or inability to remain upright after administration, B) pre-existing gastrointestinal condition (e.g., esophageal lesions/ulcers, abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), C) tried an IV bisphosphonate (PMO-ibandronate or zoledronic acid, all other diagnoses-zoledronic acid), D) severe renal impairment (creatinine clearance [CrCL] less than 35 mL/min) or chronic kidney disease (CKD), or E) patient had an osteoporotic fracture or fragility fracture at any time in the past.</p> <p>CONTINUATION THERAPY: ALL INDICATIONS: if the patient has taken teriparatide for two years, approve if the patient is at high risk for fracture. Examples of high risk for fracture include a previous osteoporotic fracture or fragility fracture, receipt of medications that increase the risk of</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	osteoporosis, advanced age, and very low bone mineral density. Note 1: a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TETRABENAZINE

### Products Affected

- tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TEVIMBRA

### Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis. Hepatocellular carcinoma-approve if (A or B): A) medication is used first-line and meets (i or ii): i) pt has liver-confined, unresectable disease and is deemed ineligible for transplant, or ii) pt has extrahepatic/metastatic disease and are deemed ineligible for resection, transplant, or locoregional therapy, or B) medication is being used for subsequent-line therapy. Nasopharyngeal carcinoma-approve if (A and B): A) pt has recurrent, unresectable, oligometastatic, or metastatic disease, and B) meets (i or ii): i) used as first-line treatment in combination with cisplatin and gemcitabine or ii) used as subsequent treatment and (a or b): a) used as a single agent, or b) used in combination with cisplatin and gemcitabine. Small bowel adenocarcinoma-approve if (A, B, C and D): A) locally unresectable or medically inoperable disease, or advanced or metastatic disease, and B) ultra-hypermutated phenotype (defined as tumor mutation burden greater than 50 mutations/megabase), and C) has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease or polymerase epsilon/delta (POLE/POLD1) mutation positive disease, and D) is used as a single agent.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. ESOPHAGEAL and ESOPHAGOGASTRIC JUNCTION CANCERS-All of (A, B and C): A.Meets ONE of the following (i or ii): i.Unresectable locally advanced, recurrent, or metastatic

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>disease, OR ii. Not a surgical candidate, AND B. Meets (i, ii, or iii): i) pt has esophageal squamous cell carcinoma with tumor expression for programmed death-ligand 1 (PD-L1) as determined by an approved test has a combined positive score (CPS) greater than or equal to 1 and medication is used as first-line or induction therapy and is used in combination with chemotherapy, or ii) pt has esophageal squamous cell carcinoma and Medication is used as a single agent and is used for subsequent therapy, or iii) pt has esophagel adenocarcinoma that is HER2 overexpression negative and tumor expression for PD-L1 as determined by an approved test has a CPS greater than or equal to 1, AND C. Patient has NOT previously received a checkpoint inhibitor or has NO tumor progression while on a checkpoint inhibitor. Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion). Gastric or gastroesophageal junction adenocarcinoma- approve if (A, B, C and D): A) unresectable, recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-negative disease, B) tumor expresses programmed death-ligand 1 (PD-L1) greater than or equal to 1 percent, C) used first line, and D) used in combination with platinum and fluoropyrimidine-based chemotherapy. Anal carcinoma-meets (A and B): A) used as a single agent and B) meets (i or ii): i) locally recurrent, progressive disease and administered before proceeding to abdominoperineal resection, or ii) metastatic disease, used as subsequent therapy and has not received prior immunotherapy [ex: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Libtayo (cemiplimab intravenous infusion), and Jemperli (dostarlimab intravenous infusion)]. CLL/SLL-approve if (A, B and C): A) patient has histologic transformation to diffuse large B-cell lymphoma, and B) has del(17p)/TP53 mutation OR is chemotherapy refractory OR is unable to receive chemoimmunotherapy, and C) is used in combination with Brukinsa (zanubrutinib capsules). Colon, rectal or appendiceal cancer-approve if pt meets (A and B): A) meets (i or ii): i) pt has mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease, or ii) has DNA polymerase epsilon/delta (POLE/POLD1) mutation, and B) pt has advanced or metastatic disease.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anal carcinoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, hepatocellular carcinoma, nasopharyngeal carcinoma, small bowel adenocarcinoma, colon/rectal/appendiceal cancer

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## THALOMID

### Products Affected

- THALOMID ORAL CAPSULE 100 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	MM, myelofibrosis, histiocytic neoplasms-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapsone, acitretin [Soriatane]). Myelofibrosis, approve if according to the prescriber the patient has anemia and has serum erythropoietin levels greater than or equal to 500 mU/mL or if the patient has serum erythropoietin level less than 500 mU/mL and experienced no response or loss of response to erythropoietic stimulating agents. Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and has relapsed or refractory disease. Castleman's disease-approve if the patient has multicentric Castleman's disease and is negative for the human

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). Histiocytic neoplasms-approve if pt has Langerhans cell histiocytosis with single-system multifocal skin disease or Rosai-Dorfman cutaneous disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Discoid lupus erythematosus or cutaneous lupus erythematosus, Myelofibrosis, Prurigo nodularis, Recurrent aphthous ulcers or aphthous stomatitis, Kaposi's Sarcoma, Castleman's Disease, histiocytic neoplasms.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TIBSOVO

### Products Affected

- TIBSOVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, IDH1 Status
<b>Age Restrictions</b>	All diagnoses (except chondrosarcoma)-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML- approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive, as detected by an approved test. Cholangiocarcinoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive and has been previously treated with at least one chemotherapy regimen (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). Chondrosarcoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive. Central nervous system cancer-approve if the patient has oligodendroglioma or astrocytoma. Myelodysplastic Syndrome-approve if patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease AND relapsed or refractory disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chondrosarcoma, Central nervous system cancer
<b>Part B Prerequisite</b>	Yes

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TIVDAK

---

### Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cervical cancer-approve if the patient has tried at least one chemotherapy agent. Vaginal cancer- approve if the patient has tried at least one chemotherapy agent.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Vaginal cancer
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TOBRAMYCIN (NEBULIZATION)

### Products Affected

- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Bronchiectasis, Non-cystic fibrosis-18 years and older
Prescriber Restrictions	CF-prescr/consult w/pulm/phys specializes in tx of CF.Bronchiectasis, non CF-prescr/consult w/pulm
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cystic fibrosis/Bronchiectasis, non-cystic fibrosis-approve if the patient has pseudomonas aeruginosa in the culture of the airway.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Bronchiectasis, non-cystic fibrosis
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TOLVAPTAN

## Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Jynarque.
<b>Required Medical Information</b>	Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion).
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 30 days for initial therapy, 3 months for continuation of therapy
<b>Other Criteria</b>	Hyponatremia, initial therapy (including new starts, patients on therapy for less than 30 days, and patients restarting therapy) - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on tolvaptan and has received less than 30 days of therapy. Hyponatremia, continuation of therapy for patients established on therapy for at least 30 days - approve if the serum sodium level has increased from baseline (prior to initiating the requested drug) OR if the patient experienced improvement in at least one symptom, such as nausea, vomiting, headache, lethargy, or confusion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TOPICAL AGENTS FOR ATOPIC DERMATITIS

---

### Products Affected

- *pimecrolimus*
- *tacrolimus topical*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TOPICAL RETINOID PRODUCTS

---

### Products Affected

- *tretinoin topical*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TOPIRAMATE/ZONISAMIDE

### Products Affected

- EPRONTIA
- *topiramate oral capsule, sprinkle 15 mg, 25 mg*
- *topiramate oral tablet*
- ZONISADE
- *zonisamide*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight loss or smoking cessation.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TRANSDERMAL FENTANYL

---

### Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute (i.e., non-chronic) pain.
<b>Required Medical Information</b>	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, sickle cell disease, in hospice or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TRANSMUCOSAL FENTANYL DRUGS

### Products Affected

- *fentanyl citrate buccal lozenge on a handle 1,200 mcg, 200 mcg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# TRELSTAR

---

## Products Affected

- TRELSTAR INTRAMUSCULAR  
SUSPENSION FOR RECONSTITUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prostate cancer: Prescribed by or in consultation with a oncologist or urologist. Head and neck cancer - salivary gland tumors: Prescribed by or in consultation with a oncologist.
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Prostate cancer: Patients new to therapy, are required to try Eligard or Orgovyx prior to approval of Trelstar. Head and neck cancer - salivary gland tumors: approve if patient has recurrent, unresectable, or metastatic disease and androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer - salivary gland tumors
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TREMFYA

### Products Affected

- TREMFYA PEN
- TREMFYA SUBCUTANEOUS
- TREMFYA PEN INDUCTION PK-CROHN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	PP/UC/CD- 18 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	PP-Prescribed by or in consultation with a dermatologist (initial therapy only). PsA-prescribed by or in consultation with a dermatologist or rheumatologist (initial therapy). UC/CD-prescribed by or in consultation with a gastroenterologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	PP, initial therapy - approve if the pt meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: a biologic that is not a biosimilar of the requested product will also count) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. ULCERATIVE COLITIS- pt will receive 3 induction doses with Tremfya IV within 3 months of initiating Tremfya SC AND (A or B): A) tried a systemic therapy (e.g., 6-MP, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a CS) or B) has pouchitis and tried therapy with an antibiotic, probiotic, CS enema, or mesalamine (Rowasa) enema. CROHN'S DISEASE (CD) [one of A, B, C, or D]: A) tried or currently taking corticosteroid (CS) or CS is contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX], certolizumab, infliximab, ustekinumab, vedolizumab), C) had ileocolonic resection, or D) enterocutaneous

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	(perianal or abdominal) or rectovaginal fistulas. PP/PsA/UC/CD continuation of therapy - approve it the pt is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TREMFYA IV

### Products Affected

- TREMFYA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic oral small molecule drug.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	3 doses for induction
<b>Other Criteria</b>	<p>ULCERATIVE COLITIS-Approve if the patient meets the following (A and B): A. Medication will be used as induction therapy, AND B. Patient meets ONE of the following (i or ii): i. Has tried one systemic therapy, Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A trial of one biologic other than the requested medication also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count., OR ii. Patient meets BOTH of the following (a and b): a.Has pouchitis, AND b. Has tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema. Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema.</p> <p>CROHN'S DISEASE (CD): Approve if the patient meets the following (A and B): A. Medication will be used as induction therapy, AND B. patient meets one of (i, ii, iii, or iv): i. tried or currently taking corticosteroid (CS) or CS is contraindicated, ii. tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX],</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	certolizumab, infliximab, ustekinumab, vedolizumab), iii. had ileocolonic resection, or iv. enterocutaneous (perianal or abdominal) or rectovaginal fistulas.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TRIENTINE

### Products Affected

- *trientine oral capsule 250 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	For Wilson's Disease, approve if the patient meets A and B: A) Diagnosis of Wilson's disease is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, or d): a. Presence of Kayser-Fleischer rings, OR b. Serum ceruloplasmin levels less than 20mg/dL, OR c. Liver biopsy findings consistent with Wilson's disease, OR d. 24-hour urinary copper greater than 40 micrograms/24 hours, AND B) Patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant, OR 6) the patient has been started on therapy with trientine.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TRIKAFTA

## Products Affected

- TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL
- TRIKAFTA ORAL TABLETS, SEQUENTIAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients with unknown CFTR gene mutations. Combination therapy with Orkambi, Kalydeco or Symdeko.
<b>Required Medical Information</b>	Diagnosis, specific CFTR gene mutations, concurrent medications
<b>Age Restrictions</b>	2 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt meets A, B and C: A) pt has at least one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# TRODELVY

## Products Affected

- TRODELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has recurrent or metastatic, human epidermal growth factor receptor (HER2) negative breast cancer and patient meets (a or b): a) patient has hormone receptor (HR) negative disease AND has tried at least one systemic regimen, OR b) patient has HR positive disease, has tried endocrine therapy, has tried a cyclin-dependent kinase(CDK) 4/6 inhibitor and has tried at least two systemic chemotherapy regimens . Urothelial Cancer-approve if the patient has locally advanced or metastatic urothelial cancer AND has tried at least one systemic chemotherapy AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TRUQAP

### Products Affected

- TRUQAP

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast Cancer-Approve if the patient meets the following (A, B, C, D and E): A) Patient has locally advanced or metastatic disease, AND B) Patient has hormone receptor positive (HR+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has at least one phosphatidylinositol 3-kinase (PIK3CA), serine/threonine protein kinase (AKT1), or phosphatase and tensin homolog (PTEN)-alteration, AND E) Patient meets one of the following (i or ii): i. Patient has had progression with at least one endocrine-based regimen in the metastatic setting (Note: Examples of endocrine therapy include anastrozole, exemestane, and letrozole.) and has had progression with at least one cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting (Note: Examples of CDK4/6 inhibitor include: Ibrance (palbociclib tablets or capsules), Verzenio (abemaciclib tablets), Kisqali (ribociclib tablets), Kisqali Femara Co-Pack (ribociclib and letrozole tablets) OR ii. Patient has recurrence on or within 12 months of completing adjuvant endocrine therapy.
<b>Indications</b>	All FDA-approved Indications.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TUKYSA

### Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast Cancer-approve if the patient has recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, has received at least one prior anti-HER2-based regimen in the metastatic setting and Tukysa is used in combination with trastuzumab and capecitabine. Colon/Rectal Cancer-approve if the requested medication is used in combination with trastuzumab, patient has unresectable or metastatic disease, human epidermal growth factor receptor 2 (HER2)-amplified disease, AND Patient's tumor or metastases are wild-type RAS (KRAS wild-type and NRAS wild-type). Biliary tract cancer- approve if the patient meets all of (a, b, c, and d): a) unresectable or metastatic disease, b) HER2 positive disease, c) tried at least one systemic regimen, d) will use in combination with trastuzumab.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Biliary tract cancer

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## TURALIO

---

### Products Affected

- TURALIO ORAL CAPSULE 125 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)-approve if, according to the prescriber, the tumor is not amenable to improvement with surgery. Histiocytic Neoplasms-approve if the patient has a colony stimulating factor 1 receptor (CSF1R) mutation AND has one of the following conditions (i, ii, or iii): i. Langerhans cell histiocytosis OR ii. Erdheim-Chester disease OR iii. Rosai-Dorfman disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic Neoplasms
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## TYENNE IV

### Products Affected

- TYENNE INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or targeted synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>INITIAL THERAPY- RHEUMATOID ARTHRITIS (RA) [A OR B]: A) Try TWO of the following: Enbrel, a preferred adalimumab product, Rinvoq, Oencia or Xeljanz. (Note: if the patient has not tried TWO of these drugs listed, previous trial(s) with the following drugs can count towards meeting the try TWO requirement: Cimzia, infliximab, Simponi (IV/SC), Kevzara or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A OR B]: A) Try TWO of the following: Enbrel, Oencia, Rinvoq, Xeljanz, a preferred adalimumab product, (Note: if they have had a trial with infliximab, Kevzara or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder.</p> <p>SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): Try one other systemic agent (eg, a corticosteroid [oral, IV], a conventional synthetic DMARD [eg, MTX, leflunomide, sulfasalazine], Kineret (anakinra), or Ilaris (canakinumab for SC injection), or a 1-month trial of a nonsteroidal</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	anti-inflammatory drug [NSAID]). GIANT CELL ARTERITIS: Try one systemic corticosteroid. CYTOKINE RELEASE SYNDROME ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY-approve. Please Note: preferred adalimumab products Humira (NDCs starting with -00074), Cyltezo, Yuflyma. CONTINUATION THERAPY-RA, PJIA, SJIA, GCA:patient has responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## UBRELVY

---

### Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Migraine, Acute treatment-approve
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## UPTRA VI

### Products Affected

- UPTRA VI ORAL TABLET
- UPTRA VI ORAL TABLETS, DOSE PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Inhaled or Parenteral Prostacyclin Agents Used for Pulmonary Hypertension.
<b>Required Medical Information</b>	Confirmation of right heart catheterization, medication history (as described in Other Criteria)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH must be prescribed by, or in consultation with, a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Patient new to therapy must meet a) OR b): a) tried one or is currently taking one oral therapy for PAH for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## VALCHLOR

### Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Cutaneous lymphoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve. Adult T-Cell Leukemia/Lymphoma-approve if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma. Langerhans cell histiocytosis-approve if the patient has unifocal Langerhans cell histiocytosis with isolated skin disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adults with T-cell leukemia/lymphoma, Langerhans Cell Histiocytosis
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VALTOCO

---

### Products Affected

- VALTOCO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiseizure medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## VANCOMYCIN

---

### Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 weeks
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VANFLYTA

---

### Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Acute Myeloid Leukemia: approve if the patient has FLT3-ITD mutation-positive disease as detected by an approved test and this medication is being used for induction, re-induction, consolidation, or maintenance treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# VENCLEXTA

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy
Age Restrictions	18 years and older (all diagnoses except ALL)
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML-approve if used in combination with azacitidine, decitabine, or cytarabine. CLL/SLL- approve. ALL- approve if relapsed/refractory disease and will be used in combination with chemotherapy. Hairy cell leukemia- approve if disease resistance to BRAF inhibitor therapy. Mantle Cell Lymphoma- approve if (A or B): A) the patient has tried at least one systemic regimen or B) patient has TP53 mutation and will use this as induction therapy in combination with Brukinsa (zanubrutinib) and Gazyva (obinutuzumab intravenous infusion). MDS- approve if pt meets (A and B): A) pt meets (i or ii): (i) has chronic myelomonocytic leukemia-2 or (ii) has higher risk disease (note: includes international prognostic scoring system (IPSS-R) intermediate-, high-, or very-high risk disease) and B) will use in combination with azacitidine or decitabine. Myeloproliferative neoplasm- approve if pt has accelerated or blast phase disease and will use in combination with azacitidine or decitabine. Multiple Myeloma- approve if the patient has t (11,14) translocation AND has tried at least one systemic regimen for multiple myeloma AND Venclexta will be used in combination with dexamethasone. Systemic light chain amyloidosis-approve if the patient has t (11, 14) translocation and has tried at least one systemic

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	regimen. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Mantle Cell Lymphoma, waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, multiple myeloma, systemic light chain amyloidosis, acute lymphoblastic leukemia, hairy cell leukemia, myelodysplastic syndrome, myeloproliferative neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VERZENIO

### Products Affected

- VERZENIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Breast cancer: HR status, HER2 status, previous medications/therapies tried, concomitant therapy, menopausal status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Breast Cancer, Early-pt meets (A,B,C and D): A)Pt HR+disease, AND B) HER2-negative breast cancer, AND C)node-positive disease at high risk of recurrence AND D)meets 1 of the following (i or ii): i.Verzenio will be used in combo w/anastrozole, exemestane, or letrozole AND pt meets one of the following (a,b, or c): a)Pt is postmenopausal woman, OR b)Pt is pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Pt had surgical bilateral oophorectomy or ovarian irradiation, OR c)Pt is man and pt is receiving a GnRH analog, OR ii.Verzenio will be used in combo with tamoxifen AND pt meets 1 of the following (a or b): a)Pt is postmenopausal woman or man OR b)Pt is pre/perimenopausal woman and meets 1 of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Pt had surgical bilateral oophorectomy or ovarian irradiation. Breast Cancer-Recurrent or Metastatic in Women-pt meets (A, B and C): A)has HR+ disease, AND B)Pt meets 1 of following criteria (i or ii): i.Pt is postmenopausal woman, OR ii.Pt is pre/perimenopausal woman and meets 1 of the following (a or b): a)receiving ovarian suppression/ablation with a GnRH agonist, OR b)Pt</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>had surgical bilateral oophorectomy or ovarian irradiation, AND C) either (1 or 2): 1) HER2-negative breast cancer and Pt meets 1 of following criteria (i, ii, or iii): i.Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.pt meets following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least 1 prior endocrine therapy, AND c)has tried chemo for metastatic breast cancer or 2)has HER2-positive breast cancer and has received at least 3 prior anti-HER2-based regimens in metastatic setting and will use this in combo with fulvestrant and trastuzumab.Breast Cancer-Recurrent or Metastatic in Men-pt meets following criteria (A and B): A)HR+ disease, AND B)either (1 or 2): 1) HER2-negative disease and Pt meets 1 of following criteria (i, ii, or iii): i.Pt meets BOTH of the following conditions (a and b): a)receiving a GnRH analog, AND b)Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.Pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least 1 prior endocrine therapy, AND c)Pt has tried chemo for metastatic breast cancer, or 2) has HER2-positive disease and has received at least 3 prior anti-HER2-based regimen in metastatic setting and will use this medication in combo with fulvestrant and trastuzumab. Endometrial cancer-pt meets all of (A, B, And C): A)has recurrent or metastatic disease, and B)has estrogen receptor (ER)-positive tumors, and C)will be using in combination with letrozole.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Endometrial cancer
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# VIGABATRIN

## Products Affected

- *vigabatrín*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, medication history (complex partial seizures)
<b>Age Restrictions</b>	Refractory complex partial seizures - patients 2 years of age or older. Infantile spasms - patients less than or equal to 2 years of age
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist
<b>Coverage Duration</b>	Infantile spasms- 6 months. Treatment-Refractory Partial Seizures- initial 3 months, cont 1 year
<b>Other Criteria</b>	Infantile spasms-requested medication is being used as monotherapy. Treatment refractory complex partial seizures initial-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs. Treatment refractory complex partial seizures continuation- the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VIMIZIM

### Products Affected

- VIMIZIM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine-6-sulfatase activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic N-acetylgalactosamine-6-sulfatase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## VITRAKVI

### Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, NTRK gene fusion status
Age Restrictions	Pediatric Diffuse High-Grade Glioma- less than or equal to 21 years old
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Solid tumors - approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity. Pediatric diffuse high grade glioma - approve if (A and B): A) tumor is positive for NTRK gene fusion and B) meets (i or ii): i) medication is used as adjuvant therapy or ii) medication is used for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pediatric Diffuse High-Grade Glioma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VIZIMPRO

### Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, EGFR status, exon deletions or substitutions
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VONJO

### Products Affected

- VONJO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Myelofibrosis (MF), including primary MF, post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient meets either (A, B, or C): (A) the patient has a platelet count of less than $50 \times 10^9$ /L (less than 50,000/mcL) OR (B) Patient has a platelet count of greater than or equal to $50 \times 10^9$ /L (greater than or equal to 50,000/mcL) and has high-risk disease, OR (C) patient has myelofibrosis-associated anemia. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease- related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Accelerated or blast phase myeloproliferative neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# VORANIGO

## Products Affected

- VORANIGO ORAL TABLET 10 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	GLIOMAS-All of (A, B and C): A. Susceptible isocitrate dehydrogenase-1 (IDH1) or IDH2 mutation-positive disease, AND B. Grade 2 oligodendroglioma OR Grade 2 astrocytoma, AND C. Prior surgery, including biopsy, sub-total resection, or gross total resection
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VORICONAZOLE (ORAL)

### Products Affected

- *voriconazole*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Aspergillus-Prophy, systemic w/risk neutropenia-Prophy, systemic w/HIV-Prophy/Tx-6 mo, others-3 mo
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Aspergillus Infections - prophylaxis, oropharyngeal candidiasis (fluconazole-refractory) - treatment, candidia endophthalmitis - treatment, blastomycosis - treatment, fungal infections (systemic) in patients at risk of neutropenia - prophylaxis, fungal infections (systemic) in patients with human immunodeficiency virus (HIV) - prophylaxis or treatment.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# VOSEVI

## Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
<b>Coverage Duration</b>	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VOTRIENT

### Products Affected

- *pazopanib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	<p>Soft tissue sarcoma other than GIST-approve if the patient has advanced or metastatic disease and has ONE of the following: alveolar soft part sarcoma, angiosarcoma, desmoid tumors (aggressive fibromatosis, dermatofibrosarcoma protuberans with fibrosarcomatous transformation, non-adipocytic sarcoma or pleomorphic rhabdomyosarcoma.</p> <p>Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Uterine sarcoma, approve if the patient has recurrent or metastatic disease. Renal Cell Carcinoma, Clear Cell or non-Clear Cell histology-approved if the patient has relapsed or advanced disease or VonHippel-Lindau disease. Ovarian Cancer (ie, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) - approve if the patient has persistent or recurrent disease. GIST - approve if the patient has succinate dehydrogenase (SDH)-deficient GIST OR the patient has tried TWO of the following: Gleevec, Ayvakit, Sutent, Sprycel, Qinlock or Stivarga. Medullary Thyroid Carcinoma, approve if the patient has tried at least one systemic therapy. Bone cancer-approve if the patient has chondrosarcoma and has metastatic widespread disease.</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Differentiated (ie, papillary, follicular, oncocytic carcinoma) thyroid carcinoma. Uterine sarcoma, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Gastrointestinal Stromal Tumor (GIST), Medullary thyroid carcinoma, bone cancer.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



# VOWST

## Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	30 days
Other Criteria	Prevention of recurrence of clostridioides difficile infection (CDI)-approve if the patient has completed a bowel prep, will not eat or drink for at least 8 hours prior to the first dose and will complete their antibacterial treatment for recurrent CDI 2-4 days before initiating treatment with Vowst and Vowst will not be used for the TREATMENT of CDI.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VUMERITY

---

### Products Affected

- VUMERITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## VYLOY

### Products Affected

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	<p>Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (all of A, B, C, D and E): A. Unresectable locally advanced, recurrent or metastatic disease, AND B. Tumor is claudin 18.2 positive as determined by an approved test, Note: Claudin 18.2 positivity is defined as greater than or equal to 75 percent of tumor cells demonstrating moderate to strong membranous claudin 18.2 immunohistochemical staining. AND C. Tumor is human epidermal growth factor receptor 2 (HER2)-negative, AND D. Used for first-line treatment, AND E. Used in combination with fluoropyrimidine- and platinum-containing chemotherapy. Note: Examples of fluoropyrimidines include 5-fluorouracil and capecitabine. Examples of platinum chemotherapy agents include oxaliplatin. Esophageal adenocarcinoma- all of (A, B, C, D and E): A. unresectable locally advanced, recurrent, or metastatic disease, AND B. tumor is is claudin 18.2 positive as determined by an approved test, AND C. tumor is human epidermal growth factor receptor 2 (HER2)-negative, and D. used for first-</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	line treatment, AND E. used in combination with fluoropyrimidine- and platinum-containing chemotherapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Esophageal adenocarcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## VYVGART

### Products Affected

- VYVGART
- VYVGART HYTRULO

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant Use with Another Neonatal Fc Receptor Blocker, a Complement Inhibitor, or a Rituximab Product
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (CIDP: initial only, GMG: initial and continuation)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (CIDP: initial only, GMG: initial and continuation)
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## WELIREG

### Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Pheochromocytoma/paraganglioma-12 years and older, Other indications-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Pheochromocytoma/paraganglioma- approve if pt has locally advanced, unresectable, or metastatic disease. Renal Cell Carcinoma- approve if pt has advanced disease AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor AND has tried at least one a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). [Note: Examples of PD-1 inhibitor or PD-L1 inhibitor include: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), and Bavencio (avelumab intravenous infusion). Examples of VEGF-TKI include Cabometyx (cabozantinib tablets), Lenvima (lenvatinib capsules), Inlyta (axitinib tablets), Fotivda (tivozanib capsules), pazopanib, sunitinib, and sorafenib.] Van Hippel-Lindau Disease-approve if the patient meets the following (A, B, and C): A) Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing, B) Does not require immediate surgery and C) Patient requires therapy for ONE of the following conditions (i, ii, iii, or iv): i. Central nervous system hemangioblastomas, OR ii. Pancreatic

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	neuroendocrine tumors, OR iii. Renal cell carcinoma, OR iv. Retinal hemangioblastoma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

# XALKORI

## Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Anaplastic large cell lymphoma/IMT-patients greater than or equal to 1 year of age. All other diagnoses-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test and patients new to therapy must have a trial of Alecensa or Lorbrena prior to approval of Xalkori. Metastatic non-small cell lung cancer, approve if the patient has ROS1 rearrangement positive disease, as detected by an approved test. Anaplastic Large Cell Lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Histiocytic neoplasm-approve if the patient has ALK rearrangement/fusion-positive disease and meets one of the following criteria (i, ii, or iii): (i. Patient has Langerhans cell histiocytosis, OR ii. Patient has Erdheim-Chester disease OR iii. Patient has Rosai-Dorfman disease. NSCLC with MET mutation-approve if the patient has high level MET amplification or MET exon 14 skipping mutation. Inflammatory Myofibroblastic Tumor-approve if the patient has ALK positive disease and the patient has advanced, recurrent or metastatic disease or the tumor is

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	inoperable. Melanoma, cutaneous-approve if the patient has ALK fusion disease or ROS1 fusion disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	NSCLC with high level MET amplification or MET Exon 14 skipping mutation, Histiocytic neoplasms, melanoma, cutaneous.
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## XDEMVY

---

### Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XELJANZ

### Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ XR
- XELJANZ ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a Targeted Synthetic DMARD for an inflammatory condition (eg, tocilizumab, anakinra, abatacept, rituximab, certolizumab pegol, etanercept, adalimumab, infliximab, golimumab). Concurrent use with potent immunosuppressants that are not methotrexate (MTX) [eg, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil].
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	AS/PsA/RA/UC-18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	RA, JIA/JRA/AS prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. UC-prescribed by or in consultation with a gastroenterologist. (all apply to initial therapy only)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. PsA initial, approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. UC-Approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least ONE tumor necrosis factor inhibitor for ulcerative colitis or was unable to tolerate a 3-month trial. Juvenile Idiopathic Arthritis (JIA) [or Juvenile Rheumatoid Arthritis] (regardless of type of onset) [Note: This includes patients with juvenile spondyloarthropathy/active sacroiliac arthritis]-initial-approve Xeljanz immediate release tablets or solution if the patient meets the following: patient has had a 3 month trial of at least one tumor necrosis factor

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	inhibitor or was unable to tolerate a 3 month trial. AS-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. Continuation Therapy - Patient must have responded, as determined by the prescriber.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XERMELO

### Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapy, concomitant therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Initial therapy - approve if the patient meets ALL of the following criteria: 1) patient has been on long-acting somatostatin analog (SSA) therapy (eg, Somatuline Depot [lanreotide for injection]) AND 2) while on long-acting SSA therapy (prior to starting Xermelo), the patient continues to have at least four bowel movements per day, AND 3) Xermelo will be used concomitantly with a long-acting SSA therapy. Continuation therapy - approve if the patient is continuing to take Xermelo concomitantly with a long-acting SSA therapy for carcinoid syndrome diarrhea.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XIAFLEX

### Products Affected

- XIAFLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Retreatment for Peyronie's Disease (i.e., treatment beyond eight injections).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Dupuytren's Contracture-administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture. Peyronie's Disease -administered by a healthcare provider experienced in the treatment of male urological diseases.
<b>Coverage Duration</b>	Dupuytren's Contracture-3 months, Peyronie's Disease-6 months
<b>Other Criteria</b>	Dupuytren's Contracture-at baseline (prior to initial injection of Xiaflex), the patient had contracture of a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint of at least 20 degrees AND the patient will not be treated with more than a total of three injections (maximum) per affected cord as part of the current treatment course. Peyronie's Disease-the patient meets ONE of the following (i or ii): i. at baseline (prior to use of Xiaflex), the patient has a penile curvature deformity of at least 30 degrees OR in a patient who has received prior treatment with Xiaflex, the patient has a penile curvature deformity of at least 15 degrees AND the patient has not previously been treated with a complete course (8 injections) of Xiaflex for Peyronie's disease.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XIFAXAN

### Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Traveler's diarrhea - 12 years of age or older. Hepatic encephalopathy, irritable bowel syndrome with diarrhea - 18 years of age or older.
<b>Prescriber Restrictions</b>	Pouchitis - prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Enceph-6 mo, IBS w/diarrhea-14 days, TD-3 days, intest bact overgrowth-14 days, Pouchitis - 1 year
<b>Other Criteria</b>	Hepatic Encephalopathy-approve Xifaxan 550 mg tablets if the patient has previously had overt hepatic encephalopathy and the requested medication will be used concomitantly with lactulose, unless the patient has a contraindication or significant intolerance to treatment with lactulose. Irritable bowel syndrome with diarrhea-approve Xifaxan 550 mg tablets. Travelers Diarrhea-approve Xifaxan 200 mg tablets if the patient is afebrile and does not have blood in the stool. Small intestine bacterial overgrowth-approve Xifaxan 200mg or 550 mg tablets if the diagnosis has been confirmed by a glucose hydrogen breath test, lactulose hydrogen breath test, or small bowel aspiration and culture. Chronic antibiotic-dependent pouchitis- approve Xifaxan 200mg or 550mg tablets if patient meets all of (a, b, c and d): a) recurrent pouchitis (Note: recurrent pouchitis is typically considered history of at least 3 pouchitis episodes within a 12 month period), and b) episodes of pouchitis respond to antibiotic therapy but relapse shortly after antibiotic discontinuation, and c) alternative causes of recurrent pouchitis have been ruled out, and d) has tried long-term

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	antibiotic therapy trials (at least 4 weeks) of BOTH ciprofloxacin and metronidazole for remission maintenance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Small intestine bacterial overgrowth, chronic antibiotic-dependent pouchitis
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XOLAIR

### Products Affected

- XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML
- XOLAIR SUBCUTANEOUS RECON SOLN
- XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older
<b>Prescriber Restrictions</b>	Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist
<b>Coverage Duration</b>	asthma/CIU-Initial tx 4 months, Polyps-initial-6 months, continued tx 12 months, Food allergy-1 yr
<b>Other Criteria</b>	MODERATE TO SEVERE PERSISTENT ASTHMA (A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, and B) baseline positive skin test or in vitro test for 1 or more perennial or seasonal aeroallergens C) received at least 3 months of combination therapy with an inhaled corticosteroid (ICS) and additional asthma controller/maintenance medication (e.g., LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody) [see Exception 1 below] and D) asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody and meets one of the following (a, b, c, d, or e): a) experienced two or more asthma exacerbations requiring systemic CSs in the past year, b) experienced one or more asthma exacerbation requiring

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>hospitalization/urgent care visit/emergency department visit in the past year, c) forced expiratory volume in 1 second (FEV1) less than 80% predicted, d) FEV1/forced vital capacity (FVC) less than 0.80, or e) asthma worsens upon tapering of oral CS. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRwNP) [all of A, B, C, D, and E]: A) diagnosis by direct exam, endoscopy, or sinus CT scan, B) baseline (prior to Xolair or another monoclonal antibody that may lower IgE) IgE at least 30 IU/ml, C) at least two of the following symptoms for 6 months: nasal congestion, obstruction, discharge, reduction/loss of smell, D) tried intranasal CS and will continue in combination with Xolair, and E) one of the following (a, b, or c): a) had systemic CS at least 5 days in past 2 years, b) contraindication to systemic CS, or c) had nasal polyp surgery. CHRONIC IDIOPATHIC URTICARIA (CIU): urticaria more than 6 weeks prior to treatment with Xolair with symptoms present more than 3 days per week despite daily non-sedating H1-antihistamine therapy. IgE-MEDIATED FOOD ALLERGY (all of A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, B) positive skin prick test or positive in vitro test for IgE to one or more foods, C) history of allergic reaction that met all of the following (a, b, and c): a) signs and symptoms of a significant systemic allergic reaction, b) reaction occurred within a short period of time following a known ingestion of the food, and c) prescriber deemed this reaction significant enough to require a prescription for an epinephrine auto-injector, and D) patient has been prescribed an epinephrine auto-injector.</p> <p>CONTINUATION THERAPY: ASTHMA: patient responded to therapy and continues to receive an ICS. CRwNP: patient responded after 6 months of therapy and continues intranasal CS. CIU: patient responded to therapy.</p> <p>Exception 1: an exception to the requirement of a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XOSPATA

### Products Affected

- XOSPATA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, FLT3-mutation status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML - approve if the disease is FLT3-mutation positive as detected by an approved test. Lymphoid, Myeloid Neoplasms-approve if the patient has eosinophilia and the disease is FLT3-mutation positive as detected by an approved test.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Lymphoid, Myeloid Neoplasms
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XPOVIO

### Products Affected

- XPOVIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Multiple Myeloma-Approve if the patient meets the following (A and B): A) The medication will be taken in combination with dexamethasone AND B) Patient meets one of the following (i, ii, or iii): i. Patient has tried at least four prior regimens for multiple myeloma OR ii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with bortezomib OR iii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with Darzalex (daratumumab infusion), Darzalex Faspro (daratumumab and hyaluronidase-fihj injection), or Pomalyst (pomalidomide capsules). Note: Examples include bortezomib/Revlimid (lenalidomide capsules)/dexamethasone, Kyprolis (carfilzomib infusion)/Revlimid/dexamethasone, Darzalex (daratumumab injection)/bortezomib or Kyprolis/dexamethasone, or other regimens containing a proteasome inhibitor, immunomodulatory drug, and/or anti-CD38 monoclonal antibody. Diffuse large B-cell lymphoma Note: this includes patients with histologic transformation of indolent lymphomas to

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	diffuse large B-cell lymphoma)-approve if the patient has been treated with at least two prior systemic therapies.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Treatment of multiple myeloma in combination with daratumumb or pomalidomide
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XTANDI

### Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Xtandi is being used.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Prostate cancer-castration-resistant [Metastatic or Non-metastatic] and Prostate cancer-metastatic, castration sensitive-approve if Xtandi will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog [for example: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets)] or if the patient has had a bilateral orchiectomy. Prostate cancer- Non-Metastatic, Castration-Sensitive - approve if pt has biochemical recurrence and is at high risk for metastasis. [Note: High-risk biochemical recurrence is defined as prostate-specific antigen (PSA) doubling time less than or equal to 9 months.]
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



PA Criteria	Criteria Details
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## XYREM

### Products Affected

- SODIUM OXYBATE (PREFERRED NDCS STARTING WITH 00054)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with Xywav, Wakix or Sunosi
<b>Required Medical Information</b>	Medication history (as described in Other Criteria field)
<b>Age Restrictions</b>	7 years and older
<b>Prescriber Restrictions</b>	Prescribed by a sleep specialist physician or a Neurologist
<b>Coverage Duration</b>	12 months.
<b>Other Criteria</b>	For Excessive daytime sleepiness (EDS) in patients with narcolepsy, 18 years and older - approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). For EDS in patients with narcolepsy, less than 18 years old-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextramphetamine) or modafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Cataplexy treatment in patients with narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## **ZEJULA**

### **Products Affected**

- ZEJULA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Ovarian, fallopian tube, or primary peritoneal cancer, maintenance therapy - approve if the patient is in complete or partial response after platinum-based chemotherapy regimen and if the patient is new to therapy they must have a trial of Lynparza prior to approval of Zejula. Patients who have had a complete or partial response to first-line platinum based chemotherapy and do not have BRCA altered disease are not required to try Lynparza. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen. In addition, patients new to therapy must have a trial of Lynparza prior to approval of Zejula. Ovarian, fallopian tube or primary peritoneal cancer in the treatment setting-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Uterine Leiomyosarcoma, Ovarian, fallopian tube or primary peritoneal cancer-treatment
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZELBORAF

### Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	BRAFV600 mutation status required.
Age Restrictions	All diagnoses (except CNS cancer)-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	<p>Melanoma, patient new to therapy must have BRAFV600 mutation for approval AND have unresectable, advanced or metastatic melanoma. HCL - must have tried at least one other systemic therapy for hairy cell leukemia OR is unable to tolerate purine analogs and Zelboraf will be used in combination with Gazyva (obinutuzumab intravenous infusion) as initial therapy. Thyroid Cancer-patient has disease that is refractory to radioactive iodine therapy. Erdheim-Chester disease, in patients with BRAF V600 mutation-approve. Central Nervous System Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, c or d): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma/neuroglioma/glioneuronal tumor OR d) pediatric diffuse high-grade glioma OR ii. Recurrent or progressive disease for one of the following conditions (a or b): a) glioma/circumscribed glioma OR b) Glioblastoma OR iii. Melanoma with brain metastases AND the medication will be taken in combination with Cotellic (cobimetinib tablets). Histiocytic Neoplasm-approve if the patient has Langerhans cell</p>

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

<b>PA Criteria</b>	<b>Criteria Details</b>
	histiocytosis and one of the following (i, ii, or iii): i. Multisystem disease OR ii. Pulmonary disease OR iii. Central nervous system lesions AND the patient has BRAF V600-mutation positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Hairy Cell Leukemia, Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Differentiated thyroid carcinoma (i.e., papillary, follicular, or oncocytic carcinoma) with BRAF-positive disease, Central Nervous System Cancer, Histiocytic Neoplasm
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZEPOSIA

### Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS-Concurrent use with other disease-modifying agents used for multiple sclerosis. UC- Concurrent Use with a Biologic or with a Targeted Synthetic Disease-modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	UC-18 years and older
<b>Prescriber Restrictions</b>	MS-Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. UC-Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	MS-approve. Ulcerative Colitis, initial-approve if the patient has tried ONE of the following: a preferred adalimumab product, a preferred ustekinumab product, a preferred infliximab product, Rinvoq, Skyrizi, Tremfya. Note-a trial of Simponi SC, Entyvio IV/SC, Omvoh IV/SC, a non-preferred adalimumab product, a non-preferred ustekinumab product or a non-preferred infliximab would also count). Cont tx-approve if the patient has been established on Zeposia. Please Note: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma. Preferred infliximab products include Remicade, Zymfentra. Preferred ustekinumab products include Stelara, Selarsdi, Yesintek.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZEPZELCA

---

### Products Affected

- ZEPZELCA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Small cell lung cancer-approve if the patient has metastatic disease and has previously received platinum-based chemotherapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZIIHERA

### Products Affected

- ZIIHERA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. BILIARY TRACT CANCER - (all of A, B, C, D and E): A. Patient has ONE of the following (i, ii, or iii): i. Gallbladder cancer, OR ii. Intrahepatic cholangiocarcinoma, OR iii. Extrahepatic cholangiocarcinoma, AND B. Patient has unresectable, resected gross residual, or metastatic disease, AND C. The tumor is human epidermal growth factor receptor 2 (HER2) positive with immunohistochemistry score of 3+ (IHC3+) as determined by an approved test, AND D. The medication is used for subsequent therapy, AND E. The medication is used as a single agent.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ZOLINZA

---

### Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ZTALMY

---

### Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder-approve if the patient has a molecularly confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and patient has tried or is concomitantly receiving two other antiepileptic drugs.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZURZUVAE

### Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Previous treatment with Zurzuvae during the current episode of postpartum depression
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a psychiatrist or an obstetrician-gynecologist
<b>Coverage Duration</b>	14 days
<b>Other Criteria</b>	Postpartum depression-approve if the patient meets the following (A, B and C): A.Patient meets BOTH of the following (i and ii): i. Patient has been diagnosed with severe depression, AND ii. Symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery, AND B. Patient is less than or equal to 12 months postpartum, AND C. Patient is not currently pregnant.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZYDELIG

---

### Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	CLL/SLL-approve if the patient has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	small lymphocytic lymphoma
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



## ZYKADIA

### Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Erdheim-Chester Disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. NSCLC, ALK positive-approve if the patient has advanced or metastatic disease that is ALK positive as detected by an approved test and for patients new to therapy must have a trial of Alecensa or Lorbrena prior to approval of Zykadia. NSCLC, ROS1 Rearrangement-approve if the patient has advanced or metastatic disease. Peripheral T-Cell Lymphoma- approve if patient has ALK-positive anaplastic large cell lymphoma (ALCL).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation. Patients with NSCLC with ROS1 Rearrangement. Erdheim-Chester disease. Peripheral T-Cell Lymphoma.
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZYMFENTRA

### Products Affected

- ZYMFENTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic disease-modifying antirheumatic drug (DMARD).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	Crohn's Disease, initial therapy-Approve if the patient meets the following (i. and ii.): i.The patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra, AND ii. Patient meets ONE of the following (a, b, c, or d): a) Patient has tried or is currently taking systemic corticosteroids, or corticosteroids are contraindicated in this patient, Note: Examples of corticosteroids are prednisone and methylprednisolone. OR b) Patient has tried one conventional systemic therapy for Crohn's disease, Note: Examples of conventional systemic therapy for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate. An exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. OR c) Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, OR d) Patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Crohn's Disease, continuation-approve if the patient has had a response to therapy.

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>Ulcerative Colitis, initial therapy-Approve if the patient meets ALL of the following (i, ii, iii, and iv): i. The patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra, AND ii. Patient meets ONE of the following (a or b): a) Patient had a trial of one systemic agent or was intolerant to one of these agents for ulcerative colitis, Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A previous trial of one biologic other than the requested medication also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count. OR b) Patient meets BOTH of the following [(1) and (2)]: (1) Patient has pouchitis AND (2) Patient has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine enema). Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema (Cortenema, generics). Ulcerative Colitis, continuation-approve if the patient has had a response to therapy.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## ZYNLONTA

---

### Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Large B-Cell Lymphoma, HIV-Related B-Cell Lymphoma and post-transplant lymphoproliferative disorder-approve if the patient has tried at least two systemic regimens.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	HIV-related B-Cell Lymphoma, Post-transplant lymphoproliferative disorders
Part B Prerequisite	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZYNYZ

### Products Affected

- ZYNYZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Merkel Cell Carcinoma-approve if the patient has not received prior systemic therapy for Merkel cell carcinoma and if the patient has metastatic disease or has locally advanced disease or recurrent regional disease. Anal carcinoma- approve if pt has either locally recurrent persistent disease or metastatic disease AND medication is used for subsequent treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anal carcinoma
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## ZYTIGA

### Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- *abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is used concurrently used with a gonadotropin-releasing hormone (GnRH) analog (see Note 1) or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)- approve if the medication is used in combination with prednisone and the medication is concurrently used with a GnRH analog (see Note 1) or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A) abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i or ii ): i. abiraterone with prednisone is used in combination with a GnRH analog (see Note 1) OR ii. Patient has had a bilateral orchiectomy. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with prednisone, the medication will be used in combination with external beam radiation therapy and the patient meets one of the

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

PA Criteria	Criteria Details
	<p>following criteria (i or ii): i. abiraterone is used in combination with a GnRH analog (see Note 1) OR ii. Patient has had a bilateral orchiectomy. Prostate cancer- radical prostatectomy or post radiation therapy-approve if patient meets (A, B, C and D): A) the medication is used in combination with prednisone, B) meets (i or ii): i) the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy or ii) PSA recurrence or positive digital rectal examination (DRE) after radiation therapy, C) patient has pelvic recurrence or positive regional lymph nodes, and D) the medication will be used concurrently with GnRH analog (see Note 1) or the patient has had a bilateral orchiectomy. Salivary Gland Tumors- approve if (A, B and C): A) used in combination with prednisone, B) androgen receptor-positive (AR+) recurrent, unresectable or metastatic tumor, and C) used in combination with a GnRH analog (see Note 1). Note 1: examples of GnRH analogs are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer- radical prostatectomy or post radiation, Salivary Gland Tumors
<b>Part B Prerequisite</b>	No

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## PART B VERSUS PART D

---

### Products Affected

- ABELCET INTRAVENOUS SUSPENSION
- ABRAXANE INTRAVENOUS SUSPENSION FOR RECONSTITUTION
- *acetylcysteine solution*
- *acyclovir sodium intravenous solution*
- ADCETRIS INTRAVENOUS RECON SOLN
- *albuterol sulfate inhalation solution for nebulization*
- ALIQOPA INTRAVENOUS RECON SOLN
- *amiodarone intravenous solution*
- *amphotericin b injection recon soln*
- *aprepitant oral capsule*
- *aprepitant oral capsule, dose pack*
- *arformoterol inhalation solution for nebulization*
- *arsenic trioxide intravenous solution*
- *azacitidine injection recon soln*
- *azathioprine oral tablet 50 mg*
- *azathioprine sodium injection recon soln*
- BAVENCIO INTRAVENOUS SOLUTION
- BELEODAQ INTRAVENOUS RECON SOLN
- *bendamustine intravenous recon soln*
- BENDEKA INTRAVENOUS SOLUTION
- BESPONSA INTRAVENOUS RECON SOLN
- *bleomycin injection recon soln*
- BLINCYTO INTRAVENOUS KIT
- BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG
- *bortezomib injection recon soln 3.5 mg*
- *budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml*
- *busulfan intravenous solution*
- *carboplatin intravenous solution*
- *carmustine intravenous recon soln 100 mg*
- *cidofovir intravenous solution*
- *cisplatin intravenous solution*
- *cladribine intravenous solution*
- CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 4.25%/D10W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 4.25%/D5W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 5%-D20W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 8%-D10W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 8%-D14W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- *clofarabine intravenous solution*
- *cromolyn inhalation solution for nebulization*
- *cyclophosphamide intravenous recon soln*
- *cyclophosphamide oral capsule*
- CYCLOPHOSPHAMIDE ORAL TABLET
- *cyclosporine modified oral capsule*
- *cyclosporine modified oral solution*
- *cyclosporine oral capsule*
- CYRAMZA INTRAVENOUS SOLUTION
- *cytarabine (pf) injection solution*
- *cytarabine injection solution*
- *dacarbazine intravenous recon soln*
- *dactinomycin intravenous recon soln*
- DANYELZA INTRAVENOUS SOLUTION
- DARZALEX INTRAVENOUS SOLUTION

- *daunorubicin intravenous solution*
- *decitabine intravenous recon soln*
- *deferioxamine injection recon soln*
- *dexrazoxane hcl intravenous recon soln*
- *dobutamine in d5w intravenous parenteral solution 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml)*
- *dobutamine intravenous solution*
- *docetaxel intravenous solution*
- *dopamine in 5 % dextrose intravenous solution*
- *dopamine intravenous solution 200 mg/5 ml (40 mg/ml), 400 mg/10 ml (40 mg/ml)*
- *doxorubicin intravenous recon soln*
- *doxorubicin intravenous solution*
- *doxorubicin, peg-liposomal intravenous suspension*
- *dronabinol oral capsule*
- **ELZONRIS INTRAVENOUS SOLUTION**
- **EMPLICITI INTRAVENOUS RECON SOLN**
- **ENERIX-B (PF) INTRAMUSCULAR SUSPENSION**
- **ENERIX-B (PF) INTRAMUSCULAR SYRINGE**
- **ENERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE**
- **ENVARUS XR ORAL TABLET EXTENDED RELEASE 24 HR**
- *epirubicin intravenous solution 200 mg/100 ml*
- **ERBITUX INTRAVENOUS SOLUTION**
- *eribulin intravenous solution*
- **ERWINASE INJECTION RECON SOLN**
- **ETOPOPHOS INTRAVENOUS RECON SOLN**
- *etoposide intravenous solution*
- *everolimus (immunosuppressive) oral tablet*
- *floxuridine injection recon soln*
- *fludarabine intravenous recon soln*
- *fludarabine intravenous solution*
- *fluorouracil intravenous solution*
- *formoterol fumarate inhalation solution for nebulization*
- *fulvestrant intramuscular syringe*
- *ganciclovir sodium intravenous recon soln*
- *ganciclovir sodium intravenous solution*
- **GAZYVA INTRAVENOUS SOLUTION**
- *gemcitabine intravenous recon soln*
- *gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)*
- **GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML**
- *gengraf oral capsule*
- *gengraf oral solution*
- **GRAFAPEX INTRAVENOUS RECON SOLN**
- *granisetron hcl oral tablet*
- **HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE**
- **HIZENTRA SUBCUTANEOUS SOLUTION**
- **HIZENTRA SUBCUTANEOUS SYRINGE**
- *idarubicin intravenous solution*
- *ifosfamide intravenous recon soln*
- *ifosfamide intravenous solution*
- **IMFINZI INTRAVENOUS SOLUTION**
- *intralipid intravenous emulsion 20 %*
- *ipratropium bromide inhalation solution*
- *ipratropium-albuterol inhalation solution for nebulization*
- *irinotecan intravenous solution*
- **ISTODAX INTRAVENOUS RECON SOLN**
- **IXEMPRA INTRAVENOUS RECON SOLN**
- **JEVTANA INTRAVENOUS SOLUTION**
- **JYLAMVO ORAL SOLUTION**
- **JYNNEOS (PF) SUBCUTANEOUS SUSPENSION**
- **KHAPZORY INTRAVENOUS RECON SOLN 175 MG**
- **KIMMTRAK INTRAVENOUS SOLUTION**
- **KYPROLIS INTRAVENOUS RECON SOLN**

- *levoleucovorin calcium intravenous recon soln*
- *levoleucovorin calcium intravenous solution*
- MARGENZA INTRAVENOUS SOLUTION
- *melphalan hcl intravenous recon soln*
- *mesna intravenous solution*
- *methotrexate sodium (pf) injection recon soln*
- *methotrexate sodium (pf) injection solution*
- *methotrexate sodium injection solution*
- *methotrexate sodium oral tablet*
- *methyprednisolone oral tablet*
- *milrinone in 5 % dextrose intravenous piggyback*
- *milrinone intravenous solution*
- *mitomycin intravenous recon soln*
- *mitoxantrone intravenous concentrate*
- *mycophenolate mofetil (hcl) intravenous recon soln*
- *mycophenolate mofetil oral capsule*
- *mycophenolate mofetil oral suspension for reconstitution*
- *mycophenolate mofetil oral tablet*
- *mycophenolate sodium oral tablet, delayed release (dr/ec)*
- MYHIBBIN ORAL SUSPENSION
- MYLOTARG INTRAVENOUS RECON SOLN
- *nelarabine intravenous solution*
- *nitroglycerin in 5 % dextrose intravenous solution 100 mg/250 ml (400 mcg/ml), 25 mg/250 ml (100 mcg/ml), 50 mg/250 ml (200 mcg/ml)*
- *nitroglycerin intravenous solution*
- NULOJIX INTRAVENOUS RECON SOLN
- ONCASPAR INJECTION SOLUTION
- *ondansetron hcl oral solution*
- *ondansetron hcl oral tablet 4 mg, 8 mg*
- *ondansetron oral tablet, disintegrating 4 mg, 8 mg*
- ONIVYDE INTRAVENOUS DISPERSION
- *oxaliplatin intravenous recon soln*
- *oxaliplatin intravenous solution*
- *paclitaxel intravenous concentrate*
- *paclitaxel protein-bound intravenous suspension for reconstitution*
- *paraplatin intravenous solution*
- *pemetrexed disodium intravenous recon soln*
- *pentamidine inhalation recon soln*
- PERJETA INTRAVENOUS SOLUTION
- PLENAMINE INTRAVENOUS PARENTERAL SOLUTION
- *plerixafor subcutaneous solution*
- PRALATREXATE INTRAVENOUS SOLUTION
- *premasol 10 % intravenous parenteral solution*
- PROGRAF INTRAVENOUS SOLUTION
- PROGRAF ORAL GRANULES IN PACKET
- PULMOZYME INHALATION SOLUTION
- RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION
- RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE
- *romidepsin intravenous recon soln*
- RYLAZE INTRAMUSCULAR SOLUTION
- SIMULECT INTRAVENOUS RECON SOLN
- *sirolimus oral solution*
- *sirolimus oral tablet*
- *sodium nitroprusside intravenous solution*
- SYLVANT INTRAVENOUS RECON SOLN
- *tacrolimus oral capsule*
- TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION
- TECENTRIQ INTRAVENOUS SOLUTION
- TEMODAR INTRAVENOUS RECON SOLN
- *temsirolimus intravenous recon soln*
- *thiotepa injection recon soln*



- TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION
- *topotecan intravenous recon soln*
- *topotecan intravenous solution*
- *travasol 10 % intravenous parenteral solution*
- TRAZIMERA INTRAVENOUS RECON SOLN
- TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION
- TYVASO INHALATION SOLUTION FOR NEBULIZATION
- TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION
- TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION
- TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION
- UNITUXIN INTRAVENOUS SOLUTION
- *valrubicin intravesical solution*
- VARUBI ORAL TABLET
- VECTIBIX INTRAVENOUS SOLUTION
- *veletri intravenous recon soln*
- *vinblastine intravenous solution*
- *vincristine intravenous solution*
- *vinorelbine intravenous solution*
- VYXEOS INTRAVENOUS RECON SOLN
- XGEVA SUBCUTANEOUS SOLUTION
- YERVOY INTRAVENOUS SOLUTION
- YONDELIS INTRAVENOUS RECON SOLN
- ZALTRAP INTRAVENOUS SOLUTION
- ZANOSAR INTRAVENOUS RECON SOLN
- ZIRABEV INTRAVENOUS SOLUTION
- *zoledronic acid intravenous solution*

### Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

## Index

### A

ABELCET INTRAVENOUS SUSPENSION .....	504
abiraterone oral tablet 250 mg, 500 mg .	502, 503
abirtega.....	502, 503
ABRAXANE INTRAVENOUS SUSPENSION FOR RECONSTITUTION .....	504
acetylcysteine solution .....	504
ACTEMRA ACTPEN .....	3, 4
ACTEMRA INTRAVENOUS .....	1, 2
ACTEMRA SUBCUTANEOUS .....	3, 4
ACTIMMUNE.....	5
acyclovir sodium intravenous solution ...	504
acyclovir topical ointment.....	6
ADBRY.....	10
ADCETRIS INTRAVENOUS RECON SOLN .....	504
ADEMPAS .....	11
ADSTILADRIN.....	12
AIMOVIG AUTOINJECTOR.....	13
AKEEGA .....	14
albuterol sulfate inhalation solution for nebulization.....	504
alcohol pads .....	96
ALDURAZYME.....	15
ALECENSA.....	16, 17
ALIQOPA INTRAVENOUS RECON SOLN .....	504
alosetron.....	18
ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG.....	20
ALUNBRIG ORAL TABLETS,DOSE PACK.....	20
alyq.....	310
ambrisentan .....	47
amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml .....	23, 24
amiodarone intravenous solution .....	504
amphotericin b injection recon soln.....	504
ampicillin sodium injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg .....	23, 24
ampicillin sodium intravenous.....	23, 24
ampicillin-sulbactam.....	23, 24
ANKTIVA .....	21, 22
aprepitant oral capsule .....	504
aprepitant oral capsule,dose pack .....	504
ARCALYST .....	26
arformoterol inhalation solution for nebulization.....	504
ARIKAYCE.....	27, 28
armodafinil.....	250
arsenic trioxide intravenous solution .....	504
ASPARLAS .....	29
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2 .....	98
AUGTYRO ORAL CAPSULE 160 MG, 40 MG .....	31
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG .....	32
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG.....	32
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG .....	32
AVONEX INTRAMUSCULAR PEN INJECTOR KIT .....	33
AVONEX INTRAMUSCULAR SYRINGE KIT .....	33
AYVAKIT .....	34
azacitidine injection recon soln.....	504
azathioprine oral tablet 50 mg.....	504
azathioprine sodium injection recon soln	504
azithromycin intravenous.....	23, 24
aztreonam.....	23, 24

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

**B**

BALVERSA .....	35
BAVENCIO INTRAVENOUS SOLUTION .....	504
BELBUCA .....	225, 226
BELEODAQ INTRAVENOUS RECON SOLN .....	504
BELSOMRA .....	104
bendamustine intravenous recon soln .....	504
BENDEKA INTRAVENOUS SOLUTION .....	504
BENLYSTA .....	36, 37, 38, 39
benztropine oral .....	156
BESPONSA INTRAVENOUS RECON SOLN .....	504
BESREMI .....	40
BETASERON SUBCUTANEOUS KIT ..	41
bexarotene .....	42, 43
BICILLIN L-A .....	23, 24
BIZENGRI .....	44
bleomycin injection recon soln .....	504
BLINCYTO INTRAVENOUS KIT .....	504
BONSITY .....	407, 408
BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG .....	504
bortezomib injection recon soln 3.5 mg..	504
bosentan oral tablet .....	47
BOSULIF ORAL CAPSULE 100 MG, 50 MG .....	48
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG .....	48
BRAFTOVI .....	49, 50
BRIUMVI .....	51
BRUKINSA .....	52
budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml .....	504
buprenorphine .....	225, 226
busulfan intravenous solution .....	504
BYDUREON BCISE .....	146
BYOOVIZ .....	53
<b>C</b>	
CABLIVI INJECTION KIT .....	55

CABOMETYX .....	56, 57
calcium acetate(phosphat bind) .....	309
CALQUENCE .....	58, 59
CALQUENCE (ACALABRUTINIB MAL) .....	58, 59
CAMZYOS .....	60, 61
CAPRELSA ORAL TABLET 100 MG, 300 MG .....	62
carboplatin intravenous solution .....	504
carglumic acid .....	63
carmustine intravenous recon soln 100 mg .....	504
CAYSTON .....	64
cefoxitin .....	23, 24
cefoxitin in dextrose (iso-osm) .....	23, 24
ceftazidime .....	23, 24
cefuroxime sodium injection recon soln 750 mg .....	23, 24
cefuroxime sodium intravenous .....	23, 24
CEPROTIN (BLUE BAR) .....	65
CEPROTIN (GREEN BAR) .....	65
CHEMET .....	66
CIBINQO .....	67, 68
cidofovir intravenous solution .....	504
CIMERLI .....	69
CIMZIA POWDER FOR RECONST .....	70, 71
CIMZIA STARTER KIT .....	70, 71
CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) .....	70, 71
cinacalcet .....	72
CINRYZE .....	54
ciprofloxacin in 5 % dextrose .....	23, 24
cisplatin intravenous solution .....	504
cladribine intravenous solution .....	504
clindamycin in 5 % dextrose .....	23, 24
clindamycin phosphate injection .....	23, 24
CLINIMIX 4.25%/D10W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION .....	504
CLINIMIX 4.25%/D5W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION .....	504

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION.....	504
CLINIMIX 5%-D20W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION.....	504
CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION.....	504
CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION.....	504
CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION.....	504
clobazam oral suspension .....	73
clobazam oral tablet .....	73
clofarabine intravenous solution .....	504
clomid .....	74
clomiphene citrate .....	74
clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg .....	154, 155
colistin (colistimethate na) .....	23, 24
COLUMVI.....	75, 76
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY).....	77
COPIKTRA.....	78
COSENTYX (2 SYRINGES) .....	79, 80
COSENTYX INTRAVENOUS.....	81
COSENTYX PEN.....	79, 80
COSENTYX PEN (2 PENS) .....	79, 80
COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML .....	79, 80
COSENTYX UNOREADY PEN .....	79, 80
COTELLIC .....	82, 83
CRESEMBA ORAL .....	84
cromolyn inhalation solution for nebulization.....	504
CRYSVITA.....	85, 86
cyclobenzaprine oral tablet 10 mg, 5 mg	157
cyclophosphamide intravenous recon soln .....	504
cyclophosphamide oral capsule .....	504
CYCLOPHOSPHAMIDE ORAL TABLET .....	504
cyclosporine modified oral capsule .....	504
cyclosporine modified oral solution.....	504
cyclosporine oral capsule.....	504
CYLTEZO(CF) PEN .....	7, 8, 9
CYLTEZO(CF) PEN CROHN'S-UC-HS ..	7, 8, 9
CYLTEZO(CF) PEN PSORIASIS-UV .	7, 8, 9
CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML.....	7, 8, 9
CYRAMZA INTRAVENOUS SOLUTION .....	504
CYSTAGON.....	88
CYSTARAN .....	87
cytarabine (pf) injection solution .....	504
cytarabine injection solution .....	504
<b>D</b>	
dacarbazine intravenous recon soln .....	504
dactinomycin intravenous recon soln.....	504
dalfampridine .....	89
DANYELZA INTRAVENOUS SOLUTION.....	504
DANZITEN .....	90, 91
DARZALEX INTRAVENOUS SOLUTION .....	504
dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg .....	378
DATROWAY .....	92
daunorubicin intravenous solution .....	505
DAURISMO ORAL TABLET 100 MG, 25 MG .....	93
decitabine intravenous recon soln .....	505
deferasirox.....	94
deferiprone .....	95
deferoxamine injection recon soln .....	505
dermacinrx lidocan.....	223

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

dexrazoxane hcl intravenous recon soln .	505	ELIGARD (3 MONTH).....	149
DIACOMIT.....	100	ELIGARD (4 MONTH).....	149
diazepam injection .....	154, 155	ELIGARD (6 MONTH).....	149
diazepam intensol.....	154, 155	ELREXFIO .....	110
diazepam oral concentrate.....	154, 155	eltrombopag olamine .....	322, 323
diazepam oral solution .....	154, 155	ELZONRIS INTRAVENOUS SOLUTION	
diazepam oral tablet .....	154, 155	.....	505
diclofenac sodium topical gel 3 % .....	371	EMGALITY PEN .....	111
dimethyl fumarate oral capsule,delayed		EMGALITY SYRINGE	
release(dr/ec) 120 mg, 120 mg (14)-	240	SUBCUTANEOUS SYRINGE 120	
mg (46), 240 mg.....	101	MG/ML .....	111
dobutamine in d5w intravenous parenteral		EMPLICITI INTRAVENOUS RECON	
solution 1,000 mg/250 ml (4,000		SOLN .....	505
mcg/ml), 250 mg/250 ml (1 mg/ml), 500		ENBREL MINI.....	112, 113
mg/250 ml (2,000 mcg/ml) .....	505	ENBREL SUBCUTANEOUS SOLUTION	
dobutamine intravenous solution .....	505	.....	112, 113
docetaxel intravenous solution.....	505	ENBREL SUBCUTANEOUS SYRINGE	
dopamine in 5 % dextrose intravenous		.....	112, 113
solution.....	505	ENBREL SURECLICK.....	112, 113
dopamine intravenous solution 200 mg/5 ml		ENGERIX-B (PF) INTRAMUSCULAR	
(40 mg/ml), 400 mg/10 ml (40 mg/ml)505		SUSPENSION .....	505
DOPTELET (10 TAB PACK) .....	102	ENGERIX-B (PF) INTRAMUSCULAR	
DOPTELET (15 TAB PACK) .....	102	SYRINGE .....	505
DOPTELET (30 TAB PACK) .....	102	ENGERIX-B PEDIATRIC (PF)	
dotti .....	160, 161	INTRAMUSCULAR SYRINGE.....	505
doxorubicin intravenous recon soln .....	505	ENTYVIO.....	115, 116
doxorubicin intravenous solution.....	505	ENVARUSUS XR ORAL TABLET	
doxorubicin, peg-liposomal intravenous		EXTENDED RELEASE 24 HR .....	505
suspension .....	505	EPIDIOLEX.....	117
doxy-100 .....	23, 24	epirubicin intravenous solution 200 mg/100	
doxycycline hyclate intravenous.....	23, 24	ml .....	505
dronabinol oral capsule .....	505	EPKINLY .....	118, 119
droxidopa .....	103	EPRONTIA.....	421
DUPIXENT PEN SUBCUTANEOUS PEN		ERBITUX INTRAVENOUS SOLUTION	
INJECTOR 200 MG/1.14 ML, 300 MG/2		.....	505
ML.....	105, 106, 107	eribulin intravenous solution.....	505
DUPIXENT SYRINGE SUBCUTANEOUS		ERIVEDGE.....	122
SYRINGE 200 MG/1.14 ML, 300 MG/2		ERLEADA ORAL TABLET 240 MG, 60	
ML.....	105, 106, 107	MG .....	123
<b>E</b>		erlotinib oral tablet 100 mg, 150 mg, 25 mg	
ELAHERE .....	108	.....	124, 125
ELAPRASE .....	109	ertapenem.....	23, 24
ELIGARD .....	149		

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

ERWINASE INJECTION RECON SOLN .....	505
estradiol oral.....	160, 161
estradiol transdermal patch semiweekly	160, 161
estradiol transdermal patch weekly.	160, 161
estradiol-norethindrone acet.....	160, 161
ETOPOPHOS INTRAVENOUS RECON SOLN .....	505
etoposide intravenous solution.....	505
everolimus (antineoplastic) oral tablet...	126, 127
everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg.....	126, 127
everolimus (immunosuppressive) oral tablet .....	505
exenatide subcutaneous pen injector	10
mcg/dose(250 mcg/ml) 2.4 ml, 5	
mcg/dose (250 mcg/ml) 1.2 ml .....	146
EYLEA .....	128
<b>F</b>	
FABRAZYME.....	129
FASENRA PEN.....	130, 131
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML .....	130, 131
fentanyl citrate buccal lozenge on a handle	
1,200 mcg, 200 mcg.....	424
fentanyl transdermal patch 72 hour	100
mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr .....	422, 423
fingolimod.....	132
FINTEPLA.....	133
FIRMAGON KIT W DILUENT SYRINGE .....	134
floxuridine injection recon soln .....	505
fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml .....	25
fludarabine intravenous recon soln .....	505
fludarabine intravenous solution.....	505
fluorouracil intravenous solution .....	505
formoterol fumarate inhalation solution for nebulization.....	505

FOTIVDA .....	135
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG .....	136, 137
FULPHILA .....	138, 139
fulvestrant intramuscular syringe.....	505
FYARRO .....	140
fyavolv .....	160, 161
<b>G</b>	
gabapentin oral tablet extended release 24 hr 300 mg, 600 mg .....	150
ganciclovir sodium intravenous recon soln .....	505
ganciclovir sodium intravenous solution	505
GATTEX 30-VIAL.....	141
GATTEX ONE-VIAL .....	141
GAUZE PAD TOPICAL BANDAGE 2 X 2 .....	97
GAVRETO .....	142
GAZYVA INTRAVENOUS SOLUTION .....	505
gefitinib .....	143
gemcitabine intravenous recon soln.....	505
gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) .....	505
<b>GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML .....</b>	<b>505</b>
gengraf oral capsule .....	505
gengraf oral solution .....	505
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml.....	23, 24
gentamicin injection.....	23, 24
gentamicin sulfate (ped) (pf).....	23, 24
GILOTRIF .....	144
glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml .....	145
glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml .....	145
glutamine (sickle cell).....	114
GOMEKLI ORAL CAPSULE 1 MG, 2 MG .....	148

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

GOMEKLI ORAL TABLET FOR SUSPENSION .....	148	IDHIFA .....	167
GRAFAPEX INTRAVENOUS RECON SOLN .....	505	ifosfamide intravenous recon soln .....	505
granisetron hcl oral tablet.....	505	ifosfamide intravenous solution.....	505
<b>H</b>		ILARIS (PF).....	168, 169
HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE .....	505	imatinib oral tablet 100 mg, 400 mg	170, 171
HIZENTRA SUBCUTANEOUS SOLUTION.....	505	IMBRUVICA ORAL CAPSULE 140 MG, 70 MG .....	172, 173
HIZENTRA SUBCUTANEOUS SYRINGE .....	505	IMBRUVICA ORAL SUSPENSION....	172, 173
HUMIRA (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML .....	7, 8, 9	IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG.....	172, 173
HUMIRA PEN (PREFERRED NDCS STARTING WITH 00074).....	7, 8, 9	IMDELLTRA .....	174
HUMIRA(CF) (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML.....	7, 8, 9	IMFINZI INTRAVENOUS SOLUTION	505
HUMIRA(CF) PEN (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML.	7, 8, 9	imipenem-cilastatin.....	23, 24
HUMIRA(CF) PEN CROHNS-UC-HS (PREFERRED NDCS STARTING WITH 00074) .....	7, 8, 9	IMJUDO .....	175, 176
HUMIRA(CF) PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074) .....	7, 8, 9	IMKELDI.....	170, 171
hydromorphone oral tablet extended release 24 hr .....	225, 226	INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE .....	177
hydroxyzine hcl oral tablet.....	158	INGREZZA.....	178
<b>I</b>		INGREZZA INITIATION PK(TARDIV) .....	178
ibandronate intravenous .....	45, 46	INGREZZA SPRINKLE .....	178
IBRANCE .....	162, 163	INLYTA ORAL TABLET 1 MG, 5 MG	181
icatibant.....	164, 165	INPEFA.....	182
ICLUSIG.....	166	INQOVI .....	183
idarubicin intravenous solution.....	505	INREBIC.....	184
		INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2.....	99
		intralipid intravenous emulsion 20 % .....	505
		ipratropium bromide inhalation solution	505
		ipratropium-albuterol inhalation solution for nebulization.....	505
		irinotecan intravenous solution .....	505
		ISTODAX INTRAVENOUS RECON SOLN .....	505
		ITOVEBI ORAL TABLET 3 MG, 9 MG .....	185, 186
		ivermectin oral tablet 3 mg, 6 mg .....	187
		IWILFIN .....	189
		IXEMPRA INTRAVENOUS RECON SOLN .....	505

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

**J**

JAKAFI.....	190, 191
JAYPIRCA ORAL TABLET 100 MG, 50 MG .....	192, 193
JEMPERLI.....	194, 195
JEVTANA INTRAVENOUS SOLUTION .....	505
jinteli .....	160, 161
JYLAMVO ORAL SOLUTION.....	505
JYNNEOS (PF) SUBCUTANEOUS SUSPENSION .....	505

**K**

KADCYLA .....	197
KALYDECO.....	198
KANUMA.....	199
KERENDIA .....	200, 201
KESIMPTA PEN .....	202
KEYTRUDA.....	203
KHAPZORY INTRAVENOUS RECON SOLN 175 MG.....	505
KIMMTRAK INTRAVENOUS SOLUTION.....	505
KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG .....	204, 205
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3) .....	204, 205
KOSELUGO .....	207, 208
KRAZATI.....	209, 210
KYPROLIS INTRAVENOUS RECON SOLN .....	505

**L**

lanreotide subcutaneous syringe 120 mg/0.5 ml .....	211, 212
lapatinib.....	213, 214
LAZCLUZE ORAL TABLET 240 MG, 80 MG .....	215
LEDIPASVIR-SOFOSBUVIR .....	216
lenalidomide.....	217, 218
LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3),	

14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2).....	219, 220
leuprolide subcutaneous kit.....	149
levofloxacin in d5w.....	23, 24
levofloxacin intravenous.....	23, 24
levoleucovorin calcium intravenous recon soln.....	506
levoleucovorin calcium intravenous solution .....	506
LIBTAYO .....	221, 222
lidocaine topical adhesive patch,medicated 5 % .....	223
lidocan iii .....	223
lidocan iv.....	223
lidocan v.....	223
lincomycin.....	23, 24
linezolid in dextrose 5%.....	23, 24
linezolid-0.9% sodium chloride .....	23, 24
LIVTENCITY .....	224
LONSURF .....	227
LOQTORZI.....	228, 229
lorazepam injection.....	154, 155
lorazepam intensol .....	154, 155
lorazepam oral concentrate .....	154, 155
lorazepam oral tablet 0.5 mg, 1 mg, 2 mg .....	154, 155
LORBRENA ORAL TABLET 100 MG, 25 MG .....	230, 231
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....	232, 233
LUMIZYME .....	234
LUNSUMIO .....	235, 236
LUPRON DEPOT.....	237, 238
lyllana.....	160, 161
LYNPARZA .....	239, 240
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) .....	241

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

## M

### MARGENZA INTRAVENOUS

SOLUTION..... 506

MAVYRET ORAL PELLETS IN PACKET  
..... 242

MAVYRET ORAL TABLET..... 242

megestrol oral suspension 400 mg/10 ml (10  
ml), 400 mg/10 ml (40 mg/ml), 625 mg/5  
ml (125 mg/ml) ..... 243

megestrol oral tablet..... 243

MEKINIST ORAL RECON SOLN 244, 245

MEKINIST ORAL TABLET 0.5 MG, 2

MG ..... 244, 245

MEKTOVI ..... 246

melphalan hcl intravenous recon soln..... 506

memantine oral capsule,sprinkle,er 24hr 247

memantine oral solution..... 247

memantine oral tablet..... 247

memantine-donepezil..... 247

MEPSEVII ..... 248

meropenem intravenous recon soln 1 gram,  
500 mg ..... 23, 24

mesna intravenous solution..... 506

methadone intensol ..... 225, 226

methadone oral concentrate ..... 225, 226

methadone oral solution 10 mg/5 ml, 5 mg/5  
ml ..... 225, 226

methadone oral tablet 10 mg, 5 mg. 225, 226

methadose oral concentrate..... 225, 226

methotrexate sodium (pf) injection recon  
soln..... 506

methotrexate sodium (pf) injection solution  
..... 506

methotrexate sodium injection solution.. 506

methotrexate sodium oral tablet..... 506

methylergonovine oral ..... 249

methylprednisolone oral tablet..... 506

metro i.v. .... 23, 24

metronidazole in nacl (iso-osm)..... 23, 24

metyrosine..... 308

mifepristone oral tablet 300 mg ..... 206

milrinone in 5 % dextrose intravenous  
piggyback..... 506

milrinone intravenous solution ..... 506

mimvey ..... 160, 161

mitomycin intravenous recon soln ..... 506

mitoxantrone intravenous concentrate .... 506

modafinil oral tablet 100 mg, 200 mg..... 250

MONJUVI..... 251

morphine oral tablet extended release.... 225,  
226

MOUNJARO ..... 146

moxifloxacin-sod.chloride(iso) ..... 23, 24

mycophenolate mofetil (hcl) intravenous  
recon soln..... 506

mycophenolate mofetil oral capsule ..... 506

mycophenolate mofetil oral suspension for  
reconstitution..... 506

mycophenolate mofetil oral tablet ..... 506

mycophenolate sodium oral tablet,delayed  
release (dr/ec)..... 506

MYFEMBREE..... 252, 253

MYHIBBIN ORAL SUSPENSION ..... 506

MYLOTARG INTRAVENOUS RECON  
SOLN ..... 506

## N

nafcillin in dextrose (iso-osm) intravenous  
piggyback 2 gram/100 ml ..... 23, 24

nafcillin injection ..... 23, 24

NAGLAZYME ..... 254

NAMZARIC ORAL

CAPSULE,SPRINKLE,ER 24HR..... 247

NAYZILAM ..... 255

nelarabine intravenous solution ..... 506

NERLYNX ..... 256

NEXLETOL..... 257, 258

NEXLIZET ..... 259, 260

nilotinib hcl oral capsule 150 mg, 200 mg,  
50 mg ..... 401, 402

nilutamide ..... 261

NINLARO..... 262

nitisinone..... 263

nitroglycerin in 5 % dextrose intravenous  
solution 100 mg/250 ml (400 mcg/ml), 25  
mg/250 ml (100 mcg/ml), 50 mg/250 ml  
(200 mcg/ml)..... 506

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

nitroglycerin intravenous solution .....	506	OPDUALAG.....	290
NIVESTYM.....	264, 265	OPSUMIT .....	291
norethindrone ac-eth estradiol oral tablet		OPSYNVI .....	292
0.5-2.5 mg-mcg, 1-5 mg-mcg .....	160, 161	ORENCIA (WITH MALTOSE).....	295, 296
NUBEQA.....	268	ORENCIA CLICKJECT.....	293, 294
NUCALA SUBCUTANEOUS AUTO-		ORENCIA SUBCUTANEOUS SYRINGE	
INJECTOR.....	269, 270, 271	125 MG/ML, 50 MG/0.4 ML, 87.5	
NUCALA SUBCUTANEOUS RECON		MG/0.7 ML.....	293, 294
SOLN .....	269, 270, 271	ORGOVYX.....	297
NUCALA SUBCUTANEOUS SYRINGE		ORKAMBI ORAL GRANULES IN	
100 MG/ML, 40 MG/0.4 ML ....	269, 270,	PACKET .....	298
271		ORKAMBI ORAL TABLET .....	298
NUEDEXTA.....	272	ORSERDU ORAL TABLET 345 MG, 86	
NULOJIX INTRAVENOUS RECON		MG .....	299
SOLN .....	506	OTEZLA.....	300
NUPLAZID.....	273	OTEZLA STARTER ORAL	
NURTEC ODT .....	274	TABLETS,DOSE PACK 10 MG (4)- 20	
NYVEPRIA .....	275, 276	MG (51), 10 MG (4)-20 MG (4)-30 MG	
<b>O</b>		(47).....	300
OALIVA.....	277, 278	oxacillin.....	23, 24
octreotide acetate .....	279, 280	oxacillin in dextrose(iso-osm) intravenous	
octreotide,microspheres .....	359, 360	piggyback 2 gram/50 ml .....	23, 24
ODOMZO .....	281	oxaliplatin intravenous recon soln .....	506
OFEV .....	282, 283	oxaliplatin intravenous solution.....	506
OGSIVEO ORAL TABLET 100 MG, 150		OXERVATE.....	301
MG, 50 MG.....	284	OXYCONTIN ORAL TABLET,ORAL	
OJEMDA ORAL SUSPENSION FOR		ONLY,EXT.REL.12 HR 10 MG, 15 MG,	
RECONSTITUTION .....	285	20 MG, 30 MG, 40 MG, 60 MG, 80 MG	
OJEMDA ORAL TABLET 400 MG/WEEK		.....	225, 226
(100 MG X 4), 500 MG/WEEK (100 MG		OZEMPIC SUBCUTANEOUS PEN	
X 5), 600 MG/WEEK (100 MG X 6) .	285	INJECTOR 0.25 MG OR 0.5 MG (2	
OJJAARA .....	286	MG/3 ML), 1 MG/DOSE (4 MG/3 ML),	
OMNITROPE .....	151, 152, 153	2 MG/DOSE (8 MG/3 ML) .....	146
ONCASPAR INJECTION SOLUTION. 506		<b>P</b>	
ondansetron hcl oral solution.....	506	paclitaxel intravenous concentrate.....	506
ondansetron hcl oral tablet 4 mg, 8 mg...	506	paclitaxel protein-bound intravenous	
ondansetron oral tablet,disintegrating 4 mg,		suspension for reconstitution .....	506
8 mg .....	506	PADCEV.....	302
ONIVYDE INTRAVENOUS DISPERSION		PANRETIN.....	303
.....	506	paraplatin intravenous solution .....	506
ONUREG.....	287	PAVBLU.....	304
OPDIVO .....	288	pazopanib .....	459, 460
OPDIVO QVANTIG .....	289	PEMAZYRE .....	305

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

pemetrexed disodium intravenous recon soln .....	506
PEN NEEDLE, DIABETIC NEEDLE 29	
GAUGE X 1/2.....	98
penicillamine oral tablet.....	306
PENICILLIN G POT IN DEXTROSE	
INTRAVENOUS PIGGYBACK 2	
MILLION UNIT/50 ML, 3 MILLION	
UNIT/50 ML.....	23, 24
penicillin g potassium .....	23, 24
penicillin g sodium.....	23, 24
pentamidine inhalation recon soln .....	506
PERJETA INTRAVENOUS SOLUTION	
.....	506
pfizerpen-g .....	23, 24
phenobarbital.....	159
pimecrolimus.....	419
PIQRAY ORAL TABLET 200 MG/DAY	
(200 MG X 1), 250 MG/DAY (200 MG	
X1-50 MG X1), 300 MG/DAY (150 MG	
X 2) .....	311, 312
pirfenidone oral capsule.....	313
pirfenidone oral tablet 267 mg, 801 mg..	313
PLEGRIDY INTRAMUSCULAR .....	314
PLEGRIDY SUBCUTANEOUS PEN	
INJECTOR 125 MCG/0.5 ML, 63	
MCG/0.5 ML- 94 MCG/0.5 ML.....	314
PLEGRIDY SUBCUTANEOUS SYRINGE	
125 MCG/0.5 ML, 63 MCG/0.5 ML- 94	
MCG/0.5 ML .....	314
PLENAMINE INTRAVENOUS	
PARENTERAL SOLUTION.....	506
plerixafor subcutaneous solution .....	506
POLIVY .....	315
POMALYST .....	316
posaconazole oral tablet,delayed release	
(dr/ec).....	317
POTELIGEO.....	318
PRALATREXATE INTRAVENOUS	
SOLUTION.....	506
premasol 10 % intravenous parenteral	
solution.....	506
PREVYMIS INTRAVENOUS .....	319

PREVYMIS ORAL TABLET .....	319
PRIVIGEN .....	188
PROCRIT .....	120, 121
PROGRAF INTRAVENOUS SOLUTION	
.....	506
PROGRAF ORAL GRANULES IN	
PACKET .....	506
PROLASTIN-C INTRAVENOUS	
SOLUTION.....	19
PROLIA .....	320, 321
PROMACTA .....	322, 323
promethazine oral.....	158
PULMOZYME INHALATION	
SOLUTION.....	506
pyrimethamine .....	324
<b>Q</b>	
QINLOCK.....	325
QULIPTA .....	326
<b>R</b>	
RADICAVA ORS.....	327
RADICAVA ORS STARTER KIT SUSP	
.....	327
RECOMBIVAX HB (PF)	
INTRAMUSCULAR SUSPENSION. 506	
RECOMBIVAX HB (PF)	
INTRAMUSCULAR SYRINGE.....	506
RELEUKO SUBCUTANEOUS .....	330, 331
REMICADE.....	332, 333
REPATHA .....	336, 337
REPATHA PUSHTRONEX.....	336, 337
REPATHA SURECLICK.....	336, 337
RETACRIT .....	120, 121
RETEVMO ORAL CAPSULE 40 MG ..	338
RETEVMO ORAL TABLET 120 MG, 160	
MG, 40 MG, 80 MG .....	338
REVLIMID .....	217, 218
REVUFORJ ORAL TABLET 110 MG, 160	
MG, 25 MG.....	339
REZDIFFRA.....	340, 341
REZLIDHIA .....	342
REZUROCK .....	343
riluzole .....	344
RINVOQ LQ.....	347

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

**RINVOQ ORAL TABLET EXTENDED**  
**RELEASE 24 HR 15 MG, 30 MG, 45**  
**MG** ..... 345, 346  
 roflumilast ..... 348  
 romidepsin intravenous recon soln ..... 506  
**ROMVIMZA** ..... 349  
**ROZLYTREK ORAL CAPSULE 100 MG,**  
**200 MG** ..... 350  
**ROZLYTREK ORAL PELLETS IN**  
**PACKET** ..... 350  
**RUBRACA** ..... 351, 352  
 rufinamide ..... 353  
**RUXIENCE** ..... 354  
**RYBELSUS** ..... 146  
**RYBREVANT** ..... 355  
**RYDAPT** ..... 356  
**RYLAZE INTRAMUSCULAR**  
**SOLUTION**..... 506  
**RYTELO** ..... 357, 358  
**S**  
 sajazir ..... 164, 165  
**SANDOSTATIN LAR DEPOT**  
**INTRAMUSCULAR**  
**SUSPENSION,EXTENDED REL**  
**RECON** ..... 359, 360  
 sapropterin..... 361  
**SARCLISA** ..... 362  
**SCEMBLIX ORAL TABLET 100 MG, 20**  
**MG, 40 MG**..... 363  
**SELARSDI INTRAVENOUS** ..... 381  
**SELARSDI SUBCUTANEOUS SYRINGE**  
**45 MG/0.5 ML, 90 MG/ML** ..... 379, 380  
 sevelamer carbonate oral tablet..... 309  
**SIGNIFOR** ..... 364  
 sildenafil (pulmonary arterial hypertension)  
 oral tablet 20 mg ..... 310  
**SIMULECT INTRAVENOUS RECON**  
**SOLN** ..... 506  
 sirolimus oral solution..... 506  
 sirolimus oral tablet..... 506  
**SIRTURO** ..... 365  
**SKYRIZI INTRAVENOUS** ..... 368, 369

**SKYRIZI SUBCUTANEOUS PEN**  
**INJECTOR**..... 366, 367  
**SKYRIZI SUBCUTANEOUS SYRINGE**  
 ..... 366, 367  
**SKYRIZI SUBCUTANEOUS WEARABLE**  
**INJECTOR 180 MG/1.2 ML (150**  
**MG/ML), 360 MG/2.4 ML (150 MG/ML)**  
 ..... 366, 367  
 sodium nitroprusside intravenous solution  
 ..... 506  
**SODIUM OXYBATE (PREFERRED**  
**NDCS STARTING WITH 00054)** ..... 485  
 sodium phenylbutyrate..... 307  
**SOFOSBUVIR-VELPATASVIR** ..... 370  
**SOMATULINE DEPOT**  
**SUBCUTANEOUS SYRINGE 60**  
**MG/0.2 ML, 90 MG/0.3 ML** ..... 211, 212  
**SOMAVERT**..... 372  
 sorafenib..... 373, 374  
**SOTYKTU** ..... 375  
**SPRAVATO NASAL SPRAY, NON-**  
**AEROSOL 56 MG (28 MG X 2), 84 MG**  
**(28 MG X 3)**..... 376, 377  
**SPRYCEL ORAL TABLET 100 MG, 140**  
**MG, 20 MG, 50 MG, 70 MG, 80 MG** 378  
**STELARA INTRAVENOUS** ..... 381  
**STELARA SUBCUTANEOUS**  
**SOLUTION**..... 379, 380  
**STELARA SUBCUTANEOUS SYRINGE**  
**45 MG/0.5 ML, 90 MG/ML** ..... 379, 380  
**STIVARGA** ..... 382, 383  
**STRENSIQ** ..... 384, 385  
**STREPTOMYCIN** ..... 23, 24  
**SUCRAID** ..... 386, 387  
 sulfamethoxazole-trimethoprim intravenous  
 ..... 23, 24  
 sunitinib malate ..... 388, 389  
**SYLVANT INTRAVENOUS RECON**  
**SOLN** ..... 506  
**SYMDEKO**..... 390  
**SYMLINPEN 120**..... 391  
**SYMLINPEN 60**..... 391  
**SYMPAZAN**..... 73

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

**T**

TABRECTA .....	392	testosterone transdermal solution in metered pump w/app.....	266, 267
tacrolimus oral capsule .....	506	tetrabenazine oral tablet 12.5 mg, 25 mg	409
tacrolimus topical.....	419	TEVIMBRA.....	410, 411, 412
tadalafil (pulm. hypertension).....	310	THALOMID ORAL CAPSULE 100 MG, 50 MG .....	413, 414
tadalafil oral tablet 2.5 mg, 5 mg .....	393	thiotepa injection recon soln .....	506
TAFINLAR ORAL CAPSULE .....	395, 396	TIBSOVO .....	415
TAFINLAR ORAL TABLET FOR SUSPENSION .....	395, 396	TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION .....	507
TAGRISSE .....	397, 398	tigecycline .....	23, 24
TALVEY.....	399	TIVDAK .....	416
TALZENNA .....	400	tobramycin in 0.225 % nacl .....	417
TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG.....	401, 402	tobramycin inhalation .....	417
tazarotene topical cream .....	403	tobramycin sulfate injection recon soln ...	23, 24
tazarotene topical gel .....	403	tobramycin sulfate injection solution..	23, 24
tazicef.....	23, 24	tolvaptan.....	418
TAZVERIK.....	404	tolvaptan (polycys kidney dis) oral tablet	196
TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION.....	506	topiramate oral capsule, sprinkle 15 mg, 25 mg .....	421
TECENTRIQ INTRAVENOUS SOLUTION.....	506	topiramate oral tablet .....	421
TECVAYLI.....	405	topotecan intravenous recon soln.....	507
TEFLARO.....	23, 24	topotecan intravenous solution .....	507
TEMODAR INTRAVENOUS RECON SOLN .....	506	torpenz.....	126, 127
temsirolimus intravenous recon soln .....	506	travasol 10 % intravenous parenteral solution.....	507
TEPMETKO .....	406	TRAZIMERA INTRAVENOUS RECON SOLN .....	507
teriflunomide.....	30	TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION .....	425
TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML).....	407, 408	TREMFYA INTRAVENOUS .....	428, 429
testosterone cypionate .....	179, 180	TREMFYA PEN.....	426, 427
testosterone enanthate .....	179, 180	TREMFYA PEN INDUCTION PK-CROHN.....	426, 427
testosterone transdermal gel.....	266, 267	TREMFYA SUBCUTANEOUS ....	426, 427
testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %) .....	266, 267	treprostinil sodium .....	334, 335
testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram), 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram) .....	266, 267	tretinoin topical .....	420
		tridacaine ii.....	223
		trientine oral capsule 250 mg.....	430, 431

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL .....	432	vancomycin oral capsule 125 mg, 250 mg .....	445
TRIKAFTA ORAL TABLETS, SEQUENTIAL.....	432	VANFLYTA .....	446
TRODELVY .....	433	VARUBI ORAL TABLET .....	507
TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION.....	507	VECTIBIX INTRAVENOUS SOLUTION .....	507
TRULICITY .....	146	velettri intravenous recon soln .....	507
TRUQAP.....	434, 435	VELPHORO .....	309
TUKYSA ORAL TABLET 150 MG, 50 MG .....	436, 437	VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	447, 448
TURALIO ORAL CAPSULE 125 MG..	438	VENCLEXTA STARTING PACK	447, 448
TYENNE AUTOINJECTOR.....	3, 4	VERZENIO.....	449, 450
TYENNE INTRAVENOUS .....	439, 440	VIBATIV INTRAVENOUS RECON SOLN 750 MG .....	23, 24
TYENNE SUBCUTANEOUS.....	3, 4	vigabatrin .....	451
TYVASO INHALATION SOLUTION FOR NEBULIZATION .....	507	vigadrone.....	451
TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION .....	507	vigpoder .....	451
TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION .	507	VIMIZIM .....	452
TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION .	507	vinblastine intravenous solution .....	507
<b>U</b>		vincristine intravenous solution .....	507
UBRELVY .....	441	vinorelbine intravenous solution.....	507
UNITUXIN INTRAVENOUS SOLUTION .....	507	VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	453
UPTRAVI ORAL TABLET .....	442	VITRAKVI ORAL SOLUTION .....	453
UPTRAVI ORAL TABLETS,DOSE PACK .....	442	VIZIMPRO .....	454
<b>V</b>		VONJO .....	455
VALCHLOR.....	443	VORANIGO ORAL TABLET 10 MG, 40 MG .....	456
valrubicin intravesical solution .....	507	voriconazole.....	25, 457
VALTOCO .....	444	VOSEVI.....	458
VANCOMYCIN IN 0.9 % SODIUM CHL INTRAVENOUS PIGGYBACK 1 GRAM/200 ML, 500 MG/100 ML, 750 MG/150 ML .....	23, 24	VOWST .....	461
vancomycin intravenous recon soln 1,000 mg, 10 gram, 5 gram, 500 mg, 750 mg	23, 24	VUMERITY .....	462
		VYLOY.....	463, 464
		VYNDAMAX.....	394
		VYNDAQEL .....	394
		VYVGART .....	465
		VYVGART HYTRULO.....	465
		VYXEOS INTRAVENOUS RECON SOLN .....	507
		<b>W</b>	
		WELIREG.....	466, 467
		<b>X</b>	
		XALKORI ORAL CAPSULE.....	468, 469

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.

XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG.....	468, 469
XDEMVY .....	470
XELJANZ ORAL SOLUTION .....	471, 472
XELJANZ ORAL TABLET.....	471, 472
XELJANZ XR .....	471, 472
XERMELO .....	473
XGEVA SUBCUTANEOUS SOLUTION .....	507
XIAFLEX .....	474, 475
XIFAXAN ORAL TABLET 200 MG, 550 MG .....	476, 477
XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML .....	478, 479
XOLAIR SUBCUTANEOUS RECON SOLN .....	478, 479
XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML.....	478, 479
XOSPATA .....	480
XPOVIO .....	481, 482
XTANDI ORAL CAPSULE.....	483, 484
XTANDI ORAL TABLET 40 MG, 80 MG .....	483, 484
<b>Y</b>	
YERVOY INTRAVENOUS SOLUTION .....	507
YESINTEK INTRAVENOUS .....	381
YESINTEK SUBCUTANEOUS SOLUTION.....	379, 380
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .....	379, 380
YONDELIS INTRAVENOUS RECON SOLN .....	507
YUFLYMA(CF) AI CROHN'S-UC-HS 7, 8, 9	
YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML. 7, 8, 9	
YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML .....	7, 8, 9
<b>Z</b>	
ZALTRAP INTRAVENOUS SOLUTION .....	507
ZANOSAR INTRAVENOUS RECON SOLN .....	507
ZEJULA ORAL TABLET.....	486
ZELBORAF.....	487, 488
ZEPOSIA .....	489, 490
ZEPOSIA STARTER KIT (28-DAY) ...	489, 490
ZEPOSIA STARTER PACK (7-DAY) .	489, 490
ZEPZELCA.....	491
ZIIHERA.....	492
ZIRABEV INTRAVENOUS SOLUTION .....	507
ZOLADEX.....	147
zoledronic acid intravenous solution .....	507
zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml .....	328, 329
ZOLINZA .....	493
ZONISADE.....	421
zonisamide .....	421
ZTALMY .....	494
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....	495
ZYDELIG .....	496
ZYKADIA .....	497
ZYMFENTRA .....	498, 499
ZYNLONTA.....	500
ZYNYZ.....	501



Health Insurance Plan of Greater New York (HIP) is an HMO plan with a Medicare contract and a HMO D-SNP plan with a Medicare contract and a contract with the New York State Department of Health. Enrollment in HIP depends on contract renewal. HIP is an EmblemHealth company. EmblemHealth Plan, Inc. is a PPO plan with a Medicare contract. Enrollment in EmblemHealth Plan, Inc. depends on contract renewal.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2026. The formulary and pharmacy network may change at any time. You will receive notice when necessary.

This document includes EmblemHealth Medicare HMO/PPO partial formulary as of August 1, 2025. For a complete, updated formulary, please visit our Web site at [www.emblemhealth.com/medicare](http://www.emblemhealth.com/medicare) or call the Customer Service number below.

EmblemHealth Medicare HMO: 1-877-344-7364, Monday through Sunday, 8 am to 8 pm.

EmblemHealth Medicare PPO: 1-866-557-7300, Monday through Sunday, 8 am to 8 pm.

TTY users should call 711.

25285 v18

Updated: 08/2025

Y0026\_205074\_C

EmblemHealth Plan, Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies.

EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.